https://www.kdctmeeting.com/participants daily 0.75 2020-09-01 https://www.kdctmeeting.com/screenshots daily 0.75 2020-09-30 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473520017-WALI8MKEG5EYNRH5PQ71/Session+1.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473520017-WALI8MKEG5EYNRH5PQ71/Session+1.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473520180-V2P652LZTRL1M9MNSVQR/Session+2.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473520961-GBM09E1LNCCCWTXXP3WL/Session+2b.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473521045-5J13DJOOBQFQ0FQ5HDMR/Session+2C.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473521934-1PB2M9A9PUEW7223N5J9/Session+3.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473522170-MXOBPEYPRNOHO2247ZXV/Session+4.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473522970-ENL8C14ETE1JJE7D17RQ/Session+5a.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473523762-LI37X8DD8KR2R4HJLQ5H/Session+5b.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473523662-0GQ46VJS2PAB50QT49FS/Session+6a.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473524426-9OACAM3QEKZWS4JXBIRO/Session+6b.JPG Screenshots https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601473524519-BCPAIWS5XJJWW5T7WRW3/Special+session.JPG Screenshots https://www.kdctmeeting.com/home-tremont daily 0.75 2025-05-12 https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1466111941034-GIIKB6HB6ADZB2O0D7HW/Stocksy_comp_461838.jpg Home https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1466119893918-X0SATSKR7JA3GP361K3R/Stocksy_comp_821143-crop.jpg Home https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1466120517882-GMTUN8QUTQPXD3SSUKAE/Stocksy_comp_486556.jpg Home https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1466120130465-9BNATBEVMW9VCWH2KMA2/Stocksy_comp_461841-color.jpg Home https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475298596761-AFLRXNLFCGXLKC1X3ZVD/image-asset.jpeg Home https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475298641096-U9QT0BCPH1WZ5V6RVG28/image-asset.jpeg Home https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475298692498-OR0RRZRYA5X3V1MX1E8R/image-asset.jpeg Home https://www.kdctmeeting.com/gallery-tremont daily 0.75 2025-05-12 https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475268649891-I1AX7P1PHMXALE5ZXLEL/Stocksy_comp_476031-darker.jpg Gallery https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475344293552-SYQMXWXICI526ZNT6NV6/15_I_FavaShucking_v2-135.jpg Gallery https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475086378753-D3Q7C4SYRFR9LQX78H5H/Stocksy_comp_821143-crop2.jpg Gallery https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475344319269-I7F3K5K5OY1KWTZG7KYA/65_AP_Gougeres_v2-127.jpg Gallery https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475083892334-KTZWGS0NASSAIC4BIUCG/Juice_RockNRolla.jpg Gallery - This is the image title caption This is the image description caption. Vestibulum id ligula porta felis euismod semper. https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475268631883-T2J2B3DVJHY3L2I4Z3Z9/Stocksy_comp_476031-darker.jpg Gallery https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475344291807-VF2BBNT3C7ZPQ3A7X7FH/2_2_HBL_BeurreCompose_v11-116.jpg Gallery https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475083821547-8BVC96CM4CF1KCYHOCZX/P_038.jpg Gallery https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475088749256-645IUUCVAMPQYIQSAPVK/Stocksy_comp_865498.jpg Gallery - This is the image title caption This is the image description caption. Donec sed odio dui. Donec ullamcorper nulla non metus auctor fringilla. https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1475088691825-RSYAUFCTHKQC1GNVT61U/54_E_Cassoulette_v1-331.jpg Gallery https://www.kdctmeeting.com/landing daily 1.0 2025-12-03 https://www.kdctmeeting.com/about daily 0.75 2019-05-03 https://www.kdctmeeting.com/publications daily 0.75 2018-02-26 https://www.kdctmeeting.com/schedule daily 0.75 2016-05-05 https://images.squarespace-cdn.com/content/v1/56d47d412b8ddea29eb012d8/1460740837580-S0L0R7CM13GK79QYW6YX/image-asset.png Schedule https://images.squarespace-cdn.com/content/v1/56d47d412b8ddea29eb012d8/1460741003978-L9H8HFU9KEYXM5CANZS6/image-asset.png Schedule https://images.squarespace-cdn.com/content/v1/56d47d412b8ddea29eb012d8/1460741014667-FZNFJ5WB363PFZEIGN2M/image-asset.png Schedule https://images.squarespace-cdn.com/content/v1/56d47d412b8ddea29eb012d8/1462461837176-5W86P1TT8ZNCOMZXZ907/image-asset.png Schedule https://www.kdctmeeting.com/feature daily 0.75 2017-03-26 https://images.squarespace-cdn.com/content/v1/56d47d412b8ddea29eb012d8/1461180000621-GJAAT1YX5BR5HIO1G89V/hero-20.jpg Feature https://images.squarespace-cdn.com/content/v1/56d47d412b8ddea29eb012d8/1460388281962-GD7BDJQYTVG5FO2KCTN7/image-asset.png Feature https://www.kdctmeeting.com/roy-chaudhury daily 0.75 2018-06-18 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1519051862482-BJWLBZKVX4Q7Z9SX2MGG/kdct+2018+Prabir+Roy-Chaudhury Co-directors https://www.kdctmeeting.com/luis-m-ruilop daily 0.75 2024-11-20 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1519050057279-KL7FTVNCTFW2W4YPA8UH/photo+Dr.+Ruilope.JPG Co-directors https://www.kdctmeeting.com/home daily 0.75 2026-01-09 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1664973387049-P2G147RVXWRLPYH3MCXH/unsplash-image-RFtxcP4odCc.jpg KDCT 2026 Workshop https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1710461914776-Q3MSAYLLP4ZY5C128ZE4/image-asset.jpeg KDCT 2026 Workshop - SAVE THE DATE 10th Kidney Disease Clinical Trialists Workshop April 10-11, 2026 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/70a5b063-fa1c-4bb2-b145-3ff01609d0d1/3.PNG KDCT 2026 Workshop - Invitation from Workshop Director Professor Patrick Rossignol https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/dc746c60-6452-48b9-a457-43a50aba593f/Group+photo+-+9th+edition KDCT 2026 Workshop Participants of the KDCT Workshop 2025 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1726842170331-C31SRY9SMER2AE0YGTZO/Rajiv%2BAgarwal%2BKDCT%2B2018.jpg KDCT 2026 Workshop - Rajiv AGARWAL https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1758624323719-HYR54HP0GI07L2HA47HH/Floege%252B2017.jpg KDCT 2026 Workshop - Jürgen FLOEGE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1710287290652-PJZ70DYDA06CGZP72A72/Meg+Jardine-May23-GeorgeFetting-009b-2.jpg KDCT 2026 Workshop - Meg JARDINE Meg JARDINE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1726841560893-AXLOX7SHOKISDQIHUMNS/Heerspink.jpg KDCT 2026 Workshop - Hiddo LAMBERS HEERSPINK https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1726841561245-7RURAPFF1SNJZ6SH4RIK/Levin.jpg KDCT 2026 Workshop - Adeera LEVIN https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060491802-UB8RCE0J3JLG2GCVB5H2/Matthieu+Legrand+photo.jpg KDCT 2026 Workshop - Matthieu LEGRAND https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599061073285-QRLE1ZSO21R92N9PAQNH/Vlado%2BPerkovic%2B2018%2BKDCT.jpg KDCT 2026 Workshop - Vlado PERKOVIC https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1710343237285-VPEYIV2VAF3OJJ8ZZMGK/Rossignol%2B.jpg KDCT 2026 Workshop - Patrick ROSSIGNOL https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1758623107935-LM95886FXNL0HD3ON2BM/Headshot+1.22.24.jpg KDCT 2026 Workshop - Brad ROVIN https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1726842170947-4S8W4H3MB5IYO97C1PZI/Roy-Chaudhury.jpg KDCT 2026 Workshop - Prabir ROY-CHAUDHURY https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1726842170084-T5TX12EW73AZQFUGTYRI/Luis-Ruilope.jpg KDCT 2026 Workshop - Luis RUILOPE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1709204173300-PK1M5NRULLPIRP0ABEKJ/210224_wanner_nephro_ukw_DSC_2179.jpg KDCT 2026 Workshop - Christoph WANNER https://www.kdctmeeting.com/termsandconditions daily 0.75 2025-09-23 https://www.kdctmeeting.com/co-directors daily 0.75 2020-09-01 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1518169166225-UHI0NTYXE6NNFMN5AAF6/photo+Rossignol.jpg Scientific Committee Patrick Rossignol (Nancy, France) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1518167556763-1VPO7CICV322FFCREKKX/AGARWAL_picture+2017.jpg Scientific Committee Rajiv Agarwal (USA) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1518168194092-9LKOETZGKOCSZNU4ZQQV/Bakris Scientific Committee George Bakris (USA) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1518168300607-567TU4VNP0EIEMH8HRLI/PERKOVIC_picture+2017.jpg Scientific Committee Vlado Perkovic (Australia) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1518168408911-1ATX3WOQPA0JP17S4GLQ/ROY+CHAUDHURY_picture+2017.jpg Scientific Committee Prabir Roy-Chaudhury (USA) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1519049464416-C143SW8B34UJTZK0MGBZ/photo+Dr.+Ruilope.JPG Scientific Committee Luis Ruilope (Spain) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1556896113065-887I6Y0UKTW4GASWDPVO/Wanner+larger.jpg Scientific Committee Cristoph Wanner (Germany) https://www.kdctmeeting.com/speakers daily 0.75 2018-02-22 https://www.kdctmeeting.com/patrick-rossignol daily 0.75 2024-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/e44de143-92ed-4d7f-a367-2a92d3b1b9e3/Rossignol+.PNG Patrick Rossignol - Patrick Rossignol Monaco, Monaco Course Director https://www.kdctmeeting.com/parking daily 0.75 2018-02-12 https://www.kdctmeeting.com/venue daily 0.75 2018-02-20 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1518450641768-ZYFWOBHXTUUHPGOQSR6F/CVCT+-+Jason+Dixson+Photography+-+135723+-+3594.jpg Venue https://www.kdctmeeting.com/vlado-perkovic daily 0.75 2024-11-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/39b139cb-2f21-48dd-9f14-cb5918305df3/2024-02-22-SH07-Vlado+Perkovic-0025.jpg Co-directors https://www.kdctmeeting.com/contact daily 0.75 2025-09-23 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599132289056-FGDPYS2430ZFBDTSLTPD/image-asset.jpeg Contact https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599133498480-OD2S0BX97YA600GSK92Q/logo_Overcome_vermillon-sans-soulign%C3%A9-V2.png Contact https://www.kdctmeeting.com/general-information daily 0.75 2018-06-12 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1528819933783-1HKNELGFZ7U1HZYAEO38/static1.squarespace.jpg How to get there https://www.kdctmeeting.com/rajiv-agarwal daily 0.75 2018-06-18 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1519052568292-41JYXB4SF7AAG1VB8R0P/Rajiv+Agarwal+KDCT+2018 Co-directors https://www.kdctmeeting.com/terms-of-use daily 0.75 2018-10-18 https://www.kdctmeeting.com/cookies-policy daily 0.75 2018-09-25 https://www.kdctmeeting.com/cristoph-wanner daily 0.75 2024-11-25 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/28c9f376-3db3-4515-bed8-78d96cf47d22/Image1.jpg Christoph Wanner https://www.kdctmeeting.com/registration daily 0.75 2024-12-02 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599145258394-DZPX2O3RNTGYYMEM60Z5/image-asset.jpeg Registration https://www.kdctmeeting.com/academia daily 0.75 2025-04-24 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599131245051-2M9KC0YGI2AYPMWQ17UE/image-asset.jpeg Academia https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745501773432-BCB8YLHUOMMQ7KUF0UX7/ascanihk%40med.umich.edu.jpeg Academia - Heather ASCANI Dr. Heather Ascani has been the Director of Business Strategy at the University of Michigan’s Kidney Translational Medicine Center (MiKTMC) since 2014. Over the past 30 years, Heather has cultivated a rich background in business, having accumulated extensive experience in strategy, business development, international marketing, and account management spanning the automotive, biotech, and pharmaceutical spheres. In her current role, she is instrumental in fostering public-private partnerships between academia and the private sector, overseeing key strategic, financial, and operational initiatives at MiKTMC to ensure continuous, positive impact in the field of Nephrology. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745501954364-LIZWOJNULO19B12UKS72/gordana.atanackovic%40bayer.com.png Academia - Gordana ATANACKOVIC Gordana Atanackovic is a pediatrician, who earned both her Medical Degree and Pediatric Specialty from the University of Belgrade, Serbia. Prior to relocating to Canada, she practiced pediatrics for seven years. She further advanced her expertise by completing a Clinical Pharmacology Fellowship at the Hospital for Sick Children, University of Toronto, before transitioning into the pharmaceutical industry. With over 20 years of experience in the pharmaceutical industry, Gordana began her journey at Bayer in 2006 as the Head of Medical Affairs in Canada. Throughout her career, she has successfully led Medical Affairs teams across multiple therapeutic areas, including women’s health, anti-infectives, diagnostic imaging, oncology, and thrombosis/cardiology. In 2015, Gordana relocated to the United States to join Global Clinical Development, women’s health. Since March 2024, she joined Pediatric Clinical Development, focusing on studies for children with chronic kidney disease and finerenone study FIONA. Gordana remains committed to driving innovative strategies and achieving superior outcomes in clinical development. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634721617085-RZEBBKVJAPCXNMCBRQ2K/bagshaw.jpg Academia - Sean BAGSHAW Dr. Bagshaw is a Clinician Scientist and Chair and Associate Professor of Critical Care Medicine in the Department of Critical Care Medicine, University of Alberta. He trained at the University of Calgary (Internal Medicine, Critical Care Medicine, Masters of Science Epidemiology) and the Austin Hospital (Critical Care Nephrology) in Melbourne, Australia. Dr. Bagshaw has been supported by a Canada Research Chair in Critical Care Nephrology (Tier 2 - Renewed). He has research expertise in epidemiology, clinical trials and health services research. His research focuses on acute kidney injury, vulnerable populations (e.g., elderly, frail), ICU organization and capacity. He has published over 300 peer-reviewed papers, numerous book chapters, and peer-reviewed for over 30 medical journals. Dr. Bagshaw is a member of several organizations including the Canadian Critical Care Society, Canadian Critical Care Trials Group, and the Acute Dialysis Quality Initiative. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745502193042-JEA14SDNQ9N1Q23G3TJE/jonathan%40jonathan-barratt-consulting.co.uk.jpg Academia - Jonathan BARRATT https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772548096270-VZ0B295JPP0OYO37NUGG/Michael+Basson.jpg Academia - Michael BASSON Michael was a graduate student at UC Berkeley and a post doc at MIT, following which he worked in biotech on early stage target discovery. Michael has been an editor at Nature Medicine since 2003, handling manuscripts in kidney disease, cardiovascular disease, aging, xenotransplantation and personalized medicine. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772548416699-I91BLOKSQ1GJUD0VK5HA/Brian+Becknell.jpg Academia - Brian BECKNELL Brian Becknell, MD, PhD, is a pediatric nephrologist and physician scientist at Nationwide Children's Hospital and Research Director of the Kidney and Urinary Tract Center at the Abigail Wexner Research Institute in Columbus, Ohio. He received his medical and PhD degrees from The Ohio State University (OSU), followed by pediatric residency and pediatric nephrology fellowship. He is currently an Associate Professor of Pediatrics in the College of Medicine at OSU. His clinical and research interests are focused on congenital anomalies of the kidney and urinary tract (CAKUT), which account for over half of children with CKD. Despite strides in comprehending the underlying causes of CAKUT, there has been inadequate progress in managing its complications and preventing CKD progression. This fuels Brian’s drive to improve health outcomes for children with CAKUT. Brian lives in Columbus, Ohio with his wife and four children. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706172097998-6XPOUCGQZO08UTOKSZQC/DSC_0472_Portrait.jpg Academia - Peter BLANKESTIJN Peter J. Blankestijn worked as a nephrologist at the department of Nephrology and Hypertension of the University Medical Center Utrecht, the Netherlands. He was principal investigator of several multicenter studies, including SMASH, MASTERPLAN, CONTRAST, SYMPATHY and CONVINCE. He received multiple grants of (inter)national funding agencies as well as of pharmaceutical, dialysis and medical devices industries. He acquired a large grant in the HORIZON 2020 program of the European Commission as chair of the CONVINCE consortium. He is (co)author of approximately 380 papers in peer reviewed scientific medical journals. Since 2017/2018, he is active on a national and international level in creating awareness for the interaction between climate change/environmental pollution and health/disease. He has been a speaker on various medical subjects also including the environmental impact of health care in many meetings all over the globe both in the medical field but also in the non-medical field, including policy makers, members of the European Parliament and others. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1767695446789-TBFCNNJLJOG2FGXM0LK5/Headshot_PB%5B54%5D.jpg Academia - Petter BJORNSTAD Dr. Petter Bjornstad is Executive Director of the UW Medicine Diabetes Institute, Professor of Pediatrics and Medicine, and the Raisbeck Endowed Chair of Diabetes Research at the University of Washington. He is an internationally recognized clinician-scientist leading a bench-to-bedside research program renowned for innovation in understanding diabetic kidney disease and its prevention. Dr. Bjornstad’s career is defined by three interconnected themes: (1) pioneering research kidney biopsies to reveal DKD at molecular resolution, (2) developing novel imaging biomarkers to detect early metabolic perturbations, and (3) translating discoveries into mechanistic clinical trials. By integrating single cell and spatial omics with hyperinsulinemic-euglycemic clamps, multiparametric MRI, and C-11 acetate PET, his group has uncovered sub-clinical metabolic injury and actionable pathways long before conventional markers signal decline. An author of more than 220 peer reviewed papers that span NEJM, Nature, JCI, and Circulation, Dr. Bjornstad sustains continuous federal support from NIH while leading foundation and industry collaborations. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745502327162-7RR39K5RD11Q8N81LE7L/jbonventre%40bwh.harvard.edu.jpeg Academia - Joseph BONVENTRE Dr. Bonventre is the Samuel A. Levine Distinguished Professor of Medicine at Harvard Medical School, Constantine L. Hampers MD Endowed Chair in Renal Medicine, Chief of Renal Medicine and Founding Chief of Engineering in Medicine at Brigham and Women’s Hospital. He is a former Harvard Director of the Harvard-MIT Division of Health Sciences and Technology. His research has been focused on the study of kidney injury and repair with a special focus on inflammation, translational biomarkers and stem cells. He discovered that the KRAB-A domain inhibits transcription, a key component of CRISPRi technology. He discovered Kidney Injury Molecule-1 (KIM-1), a urinary and plasma injury and malignancy diagnostic and prognostic biomarker. He has created protocols to convert human stem cells to kidney tissue. He has more than 450 original publications, more than 155 chapters and reviews and 3 books. His work has been referenced more than 98,000 times (h-index of 156). He has been elected to the American Society for Clinical Investigation, the Association of American Physicians and the American Institute for Medical and Biological Engineering. Dr. Bonventre is a Past-President of the American Society of Nephrology and founding member of the Board of Directors of the National Space Biology Research Institute. He has won a number of awards including the Homer Smith Award of the American Society of Nephrology, the Osler Medal of the Royal Society, the Bywaters Award from the International Society of Nephrology and the Massry Award from the National Kidney Foundation. His research has been continuously supported by the NIH and he has been awarded two MERIT awards from the NIDDK. He served as a member of the Advisory Council of the NIH-NIDDK. Dr. Bonventre is Editor of the journal, Seminars in Nephrology. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634723826820-X0VZDGUPKABVXV9D9U4G/Capture.jpg Academia - Kirk CAMPBELL Kirk Campbell, MD, is Professor of Medicine, Vice Chair for Diversity, Equity and Inclusion and Director of the Nephrology Fellowship Program. He is board certified in Nephrology. Dr. Campbell is a graduate of the University of Connecticut School of Medicine and completed residency training in Internal Medicine at Yale-New Haven Hospital followed by a clinical and research fellowship in Nephrology at Mount Sinai. In addition to treating patients with kidney disease, Dr. Campbell leads an NIH-funded research program focused on developing new therapeutic interventions for proteinuric diseases. He actively participates in clinical trials testing novel agents for primary glomerular disease and is an elected member of the American Society for Clinical Investigation. He is a Past-President of the New York Society of Nephrology, a member of the Board of Directors of the Nephcure Foundation, a standing member of the Pathobiology of Kidney Disease (PBKD) study section at the National Institutes of Health, the Medical Advisory Board of the National Kidney Foundation of Greater New York. He has served on the American Society of Nephrology Grants Review and Kidney Week Education Committees. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634559859455-PWQXW06MNI5W40XUCUMC/CV+Photograph.PNG Academia - Jonathan CASEY Dr. Jonathan Dale Casey received his baccalaureate degree (2006) in chemistry from Vanderbilt University and his MD (2010) from the University of Louisville School of Medicine, where he was the top overall graduate. During his residency from 2010-2013 at Brigham and Women's Hospital in Boston, he garnered awards for empathetic patient care and was also named Chief Resident in 2015. In 2019 Dr. Casey completed the fellowship program at Vanderbilt in pulmonary and critical care medicine. He is an excellent teacher and was presented the Roger Des Prez Award for Teaching Excellence in 2017. He further enhanced his knowledge of epidemiology, biostatistics, and clinical research during his fellowship by completing a Master of Science in Clinical Investigation (May 2019). Jonathan Casey is driven toward long-term success as a researcher. Under the direction of his mentors, Matt Semler, Todd Rice, and Gordon Bernard, he has devised novel and efficient research methodologies to study fluid management, airway management, oxygen targets, and post-extubation respiratory support. He is adept at the design, conduct, and analysis of clinical trials and has served as principal investigator on several. Dr. Casey has helped to develop the Pragmatic Critical Care Research Group, a clinical trial network of clinical researchers in 20 intensive care units and emergency departments in the U.S. He serves a critical role within the network as head of the clinical coordinating center. In addition to providing experience in the administration of large, multicenter trials, this position provides opportunities to design and lead large multicenter clinical trials. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634724358814-CG1N4C7IEZ3TNIGPW9QT/david-m-charytan-square.jpg Academia - David CHARYTAN David M. Charytan, MD, an internationally renowned clinician and researcher in the field of cardio–renal disease, recently joined the Department of Medicine at NYU Langone Health as director of the Division of Nephrology.Dr. Charytan joins NYU Langone Health from Brigham and Women’s Hospital, where he most recently served as a physician in its renal division and Director of ICU Nephrology. He also held the position of associate professor of medicine at Harvard Medical School and served as director of renal research at the Baim Institute for Clinical Research, an affiliate of Harvard and its five teaching hospitals. In addition to his clinical responsibilities, Dr. Charytan oversees the division’s research, including his own ongoing studies examining the connections between chronic kidney disease and heart disease, the leading cause of death in people with kidney failure. His particular focus is on arrhythmia in dialysis patients and investigating new therapies to minimize the risk of cardiovascular events for people with end-stage kidney failure. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634724682526-TAV5CN4UZJCECF9IPVTP/photo.jpg Academia - Steven COCA Steven G. Coca, DO, MS, is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, the Associate Chair for Clinical and Translational Research for the Department of Internal Medicine, and the Director of Clinical Research for the Division of Nephrology. Dr. Coca’s research accomplishments are diverse and far-reaching: he has focused research efforts on short- and long-term outcomes of acute kidney injury, and assessing performance of biomarkers for rapid diagnosis and risk stratification in AKI. His research has advanced understanding of the clinical utility of prognostic, predictive, and efficacy biomarkers for CKD/diabetic kidney disease in several large cohort studies, including ACCORD, VA NEPHRON-D, CANVAS, and the Mount Sinai BioMe Biobank. Most recently, he has collaborated to advance use of machine-learning techniques and multidimensional data acquisition to create risk-stratification tools for patients at risk or with prevalent chronic kidney disease, and studied the impact of exercise on longitudinal changes in the kidney. Since 2005, Dr. Coca has published numerous peer-reviewed research articles, reviews, and editorials, and has given numerous invited talks at national and international conferences and academic medical centers. He has engaged in multiple collaborative efforts in translational and clinical research, and served as a research mentor for many fellows, residents, medical students, and junior faculty members. He also serves on the editorial boards for the Journal of the American Society of Nephrology, the Clinical Journal of the American Society of Nephology, and Kidney International, and as an Associate Editor for Kidney360, and is a frequent reviewer on NIH study sections. Dr. Coca received his D.O. degree from the University of New England College of Osteopathic Medicine, and completed his residency and nephrology fellowship at the Yale University School of Medicine. He received his Master of Science in Epidemiology and Public Health from the Yale University Graduate School of Arts and Sciences. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745502450656-A12WWBY07G7A2KVGHAHW/josef.coresh%40nyulangone.org.jpg Academia - Josef CORESH Dr. Coresh is the Founding Director of the Optimal Aging Institute and the Terry and Mel Karmazin Professor of Population Health and Medicine at NYU Grossman School of Medicine. The institute leverages epidemiologic cohorts to advance discovery, prevention and treatment of aging related diseases. Dr. Coresh continues to co-lead of the ARIC Neurocognitive Study (MPI: Coresh/Mosley. Chair: Gottesman) renewal (2023-2028) and CKD Prognosis Consortium (2023-2028; MPI: Coresh/grams) as well as start new initiatives. Dr. Coresh is an international expert in aging and vascular disease epidemiology of the brain, heart and kidney, using a range of epidemiology and data science methods. Dr. Coresh is among the most cited researcher having co-authored articles cited over 300,000 times according to Google Scholar. He received the top scientific and patient impact awards of the US National Kidney Foundation (Eknoyan and Hume awards) and American Society of Nephrology (Belding Scribner award). His devotion to mentorship was recognized by awards from Johns Hopkins University and the American Heart Association. Dr. Coresh leads the ARIC Neurocognitive Study with over 15,000 people ages 45-65 years followed for >30 years. He spearheaded the proteomic components which includes over 150 Million longitudinal measurements connected to the rich data including dementia, brain MRI and PET studies. He also co-leads the Aging and Cognitive Health Evaluation in Aging (ACHIEVE) clinical trial which randomized 977 individuals to hearing rehabilitation vs. health aging control intervention and published it main results in Lancet in 2023. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634724798473-A64I6HAB4ZEMUPH49JOL/Dr-Adrian-Covic-PixTeller.jpg Academia - Adrian COVIC Prof. Covic started his clinical and research activity as a fellow in Nephrology in Manchester and Amiens. Later he performed clinical research at the Case Western University in Cleveland, Ohio. He received a Ph.D. on cardiovascular abnormalities and its determinant factors in chronic renal failure in 1997. Since 2007, he is a FRCP (London) and became in 2009 a member of the Romanian Academy of Medical Sciences. From 2011 he is also a Fellow of the ERA EDTA (FERA). Prof. Covic is a Professor of Nephrology and Internal Medicine at the “Grigore T. Popa” University of Medicine and Pharmacy, the Director of the Nephrology Clinic and the Dialysis and Transplantation Center in Iasi, Romania and Vice-Rector of the University of Medicine “Gr. T. POPA” Iasi, Romania. Prof. Covic published more than 370 original and review papers in peer-reviewed journals, 14 books and 22 chapters. The current Hirsch Index is 43. He is an Associate Editor for NDT, and Editor in Chief (Nephrology) for the International Journal of Urology and Nephrology, and editor / reviewer for several prestigious journals. His main areas of interest are: cardiovascular complications in renal disease, renal anaemia, CKD-MBD, peritoneal dialysis, and acute renal failure. Prof. Covic is the president of Romanian Society of Nephrology and a board member of KDIGO, ERBP, ERA-EDTA working group - EURECAM and ISN/COMGAN. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634724980485-PNPIHW5V8WD61PYIS7ZS/51A%2BW65q9eL._SX450_.jpg Academia - John DAUGIRDAS John T. Daugirdas, MD is a nephrologist who for a number of years has been interested in how best to treat patients who have chronic kidney disease with various forms of dialysis therapy. Currently he is Clinical Professor of Medicine at the University of Illinois at Chicago, where he has received the Chicago Top Doctor Award for multiple years. His research activities include participation in two NIH/NIDDK sponsored studies, the HEMO Trial and the Frequent Hemodialysis Network Trials, and he was involved in the group that designed the Chronic Renal Insufficiency Cohort Trial. Currently, Daugirdas is studying how much dialysis to give using various schedules, as well as factors affecting blood volume and blood pressure during hemodialysis. He also has a special interest in nutrition as it applies to chronic kidney disease and phosphorus balance. Daugirdas has a particular interest in medical education, and is Co-Editor of the Handbook of Dialysis and Editor of the Handbook of Chronic Kidney Disease Management. He is founding editor of the educational website: Hypertension, Dialysis, and Clinical Nephrology. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772549193066-DF9YXUFF0BUE7HL4DZZ9/221_KRI+cropped.jpg Academia - Ian DE BOER Dr. de Boer is Professor of Medicine, Director of the Kidney Research Institute, Joseph W. Eschbach MD Endowed Chair in Kidney Research, and Adjunct Professor of Epidemiology at the University of Washington in Seattle, WA. He is also a staff nephrologist at the Veterans Affairs Puget Sound Health Care System, where he cares for patients with a broad range of acute and chronic kidney diseases. Dr. de Boer’s research focuses on the causes and consequences of diabetic kidney disease. Particular areas of contribution include the epidemiology of diabetic kidney disease, prevention and treatment of kidney disease in diabetes, metabolic abnormalities in chronic kidney disease, and mineral metabolism and cardiovascular disease. Research methods span clinical epidemiology, physiology studies, and clinical trials. Dr. de Boer has published over 450 manuscripts in the field. He has also helped translate research to clinical care through clinical practice guidelines, including the American Diabetes Association Standards of Medical Care in Diabetes (as a member of the ADA Professional Practice Committee) and the KDIGO Clinical Practice Guideline on Diabetes and CKD (as Co-Chair). He served as a standing member on multiple NIH scientific review groups and as Deputy Editor of the Clinical Journal of the American Society of Nephrology. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060176051-BVB95L2ERT0OCHTQDME5/dember_laura.jpg Academia - Laura DEMBER Laura M. Dember, M.D. is a Professor of Medicine and Epidemiology at the University of Pennsylvania Perelman School of Medicine where she is a faculty member in the Renal-Electrolyte and Hypertension Division, a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics, and the Director of the Certificate Program in Clinical Research. Dr. Dember conducts patient-oriented research in chronic kidney disease with a particular focus on interventions to improve clinical outcomes for patients treated with maintenance hemodialysis. She has held leadership roles in several multicenter clinical trials and observational studies including the Dialysis Access Consortium, the Hemodialysis Fistula Maturation Study, the Hemodialysis Novel Therapies Consortium, and the Chronic Renal Insufficiency Cohort study, and the HOPE Consortium trial, all funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). As the Principal Investigator for the NIH Time to Reduce Mortality in End-Stage Renal Disease trial (TiME), Dr. Dember played an important role in introducing to the Nephrology community large pragmatic trials embedded in clinical care delivery, an effort that she is continuing as a Co-Investigator for the NIDDK HiLo trial. Dr. Dember has led projects for the Kidney Health Initiative, a public-private partnership spearheaded by the American Society of Nephrology and the FDA to facilitate innovation in kidney disease treatments, and is a Deputy Editor for the American Journal of Kidney Diseases. Dr. Dember is a graduate of Yale University School of Medicine and completed her internal medicine residency training at the University of Pennsylvania and nephrology fellowship training at Penn and Brigham and Women’s Hospital. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772549737700-HX0LTNCP7RTIFJ7UYCD0/ME-2.jpg Academia - Marie EGGERS https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599147159544-V28ZZ4CZU3E4CXO243AN/harv-feldman-e1460999211796.jpg Academia - Harold FELDMAN Harold (Harv) Feldman, MD, MSCE is the George S. Pepper Professor of Public Health and Preventive Medicine, a Professor of Epidemiology and Medicine (nephrology), and the Director of the Center for Clinical Epidemiology and Biostatistics (CCEB) at the University of Pennsylvania (Penn). Dr. Feldman earned his MD in 1982 from Boston University before training in Internal Medicine at UCLA, as well as nephrology and Clinical Epidemiology at the Penn. He is the former chair of the Department of Biostatistics, Epidemiology, and Informatics at Penn and Past-President of the American College of Epidemiology. He is currently the Editor-in-Chief of the American Journal of Kidney Diseases. Dr. Feldman has led NIH's Chronic Renal Insufficiency Cohort Study (CRIC) for 20 years. Under his leadership, CRIC has extensively published on numerous discoveries with great promise to advance development of novel therapies to reduce morbidity in this population worldwide. For ten years, Dr. Feldman has also led the Scientific and Data Coordinating Center for NIH’s principal initiative addressing biomarkers in chronic kidney disease, the CKD Biomarkers Consortium. His published scholarship of more than 300 research publications has appeared in many leading biomedical journals. It has been recognized through membership in the American Society of Clinical Investigation, the Association of American Physicians, and the American Epidemiological Society. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745502804218-8ELBZ9268KPHLGOCIGVC/bfernandez%40fjd.es.jpeg Academia - Beatriz FERNANDEZ FERNANDEZ Beatriz Fernández-Fernández, MD, PhD, FERA, staff nephrologist at IIS-FJD, head of the DKD clinic, nephrology coordinator of Cardiorenal unit and Assistant Professor in Medicine in Universidad Autónoma (Madrid). Expertscape already identifies her as one of the top 40 European and top 4 Spanish researchers in the DKD field according to her publication track record of the most recent 10 years. Scientist-Physician and Researcher in the Nephrology, Vascular Pathology, Hypertension and Diabetes group (IIS-FJD). Chair of CME of ERA, board member of EURECAm (European Renal and cardiovascular medicine), and GEENDIAB (Spanish Diabetic Nephropathy Group) coordinator and member of Strong Kidneys Task force (ERA). Main interested in chronic kidney disease (CKD), cardio-kidney metabolic diseases (CKM), diabetic kidney diseases (DKD) and their implications in special populations as well as gender differences. She is a PI for Spanish and EU projects. More than 90 publications in scientific Journals: h-Index 32(WOS)/38(Google Scholar-GS, h-index i10:59). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772549987569-TJQU60QASKXTOUXSNMWW/SJW_7218.jpg Academia - John FLACK Dr. John M. Flack, the Sergio Rabinovich Endowed Chair of Internal Medicine, joined SIU School of Medicine in 2015 and currently serves as the Professor and Chair of the Departments of Medicine and Population Science and Policy. Dr. Flack is an American Society of Hypertension-certified specialist in clinical hypertension and also serves as the president of the American Hypertension Specialist Certification Program. He has published more than 250 peer reviewed manuscripts and book chapters including the chapter on “Arterial Hypertension” in the current edition Goldman Cecil’s textbook of Medicine . His H-index is 51 and his work has been cited more than 15,000 times (Mendeley Statistics). Dr. Flack, an internationally renowned hypertension specialist/cardiovascular epidemiologist, has special interest and expertise in the development of clinical translational research programs; the clinical epidemiology and treatment of of complex hypertension with an emphasis on primary aldosteronism, resistant and refractory hypertension as well as hypertension therapeutics in African Americans; the transformation of clinical practice sites for quality, equity and financial performance; and the development of embedded educational systems within clinical practices. He is an active researcher, most recently in device-based treatment (renal denervation) of severe, uncontrolled resistant/refractory hypertension, and serves on Several NIH and American Heart Association scientific peer-review panels including the Integrative and Clinical Endocrinology and Reproductive Biology study section. He was previously an associate editor of the American Journal of Hypertension. Currently he is an associate editor of the journal Hypertension, the premier hypertension journal in the world. He is Vice Chair of the Bax Hypertension Trial steering committee, a multi-continent study of a novel aldosterone synthase inhibitor drug (Baxdrostat) for the treatment of uncontrolled hypertension. Dr. Flack earned his bachelor’s degree in chemistry from Langston University (1978). He received his medical degree and internal medicine residency training, also serving as chief resident, at the University of Oklahoma School of Medicine (1982 - 1986). He later completed a National Heart Lung and Blood Institute postdoctoral research fellowship in cardiovascular epidemiology (1990) and earned an MPH in epidemiology at the University of Minnesota School of Public Health (1990). Prior to his appointment at Wayne State, he served on the faculties of the University of Oklahoma School of Medicine, the University of Minnesota Schools of Medicine and Public Health and Wake Forest University School of Medicine in Winston Salem, North Carolina. Among his many honors, Dr. Flack has been named a “Top Doctor” from the Who’s Who Global Directory, was named one of Detroit’s “Super Doctors” and was Academic Physician of the Year from Oklahoma University School of Medicine. In 2009, the Detroit News named him Michiganian of the Year. Dr. Flack was recently conferred the Status of Master by the American College of Physicians (ACP) and was awarded the Laureate Award by the Illinois Downstate Chapter. Dr. Flack is also a former member of the ACP Board of Regents. He maintains an active clinical practice in complex hypertension at SIU where he teaches and mentors medical students and residents and undertakes innovative, cutting edge clinical and translational research. Dr. Flack authored the 2023 chapter on Arterial Hypertension in the top Internal Medicine textbook in the world, Cecil’s Textbook of Medicine. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745502980464-6W8NZ9GKE6QRAPO1YERT/jfloege%40ukaachen.de.jpg Academia - Jürgen FLOEGE Professor Jürgen Floege is Senior Professor at the RWTH Aachen University Medical School, Germany. He is a former executive council member of the International Society of Nephrology (ISN), the European Renal Association (ERA-EDTA), and KDIGO, recipient of the 2018 ERA-EDTA Award for Outstanding Clinical Contributions to Nephrology and past-president of the German Society of Nephrology and the German Society of Internal Medicine. He co-edits the best-selling textbook “Comprehensive Clinical Nephrology”. Finally, Professor Floege is associate editor of Kidney International and editor-in-chief of Clinical Kidney Journal. Research interests encompass the progression of kidney disease in particular renal fibrosis, as well as clinical research in immune-mediated renal disease, in particular IgA-nephropathy, as well as bone and mineral disorders (CKD-MBD) and cardiovascular disease in uremic patients. He coordinates the KDIGO world-wide guidelines on the management of glomerular diseases. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634725579999-GLCATRPGWJ5VX4HZCT1J/jenny-flythe.jpg Academia - Jennifer FLYTHE Dr. Flythe’s research interests include identifying and understanding modifiable mortality determinants among maintenance dialysis patients and developing innovative treatment strategies to reduce these risks. She is particularly interested in hemodialysis procedural risk factors. The majority of her work focuses on dialysis hemodynamics, fluid management, and blood pressure patterns among maintenance hemodialysis patients. She also incorporates patient-centered outcomes and patient preferences into her work to ensure that patient-stated priorities drive outcomes research. At UNC, Dr. Flythe is involved in the management of acute and chronic kidney disease patients with a focus on hemodialysis patients at the UNC Hospital and Kidney Center and its associated outpatient dialysis facilities. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745503148017-ID9OL1F2AO7NTNAO1LGP/tim.friede%40med.uni-goettingen.de.jpg Academia - Tim FRIEDE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745503252725-UVDHZTOHB4Q6KZ4QRKGY/marc.froissart%40chuv.ch.jpg Academia - Marc FROISSART Marc Froissart is currently professor of clinical research at the University Hospital of Lausanne (CHUV-UNIL), Switzerland. There he built the Clinical Research Center, a transversal facility providing support to the research community within the Swiss Clinical Trial Organization overarching network. Marc currently coordinates the nephrology and transplantation research team in Lausanne. As a nephrologist, nuclear medicine specialist and epidemiologist by training, he naturally focused his early research interests on measuring GFR and assessing CKD through cohort studies. Marc then joined Amgen European headquarters in Switzerland acting as clinical research medical director before returning to academia in Lausanne. His clinical research activities covered observational studies (NephroTest ND-CKD cohort, ARO initiative HD cohort), participation to research consortia (CKD-EPI, CKD-PC) and interventional trials either acting as investigator or sponsor medical lead. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1741877836563-CN0GWR79TPDP4A8BGNH0/Dana+Fuhrman.jpg Academia - Dana FUHRMAN Dr. Dana Fuhrman is an Associate Professor in the Department of Critical Care Medicine and Pediatrics at the University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh. She completed her pediatric residency training, chief residency, and pediatric nephrology fellowship at the University of Rochester, where she received a Master of Science in Clinical Investigation and was a T32 Trainee Grant recipient. She subsequently completed a pediatric critical care medicine fellowship at the University of Pittsburgh in 2015. She clinically practices both pediatric nephrology and critical care medicine at the Children's Hospital of Pittsburgh. She is currently the Program Director for the Pediatric Critical Care Medicine Fellowship Program and Director of the Continuous Renal Replacement Therapy and Acute Care Nephrology Programs in Pittsburgh. In 2019, she received a NIDDK K23 to study methods to predict and prevent kidney disease in young adults with congenital heart disease. Her research interests focus on developing diagnostic tools to predict acute kidney injury, the acute kidney injury to chronic kidney injury transition, and methods to improve the delivery of continuous renal replacement therapy. She has authored over 60 peer-reviewed publications and has spoken at numerous national and international meetings. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634725357058-YSY4EX467FFJE8RN4LKX/g_102_email.jpg Academia - Martin GALLAGHER Professor Gallagher’s research interests include large scale clinical trials exploring ways to improve outcomes of kidney patients with a focus on acute kidney injury, long term treatment effects, and applying research evidence into practice. He is Associate Professor, Faculty of Medicine, UNSW, Sydney; Director of the Renal and Metabolic Division in The George Institute for Global Health; and a clinical nephrologist in the Renal Dept. at Concord Repatriation and General Hospital. He works extensively in the ANZ Society of Nephrology in renal guidelines and clinical policy. Professor Gallagher is interested in the use of multi-disciplinary approaches and innovation to address major non-communicable health threats and works extensively in renal guidelines and clinical policy. At The George Institute for Global Health, he serves as Program Director, Acute Kidney Injury and Trials. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706172398244-X4Y6NFHSHV6A78H9ZOKM/Bruno.jpg Academia - Bruno GARCIA Dr. Bruno Garcia is specialized in internal medicine and critical care medicine in Lille, France. He completed his Ph.D. at Erasme Hospital, Brussels, Belgium, under the guidance of Prof Jacques Creteur and Prof Fabio Taccone, vice-chair of the ISICEM congress. His research is centered on the impact of both the classical and alternative renin-angiotensin systems during sepsis, using large experimental models and clinical studies. He spent 6 months working at the University of California, San Francisco, under the guidance of Prof Matthieu Legrand, focusing on the relationship between renin-angiotensin system disturbances and acute kidney injury in various conditions. Dr. Garcia is also an active member of the French College of Critical Care Medicine, contributing to various educational books, and is a member of the Young French Society of Critical Care Medicine. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706172434344-QNWL89CT4J0KX8QXU9BI/Amit+picture.jpg Academia - Amit GARG Dr. Amit Garg is the Associate Dean for Clinical Research at the Schulich School of Medicine & Dentistry, Western University in London, Ontario, Canada, where he is also a Professor of Medicine, Epidemiology and Biostatistics. He serves as a staff nephrologist at the London Health Sciences Centre, and his clinical activities include on-call hospital-based care for a renal ward and consult service, in-centre hemodialysis care, and outpatient clinics (general nephrology, advanced chronic kidney disease, and living kidney donor evaluation clinics). Working in teams, Dr. Garg conducts clinical and health services research to improve health outcomes for patients with chronic kidney disease (over 725 publications, h-index 120). A current research focus is on pragmatic, large, randomized trials, and he currently serves as the lead investigator of a pan-Canadian training program to build capacity with these methods (in all areas of healthcare). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634726263486-P29EKOOSCFRBDYZ7IWTM/cropped-cropped-cropped-cropped-cropped-Photo-S-GAUDRY-rotated-1-1.jpg Academia - Stéphane GAUDRY Stéphane Gaudry is full-time physician in the critical care department at Louis Mourier hospital (Assistance Publique – Hôpitaux de Paris). He has published on many aspects of critical care, mainly respiratory care and renal and metabolic problems in the ICU. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745504204176-EMGVTZBXLDRJMN7QF8ED/flavia.geraldes%40lancet.com.jpg Academia - Flavia GERALDES Flávia Geraldes is Senior Editor at The Lancet. She is one of the journal’s Cardiology Ambassadors and a member of The Lancet’s Fast Track team, handling high-impact submissions requiring fast turnaround. In addition to cardiology, her main topic of interest is oncology, but she handles a wide range of manuscripts on clinical topics, especially randomised clinical trials. Prior to joining The Lancet in 2020, she worked as Journal Development Specialist for the open access journal Frontiers in Oncology, and before that she was Scientific Officer at the Division of Clinical Studies of the Institute of Cancer Research (London, UK), where she worked on DNA sequencing studies for phase 1 and 2 clinical trials of targeted therapies for ovarian, lung, and prostate cancer. Flávia holds a degree in Biomedical Science in Histocellular Pathology from the Polytechnic Institute of Lisbon, Portugal. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745504311152-Y5I2IITSQ0GK0W73GLTU/barbara.gillespie%40fortrea.com.jpg Academia - Barbara GILLESPIE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745504414985-DJQ97O7PNVT8MCK7QRZJ/Gipson.Debbie.jpg Academia - Debbie GIPSON Debbie (Deb) Gipson, MS, MD is a program director for precision clinical trials at the National Institutes of Health, National Institutes of Diabetes, Digestive, and Kidney Diseases. She is a pediatric nephrologist with expertise in epidemiology, clinical trials, and patient reported outcomes for all ages. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706172457169-0CUC6P2WE9HYXIGXW9WU/algorithms_shoot_CloseUpWideSmile.jpg Academia - Tom GREENE Dr. Tom Greene is an H.A. and Edna Benning Endowed Professor of the Division of Biostatistics in the Department of Population Health Sciences at the University of Utah. Dr. Greene received his PhD in Statistics from Cornell University in 1985. He served as a statistician at Case Western University and the Cleveland Clinic Foundation from 1989 through 2006, where he was the lead statistician on multi-center clinical trials in Nephrology. Dr. Greene moved to the University of Utah in 2006, where he founded the Study Design and Biostatistics Center and subsequently the Translational Science: Implementation, Analysis and Design (TRIAD) team. Dr. Greene carries out methodological research in the areas of clinical trial design, causal inference, and validation of surrogate endpoints. He is interested in the problem of integrating information from multiple surrogate and clinical endpoints to evaluate treatment efficacy in randomized clinical trials. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634726963490-E1D40NZVFVUQDWWYSM8N/cj5ms4mip000oqwu0ah0vyoy7-harhay.0.162.956.956.full.jpg Academia - Michael HARHAY Michael Harhay, PhD, MPH is an Assistant Professor of Epidemiology and Medicine at the University of Pennsylvania. He is also a core faculty member in Penn’s Palliative and Advanced Illness Research (PAIR) Center, where he directs the PAIR Center Clinical Trials Methods and Outcomes Lab. He is the author of more than 150 scientific publications and leads a research program that primarily focuses on topics related to the design and analysis of randomized trials, missing data, and statistical epidemiology. He is the primary investigator of several research projects, including grants from the National Institutes of Health (NIH) and the Patient-Centered Outcomes Research Institute (PCORI). His funded projects focus on two separate but related areas to improve outcomes for patients with critical and serious illnesses, such as sepsis, acute respiratory failure, and other end-stage organ diseases. First, he develops statistical and causal inference methods to analyze informatively missing or censored outcomes in individually- and cluster-randomized trials. Second, he and his team are developing patient-centered outcome measures to improve the efficiency and patient-centeredness of randomized trials. Dr. Harhay is also a principal investigator or collaborator for several national and international cohort studies seeking to develop interventions and new approaches for measuring long-term outcomes after hospitalization for critical illness. These projects increasingly include a molecular and immunological focus on the recovery from critical illness, with collaborators from Penn and the UK. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634730956073-BENUH4A1Z0AQHWM5TXVL/db7ee30d3aa85c655b39e7d3178b9e5d.jpg Academia - Richard HAYNES Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he is now Programme Leader in the MRC Population Health Research Unit for the programme in Randomised Trials in Cardiovascular and Metabolic Disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634731338070-SSMVLQOWSVBULWGEQOB5/1de19e4080ffdfe791b65c29ddb3743b.jpg Academia - Will HERRINGTON Will Herrington is a Medical Research Council-Kidney Research UK Professor David Kerr clinician scientist based at the Nuffield Department of Population Health, University of Oxford and a practising Honorary Consultant Nephrologist at Oxford Kidney Unit. He joined the Renal Studies Group as a Clinical Research Fellow and trained on landmark renal trials (SHARP, 3C and UKHARP3). In 2013, he was awarded an MD from the University of Cambridge for a thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’. He co-leads the EMPA-KIDNEY trial, which is testing the effects of empagliflozin 10mg versus placebo on cardiorenal outcomes in 6609 people with chronic kidney disease with and without diabetes. He also co-chairs the UK Kidney Association guideline working group responsible for recommendations on the use of SGLT-2 inhibitors in adults with kidney disease, and has chaired the UK Renal Trials Network since 2020. He also aims to better understand the key determinants of kidney disease development and progression using observations from large blood-based prospective cohorts across a wide range of different populations. He has a particular focus on adiposity and its related risk factors, and how these may interlink to also cause cardiovascular disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745504653507-D0RFIOSYF92OI6LTXRZD/jonathan.himmelfarb%40mssm.edu.jpg Academia - Jonathan HIMMERLFARB Dr. Jonathan Himmelfarb is Professor of Medicine and Director of the Center for Kidney Disease Innovation at the Mount Sinai School of Medicine. Dr. Himmelfarb has held leadership positions in many national and international nephrology societies, including President of the ASN. He has served on expert panels for the U.S. Food and Drug Administration, Veterans Health Administration, Centers for Medicare & Medicaid Services and other organizations. He has served on editorial boards including JASN, CJASN Kidney International, BMC Medicine, Nature reviews Nephrology, the Faculty of 1000 in Medicine and Research. His research interests include developing a portable and wearable artificial kidney; development of a human 'kidney-on-a-chip. He is the Steering Committee Chair for the NIH funded Kidney Precision Medicine Project. Dr Himmelfarb leads numerous investigator-initiated clinical trials and cohort studies, as well as multicenter collaborative studies. He is the author of more than 400 peer-reviewed publications, with over 50,000 citations. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745504830330-DYCH92TDLGD5CW46M51A/grant.huang%40va.gov.jpg Academia - Grant HUANG Dr. Huang serves as the Acting Chief Research and Development Officer for the Veterans Health Administration Office of Research and Development. He is responsible for developing and executing the strategy for VA's nationwide research enterprise, which encompasses more than 7,200 active projects at more than 100 sites. VA research is supported by a $2.4 billion dollar budget (for fiscal year 2024), which includes both direct VA support and research funding from outside entities such as the National Institutes of Health, other federal agencies, and nonprofit and private organizations. This enterprise includes field-based research programs where pre-clinical, clinical, health services, rehabilitation, informatics/data science and genomics research are conducted https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1742310806883-F4RUQRGSB99XGTBZP9G8/lesley+inker.png Academia - Lesley INKER Dr. Lesley Inker is a Professor of Medicine at Tufts University School of Medicine, and attending physician and Director of the Kidney and Blood Pressure Center in the Division of Nephrology at Tufts Medical Center and. Dr. Inker’s primary research interests are in kidney function measurement and estimation and alternative endpoints for clinical trials of kidney disease progression. She also serves as co-principal investigator or training director for the Tufts K12 Junior Faculty programs and is Director of the Tufts Clinical Translational Research Center (CTRC). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706172612336-RD8NKE0RW0Y8BATYOD7T/MJ+photo.jpg Academia - Michel JADOUL Prof. M. Jadoul received his MD degree in 1983 at the Université catholique de Louvain (UCLouvain), Brussels, Belgium. He has been chairing the Division of Nephrology of the Cliniques Univ. St Luc for 20 years (2003-2023), and was Full Clinical Professor(now just emeritus) at UCLouvain. His clinical activities include the follow-up of hemodialysis and CKD patients. His main research interests have included beta2m amyloidosis, hepatitis C and other complications (falls, bone fractures, sudden death a.o.) in Hemodialysis patients, as well as CV complications after kidney TP and various causes of kidney disease (especially drugs). He has (co)-authored over 360 scientific papers, most of them published in major nephrology journals. His H index is 64. He is an Associate Editor of NDT. He has been country co-investigator for the DOPPS (2001-2023). He received in 2008 the international distinguished medal of the National Kidney Foundation. He has been a member of the KDIGO Executive Committee (2010-2015), and of the ERA Council (2013-2016). He has cochaired the 2008 KDIGO HCV in CKD Guideline and the updates in 2018 and 2022 and is KDIGO cochair since januari 1st 2019. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745505141414-9FMWUKUNNUFK0L0JLCII/Picture+Meg.jpg Academia - Meg JARDINE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745505396820-UWT3Q0TKOB76453XF4HP/nicholejeff%40gmail.com.png Academia - Nichole JEFFERSON https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745505463171-94GLBNOBAYJLDFDGRBMJ/N.+Jongs.jpeg Academia - Niels JONGS I am an Assistant Professor at the University Medical Centre Groningen, with a extensive background in statistics and clinicial trial methodolgy. My research primarily focuses on developing novel endpoints for chronic kidney disease trials. This includes my contributions to eGFR slope analysis and, more recently, the introduction of a hierarchical composite endpoint for kidney disease progression. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1741791061050-4U16FRKUZIBJ3QMOR3UM/Kashani_Kianoush_2017-Final.JPG Academia - Kianoush KASHANI Dr. Kashani is trained in the fields of Nephrology and Critical care Medicine. He is currently ranked as a Professor of Medicine and Assistant Professor of Medical Education; he serves as a consultant in the Division of Nephrology and Hypertension and the Division of Pulmonary and Critical Care Medicine at Mayo Clinic, Rochester, MN. He is currently the chair of the Nephrology-ICU Committee and Digital Health Committee under the division of Nephrology and Hypertension. His research interest is focused on acute kidney injury, kidney injury biomarkers, acid-base and electrolytes, kidney replacement therapies, extracorporeal blood purification strategies, ECMO, fluid management, simulation medicine, point-of-care ultrasonography, artificial intelligence and digital health, and education. In addition, he provides lectures regarding AKI, education, and fluid management globally. He has published 418 peer-reviewed papers and written several book chapters. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745505624945-47XKB4Z4KJ02PF9QYUV9/Sradha+Kotwal+G_1033+%281%29.jpg Academia - Sradha KOTWAL A/Prof Kotwal is a nephrologist and Program Head of the Renal and Metabolic Division at The George Institute for Global Health in Sydney, Australia. She brings expertise in innovative trial design, linked data analysis, and registry projects. A/Prof. Kotwal is a Chief Investigator for the Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE), the Global Kidney Patient Trials Network (GKPTN), and the Glomerular Disease Registry and Biobank. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706172628114-XL7CQ1GJ2W9LS1WA39X8/Koyner+Head+shot+Sept+2022.jpg Academia - Jay KOYNER Jay L. Koyner, MD, is a Professor of Medicine in the Section of Nephrology at the University of Chicago. He currently serves as the Medical Director of the Inpatient Dialysis Unit and Director of ICU Nephrology. In addition to being a dedicated clinician educator, Dr. Koyner’s critical care nephrology research interests have focused on the utilization of plasma, urine and electronic biomarkers to improve patient risk stratification and outcomes in the setting of acute kidney injury (AKI). He has contributed to several multicenter studies investigating the biomarkers of AKI, including the TRIBE-AKI study, the Furosemide Stress Test and several industry sponsored studies. He has published over 200 peer-reviewed articles and book chapters on AKI and the care of patients in with kidney injury in the ICU. He is the primary editor of The Handbook of Critical Care Nephrology (Wolters Kluwer). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634732531693-XFAM7HKVFPVFMO3RB9A7/Capture.PNG Academia - Matthias KRETZLER Matthias Kretzler is the Warner-Lambert/Parke-Davis Professor of Internal Medicine/Nephrology and Computational Bioinformatics at the University of Michigan. The overarching goal of his research is to define glomerular diseases in mechanistic terms and use this knowledge for targeted therapeutic interventions. To reach this goal his international research team at the University of Michigan has developed a translational research pipeline centered on integrated systems biology analysis of renal disease. Over the last 25 years the team has build experience in interdisciplinary data integration of large-scale data sets in international multi-disciplinary research networks and public private partnerships across diseases and continents. The reach networks Dr.Kretzler helps to coordinate (NEPTUNE, CureGN, KPMP, CPROBE and RPC2) link carefully monitored environmental exposures, genetic predispositions, transcriptional networks, proteomic profiles, metabolic fingerprints, digital histological biopsy archive and prospective clinical disease characterization to define cross-cutting disease mechanisms. The molecular mechanism identified have result in more than 350 publications, but most importantly in new disease predictors, de novo drug development and successful clinical trials of novel therapeutic modalities for glomerular diseases. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1767696409608-S06A99OUJJC7LN2A9JAH/Image1.png Academia - Rathika KRISHNASAMY Prof Krishnasamy is the Director of Nephrology at the Sunshine Coast University Hospital, Professor for the Faculty of Medicine at the University of Queensland and Co-Deputy Chair of Australasian Kidney Trials Network. She is the immediate Past President of the Australian and New Zealand Society of Nephrology. Her research is in the field of pathways to reduce cardiovascular disease in CKD with expertise in trial operations and platform trials. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745505894795-LGLEL2JOV5DSA8ZE6LWL/Vijay+Kumar.jpg Academia - Vijay KUMAR Dr. Vijay Kumar is a fellowship trained, board certified nephrologist. After completing his Nephrology Fellowship at University of Texas -Southwestern School of Medicine, Dallas, Texas, he practiced clinical nephrology for over two decades. He joined FDA in 2020 as a Medical Officer in Center for Biologics Research (CBER). He has been involved in review of variety of biological products, including gene and cell therapies, xenotransplantation, and biologic devices. He currently serves as a clinical team leader in the Office of Clinical Evaluation (OCE) housed in the Super Office of Therapeutic Products (OTP) at CBER. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1741879626497-GAIDR7C7DYIQ693Y1FIH/RS32134_Vineeta%2BKumar-20190726-013-8482RT%2B4x3.jpg Academia - Vineeta KUMAR Vineeta Kumar, M.D., F.A.S.T., F.A.S.N is a Tenured Professor of Medicine in the Division of Nephrology and the inaugural holder of the Robert and Cutessa Bourge Endowed Professor in Transplant Nephrology at the University of Alabama in Birmingham (UAB). Dr. Kumar is deeply dedicated to patient care and serves as the Director of UAB’s Incompatible Solid Organ Transplant Program, offering her expertise in consultative care for adult and pediatric high immunologic risk kidney, heart, lung, and liver organ transplants, both pre- and post-transplantation. She played a pivotal role as the lead nephrologist in UAB's Kidney Xenotransplantation efforts and in the success of the UAB Kidney Paired Donation Program, facilitating the over 100-kidney transplant chain. Her commitment to compassionate care is further demonstrated through her leadership in programs like National Schwartz Rounds for Compassionate Delivery of Care, where she fosters interdisciplinary discussions on compassionate healthcare practices. Dr. Kumar has been honored with numerous prestigious regional and national awards, including the Cobb Rutsky Award for Clinical Excellence for 10 consecutive years, the prestigious Brewer Heslin Award for Professionalism, the 2023 Medal of Excellence in the Kidney Transplant Professional Category by the American Association of Kidney Patients (AAKP) and American Nephrologists of India Origin (ANIO) service excellence award. For her innovative teaching skills she was awarded both the Deans and the Presidential Award for excellence in Teaching. Dr. Kumar has held leadership positions within AST as the chair of AST’s Education committee, the living donor community of practice (LDCOP), Chaired the planning committee for AST’s Cutting Edge in Organ Transplantation (CEoT) meeting and more recently was an elected member of AST’s board of directors. She has also lead the American Society of Nephrology (ASN) COVID-19 Transplant Response Team during the pandemic and was the co-chair of NKF ‘s Externally led patient focused drug development which led to FDA approving the emergency use authorization of porcine kidney for human Xenotransplantation. Dr. Kumar has authored over 100 peer-reviewed publications and actively participated in over 20 clinical research endeavors. She lectures nationally with NKF, ASN, AST, AFLDT, AREP and has mentored countless students, residents, fellows and faculty over the years. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745506039483-KZ8DOPWMOGQJ7DJJWRMC/RZ2_4839.jpg Academia - Hiddo LAMBERS HEERSPINK Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen. He is also a visiting professor at the University of New South Wales in Sydney, Australia. He studied pharmacology at the University of Groningen and received his PhD from the University Medical Center Groningen. Professor Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of chronic kidney disease and cardiovascular diseases. He has successfully led and currently leads numerous clinical trials, including the DAPA-CKD, FIND-CKD, ALIGN, and ZENITH High Proteinuria trials. His main expertise includes clinical trial design, personalized medicine and methodological aspects and statistical analyses of clinical trials. Professor Heerspink has authored and co-authored over 500 peer-reviewed publications and is an editorial board member of Diabetes, Obesity and Metabolism and the Clinical Journal of the American Society of Nephrology. Professor Heerspink serves as reviewer for and member of various committees of international professional organizations, including the American Diabetes Association and the American Society of Nephrology. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745506169067-HFPWYZO2TYTDLZU2K66T/Landoni-Giovanni---500x500.jpg Academia - Giovanni LANDONI Prof Giovanni Landoni, MD, is currently Full Professor and Residency Program Director of Anesthesia and Intensive Care Medicine at Vita-Salute San Raffaele University, Milan. His strong clinical and research interests in intensive care and anesthesia resulted in more than 700 scientific publications in indexed journals, cited >20,000 times, HI=78 on Scopus and HI=100 on Scholar, including randomized trials on NEJM, Lancet, and JAMA, and over 100 invitations in international congresses in 30 countries. He participated to 64 randomized controlled trials. Prof Landoni was Chief Investigator in successfully completed multicenter randomized clinical trials that randomized > 10,000 critically ill or perioperative patients over the last 10 years. He spent three years abroad performing research and working in the U.S.A., Spain, the Netherlands, India (where he married) and Uganda. He filed applications for 6 patents in the field. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1739981854853-QAV85U9MJD11JJ4UTY5V/PCORI_Lawrence+%282%29.jpg Academia - William LAWRENCE William "Bill" Lawrence, MD, MS, is the Senior Clinical Advisor, Office of the Deputy Executive Director for Patient-Centered Research Programs, at the Patient-Centered Outcomes Research Institute (PCORI). In this role, Lawrence works across the Patient-Centered Research Programs Department to advise on clinical and scientific aspects of portfolio development from inception of topics through implementation of results. Lawrence earned a BS in biomedical engineering from Duke University, and an MD from the West Virginia University School of Medicine. He completed an internal medicine residency and a general internal medicine fellowship at the University of Wisconsin. During his fellowship, he received an MS in Industrial Engineering at the University of Wisconsin, with a focus on medical decision making. He has had a general internal medicine practice and conducted research at the University of Wisconsin and at Georgetown University. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745506369442-9C265YOP3QWVQ33CNUU7/JHL+Headshot.JPG Academia - Jeffrey LAWSON Dr. Lawson received his MD and Ph.D. (Cell and Molecular Biology) from the University of Vermont and then completed his residency in General and Thoracic surgery and a fellowship in Vascular Surgery at Duke UniversityHe serves as the Chief Executive Officer, North American for Vascudyne, Inc. Dr. Lawson serves as a reviewer for numerous hemostasis, vascular, and surgical journals. He has authored over 200 journal articles and abstracts on the topics of hemostasis and vascular surgery, and lectures on these topics both nationally and internationally. As a physician, scientist, innovator and entrepreneur, Dr. Lawson has helped to raise significant capital to fund emerging technologies and has been a board member for both governmental and large capital organizations. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745506475921-ECVR2LY8LWJ2C1Y11TYD/rlee172%40comcast.net.jpg Academia - Robert LEE Robert E. Lee, MD recently retired after a decade as an FDA medical officer on the Vascular and Endovascular Devices Team in CDRH. This group is primarily responsible for those devices used to create vascular access for hemodialysis and to treat patients with dysfunctional AV access. He is a native of Detroit and a graduate of the University of Michigan Medical School. Dr. Lee completed a general surgery residency and a vascular surgery fellowship at Henry Ford Hospital in Detroit. Prior to joining the FDA, he practiced vascular and endovascular surgery in academic and private settings in southeast Michigan for three decades, maintaining a special interest in hemodialysis vascular access. Since retiring from FDA, Dr. Lee cofounded the Echelon Development Group, a consulting firm focused on supporting companies with novel devices used for hemodialysis access through the product development, clinical trial design, regulatory approval and commercialization phases. He can be contacted at bob.lee@echelondg.com https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745506577821-421O9ZNGRBIKZ1QSIEAY/matthieu.legrand%40ucsf.edu.jpg Academia - Mathieu LEGRAND https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1740144522456-AH14GUGBPDU8XA0SCLV9/Levin.jpg Academia - Adeera LEVIN Professor of Medicine, Head, Division of Nephrology at the University of British Columbia, and Consultant nephrologist at Providence Health Care/ St Paul’s Hospital, in Vancouver Canada, and the Executive Director of BC Renal, overseeing Kidney services in British Columbia Major research interests include non- traditional risk factors for CVD in CKD patients, progression of CKD variability, health systems research and optimal models of care. She has over 1000 peer reviewed publication. She mentors medical students, residents fellows, and junior staff from multiple disciplines. She has received numerous teaching and research awards, from Canadian Society of Nephrology, Kidney Foundation of Canada, Michael Smith Health Research; and is Fellows of Canadian Academy of Health Sciences. She received the ISN Jean Hamburger Award for contributions to research in 2024, The Order of Canada in 2015, and in 2025 she was awarded the King Charles III Coronation Medal. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1733301204766-O0LG5JXWNFBB5BQOPDRN/Mark+Lim+Headshot+1-Medium+Res.jpg Academia - Mark LIM Mark D. Lim is the Vice President of Research, Discovery, and Innovation at the American Society of Nephrology’s Alliance for Kidney Health (ASN). The department aims to sustain the growth of innovations for people with kidney diseases, building on two public private partnerships with the US Government and KidneyCure, a separate non-profit foundation that supports research fellowships. KidneyX is a partnership with US Department of Health and Human Services that incentivizes entrepreneurs, and the Kidney Health Initiative is a partnership with the US Food and Drug Administration and over 90 member organizations to create regulatory science solutions as a pre-competitive consortium. Mark also serves on the Scientific Advisory Board of the Quebec Consortium of Drug Discovery, a multi-pharmaceutical and government effort to support the development of drug development technologies. Prior to ASN, Mark supported the biomedical funding strategies of the Bill and Melinda Gates Foundation, Department of Defense, and US National Cancer Institute, and also supported the Milken Institute’s FasterCures. Mark has over 33 publications on global health diagnostic product development, role of public private partnerships, biospecimen science, and nanotechnology, with a PhD in Inorganic Chemistry from UC Santa Barbara and postdoctoral training in Pharmaceutical Chemistry at UC San Francisco. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745506706802-BO5AFZ2WD87VT1UEKZMV/JL_headshot.jpeg Academia - Jacob LITTLE Jacob Little, MD, MS is a clinical reviewer in General Medicine Branch 4, Office of Therapeutic Products, Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration. He maintains board certifications in pediatric nephrology and general pediatrics. His review work is focused on ensuring the safety and efficacy of novel cellular and gene therapy products, xenografts, plasma protein derived products, and medical devices throughout clinical development. His special interests include porcine kidney xenotransplantation, cellular therapies for lupus nephritis, and gene therapies for rare diseases affecting the kidneys. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634741072992-0DKSL1APUI6PCTFICS9Z/liu.kathleen.jpg Academia - Kathleen LIU Dr. Kathleen D. Liu is a nephrologist in San Francisco, California and is affiliated with multiple hospitals in the area, including UCSF Medical Center and Zuckerberg San Francisco General Hospital and Trauma Center. Her research is focused on two important clinical entities, kidney injury and the acute respiratory distress syndrome. In the area of kidney disease, herwork has focused on the predictive value of novel biomarkers for acute kidney injury and on the impact of fluid overload on acute kidney injury, along with clinical trials of dialysis in AKI-D. She has examined the mechanisms that lead to the long-term sequelae of acute kidney injury, including cardiovascular disease, chronic kidney disease, end-stage renal disease and death. In the area of acute respiratory distress syndrome, She has played a major role in numerous multi-center clinical trials, including as co-principal investigator for phase 1 and 2 studies of mesenchymal stromal cells. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600070755178-DCQ5BBJG5MJ13M1SY3U6/Lok+photo.jpg Academia - Charmaine LOK Dr. Charmaine Lok is a Professor of Medicine at the University of Toronto and a Senior Scientist at the Toronto General Research Institute, Toronto, Canada. She is the Medical Director of the multidisciplinary chronic kidney disease (CKD) and hemodialysis programs at the University Health Network-Toronto General Hospital, Toronto, Canada. Her research interests are in clinical trials, patient health outcomes and functional ability, dialysis access and cardiovascular disease in CKD and ESKD. Dr. Lok is also active in raising awareness of CKD and ESKD and its importance in public health. She is the Chair of the KDOQI Vascular Access Guidelines and is involved in a variety of local and international scientific and educational programs, including ASN, CIHR, DOPPS, National Kidney Foundation (NKF), and Kidney CARE Network International. Dr. Lok was recently awarded the NKF’s prestigious Garabed Eknoyan award for improving kidney patients’ quality of life through her exceptional contributions. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060780442-C56MPM6WIFLT067TZSK8/Maerz+Winfried+photo.JPG Academia - Winfried MAERZ Winfried Maerz is chair of the Clinical Institute of Medical and Chemical Laboratory Diagnostics at the Medical University of Graz, Austria and has become affiliated with the Mannheim Institute of Public Health, Social and Preventive Medicine at the Medical Faculty Mannheim, University of Heidelberg. Dr. Maerz was deputy head the Division of Clinical Chemistry, University of Freiburg until 2003. Dr. März is also a member of the management advisory board of the Synlab Holding GmbH, head of the Synlab Academy for Continued Medical Education and head of business development at the Synlab Services GmbH. His research interests are epidemiology, the genetics of vascular diseases and the pharmacological treatment of lipid disorders. He has published more than 350 original articles, several book articles and reviews in these fields; He is among the ten mostly cited scientists both in the areas of laboratory medicine and metabolism research in Germany. Dr. Maerz is principal investigator of the Ludwigshafen Risk Factor and Cardiovascular Health Study (LURIC), has been a member of the steering committee of the 4D trial (Die Deutsche Diabetes Dialyse Studie), an endpoint study of atorvastatin in diabetic patients with end-stage renal disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634742230305-NQ0RA2JGFO68IBDRIX46/Professional+Portrait+2017.jpg Academia - Michael MATHIS Michael Mathis is a tenure-track Assistant Professor in the Cardiac Division of the Department of Anesthesiology, an Affiliate Faculty in the Department of Computational Medicine & Bioinformatics, a member of the Institute for Healthcare Policy and Innovation, and Director of Cardiothoracic Anesthesiology Research at the University of Michigan. He is a practicing cardiovascular anesthesiologist clinician investigator and a K-award recipient from NHLBI to apply data science methodologies to intraoperative and early ICU data for informing diagnosis and perioperative management of patients with advanced cardiovascular diseases including heart failure. He additionally serves as a Co-Investigator on research grants from NHLBI - studying intraoperative assessments of cardiac surgery quality with (PI Dr. Donald Likosky) - and the Department of Defense - studying early ICU data for prediction of clinical deterioration following cardiac surgery. He is triple board certified in anesthesiology, transesophageal echocardiography, and clinical informatics.Nationally, Dr. Mathis serves as the Associate Research Director for the Multicenter Perioperative Outcomes Group (MPOG), a research and quality improvement consortium of over 50 anesthesiology and surgical departments across the US, with the University of Michigan serving as the Coordinating Center. The MPOG centralized database contains more than 16 million perioperative records with risk-adjusted long term outcome data and detailed clinical intervention data. He has published on the leveraging of intraoperative anesthesia data for informing risk of postoperative acute kidney injury. Dr. Mathis additionally serves on the Research Committee for the international Society of Cardiovascular Anesthesiologists and serves as a reviewer for anesthesiology career development grants from the International Anesthesia Research Society. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772613964171-MKPB91VP2XG58CGQHGU5/McGill+headshot+new.jpg Academia - Janet McGILL ‍ ‍ Dr. Janet McGill is Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine and attending physician at Barnes-Jewish Hospital in St. Louis, Missouri. In addition to treating patients with all forms of diabetes, Dr. McGill has been an active clinical investigator, conducting over 230 clinical trials in type 1 and type 2 diabetes and diabetes complications. Her experience with clinical trials in type 1 diabetes with kidney disease includes the Captopril in Diabetic nephropathy trial, trials of aminoguanidine, pyridoxine, ACE inhibition and zopolresat and more recently PERL, FINE-ONE and Sugar ‘n Salt. She has been on steering or executive committees for RENAAL, TREAT, PERL, Sugar ‘n Salt and is the lead co-investigator for FINE-ONE. She is widely published and has won numerous awards including the 2022 Outstanding Physician Clinician in Diabetes Award from the ADA. ‍ ‍ https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059371885-YEXK01ECERY77FVUH9AH/Mehta+Ravindra+photo.jpg Academia - Ravindra MEHTA Dr Mehta is a Professor Emeritus of Medicine at University of California San Diego where he directs the UCSD Masters in Clinical Research Program and is the site PI of the NIH funded UAB/UCSD O’Brien Center for AKI research. He chairs the annual International AKI and CRRT Conference in San Diego that is in its 26th year in 2021. He is a founding member of the Acute Dialysis Quality Initiative (ADQI) and the Acute Kidney Injury network (AKIN). His research has informed the development of the KDIGO guidelines for AKI. He has spearheaded several innovative multicenter studies on AKI including the International Society of Nephrology (ISN) AKI 0by25 project. He received the ISN Bywaters Award for lifetime achievement in AKI in 2011 and in 2020 the ISN honored him by establishing a fellowship in AKI in his name. He received the M.B.B.S. degree (1976) from the Government Medical School in Amritsar, India, and the M.D. (1979) and D.M. (1981) degrees from the Post Graduate Institute of Medical Education and Research in Chandigarh, India. He obtained his boards in Internal Medicine (1986) and Nephrology (1988) at the University of Rochester in Rochester New York. He has been on the faculty at San Diego since 1988. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773233741029-CEZGW97CRXCP7G8R4KLG/Greg+Miller+photo+Crop2+Mar2017.jpg Academia - Greg MILLER Greg Miller, PhD, is a Professor in the Pathology Department at Virginia Commonwealth University where he serves as Co-Director of Clinical Chemistry and Director of Pathology Information Systems. He is an active contributor to several committees and working groups for standardization and harmonization of laboratory results. He currently chairs the NIDDK laboratory working group and the International Federation of Clinical Chemistry and Laboratory Medicine working group for standardizing albumin measurement in urine. He is a member of the National Kidney Foundation laboratory engagement initiative and the workgroup for implementation of race-free eGFR-based medication-related decisions. He was a member of the National Kidney Foundation-American Society of Nephrology task force to reassess the inclusion of race in diagnosis of kidney diseases. He is a past-president of the Association for Diagnostic Laboratory Medicine and of the Clinical and Laboratory Standards Institute. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745506937335-DKZR8VDUSLHIDI74CBUM/amymottl_work+pic.jpeg Academia - Amy MOTTL Amy Mottl is a Professor of Medicine in the Division of Nephrology and Hypertension at the University of North Carolina School of Medicine. She received her undergraduate degree at Northeastern University and attended medical school at the Albert Einstein College of Medicine before moving to the University of North Carolina for residency, fellowship and now as faculty. Her clinical interests include the multidisciplinary care, education and health equity for patients with diabetic kidney disease (DKD), genetic and glomerular kidney diseases. Dr. Mottl's research interests include the pathogenesis, natural history and treatment of DKD and immune mediated glomerular diseases. She is an avid clinical trialist and investigator in observational studies, including serving as a recruitment site PI for the NIDDK sponsored U01 Kidney Precision Medicine Program and an R01 Cure Glomerulopathy Network ancillary study, CureGN-Diabetes. Dr. Mottl is a member of the ASN Diabetic Kidney Disease Collaborative and the ASN Kidney Health Guidance Committee. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1767695144947-YQNSWMDWVILBWUW61CSD/Photo_MarianaMurea.png Academia - Mariana MUREA Mariana Murea, MD, FASN, is Professor of Medicine in the Section on Nephrology at Wake Forest University School of Medicine, where she practices as a nephrologist and leads clinical research aimed at improving outcomes for patients on chronic dialysis. Dr. Murea is the Lead Principal Investigator for the PCORI-funded TwoPlus trial, a multicenter, type I hybrid implementation-effectiveness randomized clinical trial comparing incrementally prescribed twice- versus thrice-weekly hemodialysis with conventional thrice-weekly hemodialysis in patients with residual kidney function at dialysis initiation. This trial integrates clinical outcomes with patient- and caregiver-reported measures, as well as stakeholder interviews with physicians, advanced practice providers, and dialysis personnel. She also serves as Lead Principal Investigator for the NIH/NIA-funded AV Access Trial, the first multicenter randomized controlled trial evaluating clinical and patient-reported outcomes of surgical fistula versus graft strategies for arteriovenous access in older adults with comorbidities and on chronic hemodialysis with a central venous catheter. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773233872265-YZ32SM4U3IGLIGR54S20/mustafa-reem+photo.jpeg Academia - Reem MUSTAFA Dr. Mustafa is a nephrologist with a master’s degree in public health and a PhD degree in Health Research Methodology/Clinical Epidemiology. She is a Professor of Internal Medicine/Nephrology at the University of Kansas Health System and the Director of Evidence-Based Practice, outcomes and Impact Center. Dr. Mustafa is a leading figure in evidence-based medicine and a key member of the GRADE guidance group (Executive committee). She is a co-founder of the U.S. GRADE Network and the Evidence Foundation. Dr. Mustafa is a member of the executive committee and chairs the methods committee for the Kidney Disease Improving Global Outcomes (KDIGO) guidelines. She authored more than 370 peer reviewed publications with numerous methodological and clinical guidelines. Dr. Mustafa is passionate about improving decision-making in healthcare via collaborative efforts among a variety of stakeholders including clinicians, patients and researchers. Dr. Mustafa has been recognized as one of “true pioneers in their fields over the last decade demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations in the Web of Science™” since 2021. She received multiple awards including the American Society of Nephrology Midcareer distinguished leadership award in 2025. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1767695880835-784COOOMZ0DUO84J581N/Nachman+photo.jpg Academia - Patrick H. NACHMAN Dr Nachman is Professor of Medicine, Director of the Division of Nephrology and Hypertension at the University of Minnesota. He is also and Director of the Minnesota Multidisciplinary Vasculitis Program, and the Minnesota Glomerular Disease Program. His research efforts have focused on the study of glomerulonephritis and small vessel vasculitis, spanning the full spectrum from bench to bed-side; including translational studies in glomerulonephritis and vasculitis, and epidemiologic and clinical studies in Nephrotic Syndrome. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1732533586265-0IWLMA0AQOAR6J1XYXY1/VandanaNiyyar.JPG Academia - Vandana NIYYAR Vandana Dua Niyyar is Professor of Medicine at Emory Nephrology, is designated as Master Physician at Emory DOM and serves as the site Principal Investigator for the Two Plus Study on Incremental Hemodialysis. Nationally, she is the Immediate Past President of the American Society of Diagnostic and Interventional Nephrology (ASDIN), Chair of ASN’s Transforming Dialysis Access Together (TDAT) Initiative, serves on the Board of Directors and chairs the Device Committee for the Kidney Health Initiative (KHI). Dr. Niyyar has specific expertise in hemodialysis vascular access and ultrasonography and is passionate about promoting multidisciplinary collaborations to optimize access care and processes for dialysis patients. Dr. Niyyar is a sought-after educator and has chaired and led numerous didactic presentations and hands-on training workshops regionally, nationally, and internationally. Dr. Niyyar has been recognized for her exemplary clinical and service achievements through various awards including ASDIN Distinguished Service Award in 2019, Emory Nanette Wenger Service Award in 2019, American Society of Nephrology Mid-Career Distinguished Clinical Service Award 2020, American Nephrologists of Indian Origin Clinical Excellence Award in 2021, Emory DOM Outstanding Quality Achievement Award in 2022 and ASDIN Gerald Beathard Award in recognition of her teaching excellence, scholarly activity, and clinical excellence in 2024.. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706172841954-72Z62ZHLIL1SH5FVHV2V/Foto+%28Aug+2023%29.jpg Academia - Marlies OSTERMANN Marlies Ostermann is Professor of Intensive Care and Nephrology at Guy’s & St Thomas Hospital in London. Her academic and clinical interests relate to acute kidney injury, sepsis and extracorporeal organ support in critically ill patients. She is President Elect of the European Society of Intensive Care Medicine, Director of Research of the Intensive Care Society UK, Co-Chair of the KDIGO AKI guideline, and a member of the guideline panel of the Surviving Sepsis Campaign. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745507255591-NSJEA81DVWPXVYC2AWTJ/Chirag+Parikh-2024.jpg Academia - Chirag R PARIKH Dr. Chirag R. Parikh is a Professor of Medicine and the Director of the Division of Nephrology at the Johns Hopkins University School of Medicine. Originally from India, Dr. Parikh attended medical school at Seth G.S. Medical College and KEM Hospital in Mumbai. He completed his fellowship in Nephrology and Hypertension and UNOS Transplant Certification at the University of Colorado, under the mentorship of Dr. Robert Schrier. While completing his fellowship, he also earned a doctorate in Clinical Investigation. Dr. Parikh has been awarded several active NIH grants, has published over 500 original articles, and has been cited over 50,000 times in literature. His research focuses on the translation and validation of novel biomarkers for the diagnosis and prognosis of acute kidney injury. Dr. Parikh is the driving force in a series of discoveries contributing to groundbreaking progress in clinical care for acute kidney injury and setting the stage for creating novel treatment paradigms, based on phenotyping with novel proteins of injury, inflammation, and repair to eliminate the global epidemic of AKI. He followed up these discoveries with paradigm-shifting, multicenter studies of AKI that generated evidence for these proteins for various clinical applications. At Johns Hopkins, Dr. Parikh also directs the Precision Medicine Center of Excellence for Kidney Diseases, leading transformative changes in clinical care and research studies that aim to personalize treatment for each patient. Dr. Parikh's passion for advancing kidney care is evident in his numerous accomplishments. He received the Young Investigator Award from the American Society of Nephrology in 2017, was inducted into the ASCI Society in 2018, and was elected to the AAP in 2021. He is a renowned speaker, presenting at universities and conferences worldwide, and an esteemed mentor who has proven valuable to students, postdoctoral fellows, and faculty. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773234285504-WQ1W39LYY6WO84FMKHCU/Headshot_parodis.png Academia - Ioannis PARODIS Dr Ioannis Parodis is a rheumatologist and clinical scientist specialising in B-cell biology and novel treatments for systemic lupus erythematosus (SLE) and lupus nephritis (LN). He received his medical degree from the National and Kapodistrian University of Athens in 2006 and completed his PhD on biomarkers and biologics in SLE at Karolinska Institutet in 2017. His primary appointment is at Karolinska University Hospital and Karolinska Institutet, where he is a senior consultant rheumatologist and associate professor, and leads clinical and translational research in inflammation and autoimmunity at the Center for Molecular Medicine. He also holds an affiliation with Örebro University. Dr Parodis is global principal investigator of the ReBioLup study and principal investigator of several SLE studies, including within the European 3TR project and X-HiDE consortium. He has contributed to EULAR guidelines and serves as President-Elect of the European Lupus Society (SLEuro). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745507340156-0YJ452036URC575ZF32E/2024-02-22-SH07-Vlado+Perkovic-0025+%281MB%29.jpg Academia - Vlado PERKOVIC He is a Nephrologist and a leading clinical trialist in Nephrology. His research focuses on preventing the progression of kidney disease, and its complications. He has led the Steering Committees of a large number of ground-breaking international clinical trials including FLOW, APPLAUSE, DUPLEX, PROTECT, CREDENCE, TESTING, ASCEND, CARMELINA and other, and leads several that are ongoing. He has received several international awards and is a Fellow of the Australian Academy of Health and Medical Sciences. He serves on the Editorial Board of the New England Journal of Medicine, and is a Highly Cited Researcher (Clarivate, top 0.1% of cited authors). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773234495054-LIC0R517N7MK3PZFQGUS/Perrone_Ronald_1265541155_TMC.jpg Academia - Ronald PERRONE Dr. Perrone is Professor of Medicine and Distinguished Faculty at Tufts Medical Center and Tufts University School of Medicine. He has participated in all of the US interventional trials in ADPKD serving as Tufts site PI and member of the Steering Committees for HALT-PKD, TEMPO 3/4 and REPRISE trials of tolvaptan, TAME-PKD study of metformin, and Venglustat STAGED-PKD study; also has served as site PI for the Tesevatinib (Kadmon) and Bardoxolone (Falcon) studies. He initiated and is co-Director of the PKD Outcomes Consortium, the goal of which is to accelerate trials for ADPKD and ARPKD. He was principal individual involved in bringing together academia, pharma, NIH, FDA, EMA, CDISC, and C-Path resulting in the concurrent approval of Total Kidney Volume as a prognostic biomarker by FDA and the EMA. Dr. Perrone was a workgroup member for the ADPKD KDIGO Guideline published in the February issue of Kidney International. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706173100128-1H8EW663MAKEGNPSQB1T/Pinter_Jule_2023_page-0001+%281%29.jpg Academia - Jule PINTER Dr. med. Jule Pinter is a physician in the Nephrology Department at the University Hospital Würzburg, Germany. She is holding a Master's in Clinical Trials from the University of Oxford, where she graduated with honors. Her international research journey began during an elective at McMaster University in Canada, where she conducted a cohort study on the prophylaxis of venous thromboembolism in patients with kidney diseases. Inspired by this experience, she continued her research at the Renal Cochrane Center in Sydney, Australia, eventually before joining the University Hospital Würzburg under the mentorship of Prof. Dr. med. Christoph Wanner. As a clinician and scientist, Dr. med. Jule Pinter, funded by the German Research Foundation (DFG) since 2019, is dedicated to enhancing patient care through evidence-based practices and scalable healthcare solutions. She now brings her expertise and full commitment to leading RESOLVE (Randomised Evaluation of Dialysate Sodium on Vascular Events Study) in Germany. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634743132927-AVYBND3AB50PVFWFDFDU/Capture.jpg Academia - Romain PIRRACCHIO Dr. Romain Pirracchio, M.D., Ph.D., hailing from Paris. He obtained his M.D. in 2003, with a specialization in Anesthesiology and Critical Care Medicine. In 2008, he obtained a Master degree in Medical Research Methodology and Biostatistics and completed his doctoral studies in the Department of Biostatistics and Medical Informatics (DBIM, unité INSERM U-1153) at Hôpital Saint Louis, Paris, France in 2012 under the guidance of Prof Sylvie Chevret. In 2012-2013, he spent a year as a postdoctoral fellow in Biostatistics in the School of Public Health at the University of California, Berkeley, where he worked under the supervision of Prof. Mark J. van der Laan and Prof Maya L. Petersen. Back in Paris, He was the clinical director of the surgical and trauma ICU at European Hospital Geroges Pompidou (2013-2015) and a researcher in Biostatistics at the INSERM U-1153 unit. In January 2015, he have joined the Department of Anesthesia and Perioperative care at the San Francisco General Hospital & Trauma Center (UCSF) as Associate Professor. In September 2016, he started serving as Full Professor and then Chairman for the Department of Anesthesia and Critical Care Medicine at European Hospital Geroges Pompidou. Since September 2018, he is the Chief of Anesthesia and Preoperative Medicine at ZSFG and Vice chair for the Department of Anesthesia and Preoperative Medicine at UCSF. In December 2019, he had the immense honor to become the inaugural recipient of the Ronald D. Miller Professorship in Anesthesia and Perioperative Care. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634743360653-HLI9E0IXFWQXU6MVYZ6Q/Dheeraj-Rajan-766x512.jpg Academia - Dheeraj RAJAN Dr. Rajan completed his undergraduate medical degree at the University of Toronto, followed by Diagnostic Radiology at Wayne State University in Detroit, MI. He subsequently completed a fellowship in Vascular and Interventional Radiology at the University of Pennsylvania. Dr. Rajan is now an Associate Professor and the Division Head for Vascular and Interventional Radiology at the University of Toronto. He has specific interests in vascular arterial interventions not limited to aneurysm repair and renal denervation as well as hemodialysis interventions. Within these areas, Dr Rajan has provided expert advice and support to industry partners. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1738943976127-4YZI9QMXCU013OOUY5XP/JR%2Bfile%2Bphoto%2Bcropped.jpg Academia - Janani RANGASWAMI Janani Rangaswami is the chief of nephrology at the Washington DC VA Medical Center, and a professor of medicine at the George Washington University (GWU) School of Medicine. She is a clinician-researcher with expertise in cardiovascular-kidney medicine. She is the immediate past chair for the Council on the Kidney in Cardiovascular Disease of the American Heart Association (AHA), and led the AHA Scientific Statements on Cardio-Renal Syndrome (2019) and the Cardiorenal Benefits with the Newer Antidiabetic Agents in Kidney Disease (2020). She co-chaired the Cardiovascular-Kidney-Metabolic Health (CKMH) scientific advisory group for the American Heart Association which published a presidential advisory, scientific synopsis, and a novel cardiovascular disease risk prediction equation in individuals with CKM syndrome. Dr. Rangaswami has authored several publications in cardiovascular-kidney medicine, and is the lead editor of two textbooks in this field: Textbook of Cardio-nephrology and the Textbook of Kidney Disease in the Cardiac Catheterization Laboratory. She has won several awards for teaching and leadership in her career, and co-founded the Philadelphia Agreement on Gender Equity (PAGE) in Internal Medicine, supported by the American College of Physicians. She is a frequent speaker in cardiology, nephrology, and endocrinology conferences globally. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706173124039-QF1QUYYC7J4SG6UVJ2F5/Dana+Rizk-rev-2021.jpg Academia - Dana RIZK Dr Dana Rizk is Tenured Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB). She also serves as Director of Clinical Trials Research in the Division of Nephrology and as Medical Director for the Clinical Trials Administrative Office (part of the CCTS) at UAB. She has a passion for education and has served as a member of the Clinical Competency Committees for the Internal Medicine as well as the Nephrology Programs. She is the recipient of several teaching awards. Her clinical and research interests revolve around glomerular diseases and, in particular IgA Nephropathy (IgAN). She has served as the site principal investigator on many clinical trials and is part of several multi-disciplinary translational research projects focused on the role of biomarkers in the diagnosis and prognosis of IgAN. Her research efforts have resulted in more than 60 peer-reviewed publications in prestigious medical journals including the New England Journal of Medicine. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773234900470-WMJDYGZVUX3RDYIDMNYJ/Cal+Robinson+-+ASK+Headshot.jpg Academia - Cal ROBINSON Dr. Cal Robinson is a pediatric nephrologist at SickKids, Toronto and an early career investigator whose research focuses on the treatment of rare childhood kidney diseases. He completed his medical training in the United Kingdom at St. Andrews and Manchester, followed by pediatric residency at McMaster University, and pediatric nephrology fellowship at SickKids. He recently completed a PhD in Clinical Epidemiology at The University of Toronto, studying the use of innovative clinical trial and causal inference methods, including Bayesian adaptive trials and target trial emulation, to compare immunosuppressive treatments in childhood glomerular diseases. His research is supported by the SickKids Clinician-Scientist Training Program, CureGN Career Development Fellowship, IMPaCT Clinical Trials Training Platform, CIHR Fellowship, and Kidney Foundation of Canada KRESCENT Fellowship. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745507788243-HYL8DOUUDV1NR4M9GDKA/alain.romero%40gmail.com.jpg Academia - Alain ROMERO https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745507901637-SOOQ7XKFINQSTEKBA82B/Sylvia+Rosas+20220714_17_1x1.jpg Academia - Sylvia ROSA Sylvia E. Rosas, MD, MSCE is a nephrologist and epidemiologist at the Joslin Diabetes Center and an Associate Professor of Medicine at Harvard Medical School. Dr. Rosas’s primary research focus is on diabetic kidney disease. She is the clinical center PI in the NIDDK-funded multicenter APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) and the Kidney Precision Medicine Program (KPMP). She is the Immediate Past President of the National Kidney Foundation. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745508434265-M7597E3Y7RUC079KY2KX/Yves+rosenberg.png Academia - Yves ROSENBERG Dr. Rosenberg is the Chief Medical Research Officer of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI), part of the US National Institutes of Health (Bethesda, MD). Prior to that appointment he was Chief of the Atherothrombosis and Coronary Artery Disease Branch at NHLBI. Dr. Rosenberg obtained his MD from the University of Lyon, France, and is Board certified in Preventive Medicine. He also has an MPH from Johns Hopkins. Dr. Rosenberg’s main research interests are the design and conduct of large multicenter phase III clinical trials, especially trials of treatment strategies, comparative effectiveness and pragmatic trials. He has led and participated in the development, conduct, analysis and reporting of more than a dozen major international cardiovascular clinical trials. Dr. Rosenberg is also involved in the design and conduct of NIH supported large multi-sites platform, adaptive therapeutic COVID and Long COVID-related clinical trials. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745508556662-X95WFWC1C55BP4SUMWHJ/J+Rossert.jpg Academia - Jerome ROSSERT Jerome Rossert is an independent consultant who helps companies design and execute drug development programs. Before establishing himself as a consultant, Jerome held senior executive roles in various pharmaceutical companies, where his primary focus was on the clinical development of novel therapies for patients with kidney disease. Prior to transitioning to the pharmaceutical industry, Jerome was professor of nephrology in Paris. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1706173134190-0KZURT5MPHLCK0XDL75I/PR1.JPG Academia - Peter ROSSING Peter Rossing is a clinician researcher devoted to complications in diabetes with focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center Copenhagen research team dedicated to the research of micro-and macrovascular complications of diabetes. Since 2012 Professor in diabetic angiopathy at University of Copenhagen. Peter Rossing has in epidemiological studies investigated key features of the pathophysiology of the diabetic kidney at different stages. He has identified several markers for development of diabetic nephropathy; making it possible to predict the individual risk. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis. He was coordinator of the EU FP7 project PRIORITY demonstrating that urinary proteomics can be used to stratify prevention of renal complications in type 2 diabetes, and the Novo Nordisk Foundation grant PROTON aiming at personalising prevention of diabetic nephropathy, the STENO1 and member of several trial steering groups and guideline committees. He has co-authored >650 papers and his h-index is 86. He received the Minkowski prize in 2005 and the Golgi prize in 2016 both from the EASD and the E. Bierman award from ADA and the Hormon Medal from European Society of Endocrinology. Past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745566385432-DTF46N8GU1DSC9DV60C9/Headshot+1.22.24.jpg Academia - Brad ROVIN Dr. Brad H. Rovin is the Lee A. Hebert Professor of Nephrology. Dr. Rovin received his Bachelor of Science in Chemical Engineering from Northwestern University in Evanston Illinois and his Doctor of Medicine from the University of Illinois Medical School in Chicago, Illinois. He completed a residency in Internal Medicine at Barnes Hospital in St. Louis Missouri, and a Fellowship in Nephrology at Washington University School of Medicine, St. Louis. He joined the Ohio State University College of Medicine Faculty in 1990, became Director of the Division of Nephrology in 2004, and served as Vice Chairman of Medicine for Research from 2009- 2019. In 2019 he became the Medical Director of the Ohio State University Center for Clinical Research Management. Dr. Rovin has had several committee and leadership roles in the American Society of Nephrology, including the annual meeting program committee, running the Glomerular Diseases Pre-Course and Co-Editing NephSAP-Glomerular Diseases, a continuing education program of the Society. He serves as deputy Editor of Kidney International, the flagship journal of the International Society of Nephrology, and he is Co-Chair for glomerular disease guideline development for the Kidney Disease Improving Global Outcomes effort. Most recently he received the Evelyn Hess Award from the Lupus Foundation of America for research contributions to improve the understanding of lupus nephritis. Dr. Rovin’s laboratory studies the immunopathogenesis of glomerular and autoimmune diseases and focuses on biomarker development for non-invasive assessment of kidney pathology. He is heavily involved in clinical trial development and design for investigator-initiated and industry-sponsored trials. He is a founding member of NephroNet, a grass-roots nephrology clinical trial organization, and the Lupus Nephritis Clinical Trials Network. He is and has been the Principal Investigator on several trials of novel therapeutics for glomerular diseases. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745566482864-OM359I5TE1EXL3DQDVU0/prabir-roy-chaudhury+-+Photo.png Academia - Prabir ROY-CHAUDHURY I am currently the Drs. Ronald and Katherine Falk Eminent Professor of Nephrology and the Co-Director of the University of North Carolina Kidney Center. Our primary research mission over the last 15 years has been to better understand the pathobiology of dialysis access stenosis and to then use this information to develop and test out novel therapies in both experimental and clinical/outcome studies. We have been funded in this endeavor through the National Institutes of Health, the Veterans Administration, the National Science Foundation and multiple industry grants and contracts. More recently, we have broadened the scope of our translational research program to address “uremic vascular biology” as a whole. At a translational level this question encompasses both vascular access dysfunction and cardiovascular disease in patients with CKD and ESKD with a special emphasis on biomarkers for risk stratification and prediction, and future clinical trials. I have to date participated in over 75 clinical trials in the transplant and ESKD population, both industry (several national PI roles) and investigator initiated (including large NIH consortia). I have also mentored almost 40 students at different levels of seniority (from high school to post docs). In addition, I am the PI for two R-25 training grants and lead the professional development core for the U2C TRIO training grant. I have also been actively involved in the public policy and administrative aspects of kidney disease through past and current leadership roles in multiple organizations such as the American Society of Nephrology (ASN), International Society of Nephrology (ISN), American Society of Diagnostic and Interventional Nephrology (ASDIN), and Vascular Access Society of the Americas (VASA), amongst others. In addition, I was the founding ASN co-chair for the Kidney Health Initiative (KHI) from January 2013 to December 2018. KHI is a public-private partnership between the ASN and the FDA comprising over 100 member organizations, which aims to facilitate the passage of drugs, devices and biologics into the kidney space. I am also the current President of the American Society of Nephrology, the largest professional nephrology organization in the world with over 21,000 members across 141 countries. Of note, I was recently appointed as a member of the Cardiorenal Drugs Advisory Committee of the FDA and am also the Founder and Chief Scientific Officer of Inovasc LLC, which is developing smart magnesium based biodegradable stents for preventing AVF maturation failure. I strongly believe that the above experience as a translational scientist, clinical nephrologist, innovator, entrepreneur, and public policy leader make me ideally suited to contribute to the current proposal, https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634743527636-TOGOPJIDH06H20T5A107/image.png Academia - Peter SCHNEIDER Peter A. Schneider, M.D. is Professor of Surgery in the Division of Vascular & Endovascular Surgery at University of California San Francisco. Dr. Schneider received his MD from the Johns Hopkins School of Medicine and completed vascular surgery at the University of California San Francisco. Dr. Schneider was the founding member and chief of the Division of Vascular Surgery at Kaiser Permanente in Hawaii from 1994-2018. At Kaiser, he developed a Diabetic Limb Treatment Program and a surveillance program for patients with aneurysms and a registry for patients with carotid disease used for surveillance. He oversaw the development of the first endovascular operating room in the Kaiser healthcare system. Dr. Schneider is a Distinguished Fellow of the Society for Vascular Surgery and is the past president of Western Vascular Society and Vascular and Interventional Advances (VIVA). He has been invited to numerous national and international visiting professorships, served as director, faculty or course director for many specialty courses and performed revascularization procedures in more than a dozen countries. He authored "Endovascular Skills," the 4th edition published in 2019, and has co-authored three other books on various aspects of vascular disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745566659937-ZNNGYQUC5POQHYSHPUTI/ivonne.schulman%40nih.gov.jpg Academia - Ivonne SCHULMAN https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745566775925-DGZXYODVIK1LKBCFU1DX/headshot+%282%29.jpg Academia - Abhinav SHARMA Dr. Abhinav Sharma is an assistant professor in Cardiology at McGill University Health Centre (MUHC) and an FRQS Junior 2 clinician-scientist, with 50% protected research time. His work focuses on type 2 diabetes (T2DM) and heart failure (HF), leveraging machine learning (ML) and large data modeling. His research includes sex-specific HF risk models (CIHR 2021-23), phenotype identification in T2DM (Heart/Stroke 2022-27), and AI-driven digital biomarkers for T2DM screening (MEDTEQ 2021-24). He is also co-leading clinical trials focused on implementation of guide directed medical therapies in patients with Cardio-Renal disease including SGLT2i in patients on dialysis. He is the Director of the Cardio-Metabolic Program (DECIDE-CV) at the McGill University Health Centre. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745566937579-P4SG0YI7YS9GV61QYABP/Singapogu+headshot.jpg Academia - Joseph SINGAPOGU Dr. Joseph Ravi Singapogu is Associate Professor in the Department of Bioengineering at Clemson University. He is also an adjunct faculty at the University of South Carolina-Greenville School of Medicine. Dr. Singapogu’s research focuses on the improvement of clinical skills training using advanced sensors, devices and data- driven methodologies. From 2013-2018, Dr. Singapogu was part of the Embedded Scholar program at Clemson and Prisma Health fostering collaborations between clinicians and researchers in medical skills training with simulation technologies. Dr. Singapogu’s research has been funded by both federal and private agencies in the US. He is also the Founder of Sojourn MedTech LLC, a startup that provides simulation tools for vascular access. He has served as a reviewer for several leading journals including New England Journal of Medicine, Scientific Reports and IEEE Transactions on Biomedical Engineering. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773235084816-KZNGFX76NKWPPU5Y2Q6C/Smoyer+Head+Shot+%233++2.14.24.jpg Academia - William SMOYER William E. Smoyer, MD serves as the C. Robert Kidder Endowed Chair and Director of the Center for Clinical and Translational Research at the Research Institute at Nationwide Children’s Hospital in Columbus, Ohio. He is also a Professor of Pediatrics at The Ohio State University and serves as the Co-PI for Research Resources at the OSU Clinical and Translational Sciences Institute (CTSI). Prior to joining NCH, Dr. Smoyer also served as both the Pediatric Nephrology Division Director and Fellowship Program Director at the University of Michigan. For the past 33 years, Dr. Smoyer has focused his career on basic, clinical, and translational research to improve our understanding of the molecular regulation of podocyte injury during nephrotic syndrome, and to develop more effective and safer novel treatments for childhood nephrotic syndrome. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634745146376-3AF3C18DJ52I264KLFOT/97289_spencer_stuart-_hd2012_w.jpg Academia - Stuart SPENCER Dr. Stuart Spencer, born in 1949, has a Ph.D. from the University of London and is the Executive Editor at the prestigious British medical journal The Lancet. He leads an editorial team that executes quick publishing (within one month after the sent in manuscript) of about 50 selected scientific articles per year. Subject-wise, he is responsible for cardiology and blood pressure issues. He also has the editorial responsibility for investigating complaints about a lack of ethics in research and publication. As of 2006, Stuart Spencer has taught at the Faculty of Medicine, Umeå University, partly for the introductory course in research methodology, and partly at the National Research School in General Practice, funded by the Swedsh Research Council. He belongs to the steering committee for the National Research School in General Practice and has made great efforts to give it an international flavor, not least by teaching the art of writing scientific papers are good enough for publication. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745567181522-4HVFT6JJ58PXHFJ1M4DV/natalja.stanski%40cchmc.org.jpg Academia - Natalja STANSKI https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1738943953328-KTDKEBKHPVOJJ8MTQC8H/NTheadshot2025.jpg Academia - Navdeep Tangri Dr. Tangri is an attending physician and Professor in the Division of Nephrology, Department of Internal Medicine and Department of Community Health Sciences in the Rady Faculty of Health Sciences at the University of Manitoba. Dr. Tangri’s research program is multidisciplinary and focused on improving clinical decision making for patients with or at risk for chronic kidney disease. He developed and validated the Kidney Failure Risk Equation (KFRE) to predict the need for dialysis in patients with CKD, and is presently engaged in implementation efforts with guidelines, lab providers and EMRs to increase the uptake of the KFRE worldwide. In addition, Dr. Tangri leads large observational studies and randomized trials in CKD, and is developing the next generation of prediction models to help transform CKD care. He has published over 400 manuscripts, presented at multiple national and international scientific meetings, and is the nominated champion of the American Society of Nephrology’s efforts on AI in kidney health. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745567336733-1T7LMUWVQO4I9R2KTZW0/Profile.jpg Academia - Anam TARIQ Anam Tariq is a clinician, epidemiologist and regulatory scientist, dual board certified in Nephrology and Internal Medicine. During her clinical training at Johns Hopkins, Anam was involved in several research projects, NIH funded, and worked on numerous projects, such as in metabolomics, autoimmune disease, rare diseases, chronic kidney disease, nutrition, and non-communicable diseases. Dr. Tariq is also an Assistant Professor of Medicine at the George Washington University. She is currently a clinical reviewer at the Office of Clinical Evaluation, in the Office of Cell and Gene Therapy, at the Center for Biologic Evaluation and Research, at the US Food and Drug Administration. She has also worked in Office of New Drugs at the Center for Drug Evaluation and Research and presented at an Advisory Committee Meeting in 2022. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745567585572-66Z7GAE4J77PX3045VT8/Head+shot.jpg Academia - Howard TRACHTMAN Howard Trachtman MD is an adjunct professor of pediatrics at the University of Michigan. He is on the Board of the Kidney Health Initiative and the Alport Syndrome Foundation and the editorial boards of Glomerular Diseases, Pediatric Nephrology, and Expert Opinion in Emerging Drugs. He is a participant in the NEPTUNE and CureGN observational cohort studies. He has been the principal investigator for NIDDK- and industry-sponsored randomized clinical trials for pediatric and adult patients with glomerular disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773999908804-ZCQOSOICUELUGN27ZJ0D/IMG_CTSI_VT.JPG Academia - Vasishta Tatapudi I am an Associate Professor of Medicine at the NYU Grossman School of Medicine and a Transplant Nephrologist at the NYU Langone Transplant Institute. Additionally, I serve as the Program Director of the Transplant Nephrology Fellowship and the Medical Director of the Immunogenetics Lab at NYU Langone. I have played a vital role in expanding our kidney transplant program, establishing it as the largest in New York State. I have significant expertise in HLA, ABO-incompatible kidney transplantation, and domino-paired kidney donation. I attribute my success to the mentorship of the distinguished Dr. Robert Montgomery, Chairman of the Department of Surgery at NYU. As the primary nephrologist in the team led by Dr. Montgomery's team, I contributed to the world's first pig-to-human kidney transplant procedure performed in September 2021. This groundbreaking xenotransplantation study was published in the New England Journal of Medicine (NEJM) in May 2022. In this study, I oversaw glomerular filtration rate (GFR) measurements to assess xenograft function and played an instrumental role in conducting comprehensive histological assessments to determine the presence or absence of rejection in the transplant. Furthermore, I led studies on renal function and physiology in subsequent long-term decedent and first-in-living human renal xenotransplants performed at NYU. These studies focus on identifying and addressing the physiological challenges that must be overcome to make xenotransplantation successful in live human recipients. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745567674810-JWHR93LCB4NVVZKBG5OI/James+Tumlin+MD-Head+Shot-Latest-8-29-19.jpg Academia - James TUMLIN I am the founder and medical director of the NephroNet Clinical trials consortium, a non- profit organization that provides education for patients on the nature of their disease, treatment options, and long-term options including the need for dialysis or transplantation. This consortium was born out of an urgent need to bring new drugs and treatment paradigms to the field of Nephrology, and builds on my experience and expertise gained over the past 30 years as a practicing nephrologist and clinical trialist. NephroNet also partners with academic and industry leaders to advance new therapies and devices that will ultimately improve patients’ lives. I am internationally recognized expert in glomerular disease and author of over 130 peer reviewed manuscripts covering the breadth and depth of basic and clinical research in the field of Nephrology. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600764589826-Y1SJBL1ZCV84COQIO86G/Turan%2Bphoto.jpg Academia - Alparslan TURAN Dr. Alparslan is an Associate Professor of Anesthesiology and staff in the Department of Outcomes Research at the Cleveland Clinic. He is the author of more than 100 peer reviewed papers including a landmark paper on post operative nausea and vomiting (New England Journal of Medicine). Post surgical chronic pain is one of his areas of interest and he has conducted numerous clinical studies on the role of gabapentin in the peri-operative setting. Dr. Alparslan has extensive experience in the training of fellows and residents including supervision of three PhD theses. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773235513396-22AZVKP8FP0GO3MVJU6Q/Foto+2021.jpg Academia - Marina VIVARELLI Marina Vivarelli MV trained in Medicine and in Pediatrics at the University of Pavia, Italy, completed a Research Fellowship at Harvard University-Children’s Hospital Boston, focusing on B cell biology. Since 2006, she has been in the Division of Pediatric Nephrology of Bambino Gesù Children’s Hospital, focusing on the care of children with immune-mediated kidney diseases. Since 2023, she heads the Laboratory of Nephrology and the Clinical Trial Center of the Bambino Gesù Children’s Hospital in Rome, Italy. She co-chairs the ERKNet Working Group on TMAs and is on the executive Committee of the ERKRegistry, has led IPNA guidelines for CNS, SRNS, SSNS and IgAN/V, KDIGO Guidelines of glomerular diseases and complement-mediated renal diseases. She is a Fellow of the ESPN and on the Scientific Advisory Board of ERA, member of the Editorial Board of KI, Pediatric Nephrology and JASN. Since 2025, she has also been nominated by the Italian Drug Agency, AIFA, as member of the National Pediatric Ethics Committee and by the Italian Ministry of Health as member of the Consiglio Superiore di Sanità, the Minister’s expert consulting committee. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773235752068-QR02IQEJLTAYFP2I7IEI/Wang.headshot2.2023.jpg Academia - Chia-shi WANG Chia-shi Wang, MD, MSc is a pediatric nephrologist and Associate Professor of Pediatrics at Emory University School of Medicine in Atlanta, Georgia, U.S.A. She serves as Director of Professional Development Core for the Atlanta Network for Training in Kidney, Urologic, & Hematologic Diseases sponsored by the U.S. National Institutes of Diabetes, Digestive and Kidney Diseases, and is the Director of Clinical and Translational Research of the Emory Pediatric Nephrology Division. She has previously served as Chair of the American Society of Pediatric Nephrology Research Committee and co-Chair of the Pediatric Working Group in the multicenter consortium, Nephrotic Syndrome Study Network. She is a health services researcher and clinical trialist with focus on glomerular diseases and pediatric chronic kidney disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745567781232-PR5E6RT5385VGN3I9PKG/210224_wanner_nephro_ukw_DSC_2055.jpg Academia - Christoph WANNER Christoph Wanner is a Senior Professor of Medicine in the Department of Clinical Studies and Epidemiology, Renal Research Unit, University Hospital of Würzburg and a Visiting Professor of Renal Medicine at the Nuffield Department of Population Health, Clinical Trial Service Unit, University of Oxford UK. His research in the field of diabetic and non-diabetic kidney disease, as well as lipid disorders has been published in more than 1000 pubmed articles. His Hirsch Index - web of science - is 117. Wanners’ two landmark studies in this field have been published in 2005 - The 4D Study - and in 2015 & 2016 - EMPA-REG Outcome Dr. Wanner is the immediate Past President of the European Renal Association https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060102663-VGPCQPDLHRVUZKJJO30E/Weir+Matt+photo.jpg Academia - Matthew WEIR Matthew R. Weir, M.D. is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore. He is also Professor of Medicine at the University of Maryland School of Medicine. Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, cardiovascular disease in patients with chronic kidney disease, and mineralocorticoid receptor antagonism to treat atherosclerosis. He has written more than 600 manuscripts and book chapters about these topics. He has edited 8 books on topics in nephrology, transplantation, and hypertension. He has presented at numerous international scientific association meetings, hospitals, and medical schools. Dr. Weir currently reviews manuscripts for more than 30 major medical journals, including the American Society of Nephrology, and Archives of Internal Medicine. He is on the editorial board of 18 journals and is Section Editor of Current Hypertension Reports and Current Opinion in Hypertension and Nephrology, and Associate Editor of Clinical Nephrology and the American Journal of Nephrology. He has 5 active NIH supported grants: three from NIDDK, and two from NHLBI. In addition, he is a member of numerous associations, including the American Society of Nephrology, the National Kidney Foundation, the American Heart Association, and the American Society of Transplantation. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599553108245-EKPHLJL4WEBH7J2TJHA4/MWest%283%29.jpg Academia - Melissa WEST Melissa West is the Senior Director for Strategic Relations and Patient Engagement at the American Society of Nephrology. The ASN Alliance for Kidney Health consists of several portfolios and international programs that touch on patient care, research, discovery and innovation, policy, education, training, and the future of kidney medicine’s workforce. In her role, Ms. West will ensure the ASN and the ASN Alliance for Kidney Health sustains and grows by identifying new opportunities and relationships, researching leads, and focuses on what is best for people with kidney diseases, kidney failure, and kidney transplants. Before this role, Ms. West lead ASN’s portfolio for Research, Discovery, and Innovation (RDI). The ASN RDI portfolio includes KidneyX, a public-private partnership with the Department of Health and Human Service (HHS) to accelerate innovation in the prevention, diagnosis, and treatment of kidney diseases and Kidney Health Initiative (KHI), a public-private partnership between the American Society of Nephrology, U.S. Food and Drug Administration and over 100 member companies and organizations focused on fostering innovation and enhancing patient safety in kidney disease. Before joining ASN in 2012, Ms. West served as a consultant for the pharmaceutical industry. She was employed with Abbott Laboratories during their launch of Zemplar Capsules in 2004-2006. Her career started in the not-for-profit industry with Smith, Bucklin, and Associates, including management positions with the American Society of Psychiatric Nurses, International Society of Clinical Densitometry, and ending with ASN. She joined ASN as a full-time employee in 2000 as Director of Programs with Kidney Week and assisting with corporate development. With her 20-year career in nephrology, Ms. West is pleased to support ASN’s efforts to transform kidney medicine through partnerships, collaboration, and patient engagement. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634744269450-T6ZKHPRA7EKP30BITYDB/FrancisWilsonProfile.jpg Academia - F. Perry WILSON F. Perry Wilson, MD, MSCE, grew up in Connecticut before attending Harvard College where he graduated with honors in biochemistry. He then attended medical school at Columbia College of Physicians and Surgeons, before completing his internship, residency, and fellowship at the University of Pennsylvania. In 2012, he received a Masters degree in Clinical Epidemiology, which has informed his research ever since. At Yale since 2014, his goal is using patient-level data and advanced analytics to personalize medicine to each individual patient. He is the creator of the popular online course "Understanding Medical Research: Your Facebook Friend Is Wrong" on the Coursera platform. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745568175291-RX7UTYC2RJ5EGUVEL0W0/janet%40wittesllc.com.jpg Academia - Janet WITTES https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634744455528-4LWLWU34AZ9822P67187/Muh-Geot-Wong_v01.jpg Academia - Muh Geot WONG Dr Wong is Renal Physician at the Royal North Shore hospital, Sydney, Australia. He is also a senior research fellow at the George Institute of Global Health and a senior clinical lecturer at UNSW Sydney. His PhD entitled “Novel therapeutic options in models of nephropathy” was awarded in 2011. His main area of research is in understanding the pathomechanisms of kidney tubulointerstitial fibrosis and biomarkers in predicting progression of chronic kidney disease particularly in diabetic kidney disease. Dr Wong has worked on kidney injury molecule-1, transforming growth factor-β1, bone morphogenetic protein-7, Farnesoid X receptor and novel anti-fibrotic and anti-inflammatory agents in extracellular matrix deposition in human proximal tubular cells and in vivo model of fibrosis. His is also passionate in translation medicine and is involved in the post hoc analyses of the IDEAL study and currently involved in multicentre international trials at the George Institute including TESTING and SONAR study. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1732724210634-DSO6R8E4XKFNU6AVY63J/zarbock.jpg Academia - Alexander ZARBOCK Dr. Zarbock is a Clinician Scientist and the Director and Chair of the Department of Anesthesiology and Critical Care Medicine, at the University of Münster, Germany. He acquired training at the University of Münster (Anesthesiology and Critical Care Medicine). Dr. Zarbock is supported by the German Research Foundation. His research interests span various aspects of Critical Care Medicine, but center in critical care nephrology (renal replacement therapy), sepsis and organ protection. Dr. Zarbock’s current projects include measures to avoid acute kidney injury after surgery and the timing of renal replacement therapy in critically ill patients with acute kidney injury. He is also author and co-author of over 300 scientific articles and book chapters. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634744759502-LLFS3X9WRGCA9R9PL5IZ/Professor_Carmine_Zoccali_nephrologist.jpg Academia - Carmine ZOCCALI Carmine Zoccali is an Italian nephrologist associated clinical investigator with the Institute of Clinical Physiology of Pisa, National Research Center (IFC-CNR) at the Reggio Calabria Unit, Italy. He has contributed to research in a number of fields, most notably hypertension, cardiovascular complications of chronic kidney disease (CKD), and CKD progression. He has more than 500 publications listed in PubMed and his h-index is 70.Zoccali is editor-in-chief of Nephrology Dialysis Transplantation, member of the Scientific Advisory Board of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA), member of the ERA-EDTA European Best Practice Committee, ERA EDTA Registry past chairman and past member of the ERA-EDTA Education Committee.Zoccali is also an editorial board member of the Journal of the American Society of Nephrology, the Clinical Journal of the American Society of Nephrology, Hypertension, the European Journal of Clinical Investigation.,Nutrition Metabolism and Cardiovascular Diseases., Turkish Nephrology, Dialysis and transplantation Journal. and Editorial Advisor to BMC Nephrology.Zoccali has been the recipient of the National Kidney Foundation International Award. He is a distinguished fellow of ERA-EDTA, of the American Society of Nephrology, and of the National Kidney Foundation. He is a faculty member of the Global Kidney Academy. https://www.kdctmeeting.com/patients daily 0.75 2026-03-03 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059983384-YLF64GREV8LELEE3UYDW/image-asset.jpeg Patients https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634811594104-6I53J70RDSAG2UPAU6EJ/Cynthia+Chauhan.jpeg Patients - Cynthia CHAUHAN Cynthia L. Chauhan, M.S.W., has stage IV kidney failure secondary to kidney cancer as well as stage III heart failure with preserved ejection fraction and multiple comorbidities among which are hypothyroidism, glaucoma and AMD as well as multiple joint replacements secondary to three types of arthritis. Balancing the requirements of kidney failure and heart failure requires thoughtfulness. The two issues interact with each other to the detriment of her health. Their influence has turned her life into having to take twice as long to do things half as well, but she remain an active, engaged, contributing member of society including working to increase awareness of both and bringing the patient perspective to the cancer, nephrology and cardiology research tables as well as to professional discussions. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772547436458-XXKU0NJ0XIWE18LX3WCH/cc+headshot.JPG Patients - Christopher CHEN Dr. Chen is the Vice President of Research Programs at the PKD Foundation. He has more than 20 years of experience studying PKD and gene therapy. Prior to the PKD Foundation, Dr. Chen was the Assistant Director of Research Support at the Southwest National Primate Research Center. He has also worked for the start-up viral gene therapy companies Imanis and Dyno Therapeutics. Dr. Chen obtained his bachelor’s degree in Genetic Biology from Purdue University and a PhD in Molecular and Human Genetics from Baylor College of Medicine. He completed postdoctoral research at Yale University and Mayo Clinic where he focused on identifying RNA and microRNA PKD biomarkers. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745571099548-Z6PU6GFQCJBE5Z3FZON0/dvcjduquette%40shaw.ca.jpg Patients - D'arcy DUQUETTE D’Arcy is a member of the Surgical and Critical Care SCN’s along with the co-chair of the Citizen Advisory Team, South Health Campus. He is past Chair for the Patient and Family Advisory Committee with the Health Quality Council of Alberta and Senior Patient Partner with Choosing Wisely Canada. D’Arcy is also a committee member of Imagine Citizens Network, the Quality Assurance Committee and Alberta Surgical Initiative Advisory Network. D’Arcy also volunteers as a patient advisor for the Cancer Screening Virtual Education along with Continuing Care, Home Care and Long-Term Care. D’Arcy is also the Patient Advisor for the Acute Disease Quality Initiative (ADQI), Peri-Operative Quality Initiative (POQI) and the kidney disease - Improving Global Outcomes (KDIGO) and a member of the Provincial Emergency Medical Services Standing Committee. (PEMSSC). D’Arcy is committed to providing a safe and quality healthcare system for all Canadian’s. On January 26th, 2023, D'Arcy received the Queen Elizabeth II Platinum Jubilee Medal for Community and Healthcare advocacy. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634811153835-IZHQCNG3JMTAEIDXWRCO/t%C3%A9l%C3%A9chargement.jpeg Patients - Patrick GEE Patrick O. Gee, Sr., Ph.D., JLC Founder & Chief Executive Hope Dealer, iAdvocate, Inc. Patrick Gee graduated from the American University School of Public Affairs in 2012 with a Doctor of Philosophy in Justice, Law, & Criminology. Patrick is a former Peritoneal/Hemodialysis patient due to suffering from Diabetic Kidney Disease. Patrick has been a Post-Kidney Transplant Recipient since April 2017. Patrick is also a retired Major/Chief of Security from the Virginia Department of Corrections; and currently serves as the Founder & CEHD of iAdvocate, Inc., a non-profit Faith-based Health & Wellness organization. He is also an Ordained Minister at Mountain Movers Ministry in Richmond, VA. As a Patient Representative for the Diabetes Kidney Disease-Collaborative Task Force and an advocate for those living with chronic kidney disease and the morbid conditions that contribute to this disease, such as diabetes, cardiovascular disease, hypertension, and obesity, Patrick uses his personal experiences to teach, coach, mentor, and educate others on how best to manage their outcomes. He also ensures that underserved, undervalued, and disenfranchised communities of color have a voice in their quality of life and equitable healthcare access. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634817552602-1PQVR9AFFNO2IOVW23LU/image002.jpg Patients - Tess HARRIS Tess Harris, a British citizen and CEO of Polycystic Kidney Disease Charity, was diagnosed with ADPKD (autosomal dominant polycystic kidney disease) over 40 years ago. She recounts her battle with the disease and how self-education helped her overcome the challenges she faced. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634811446895-X97QZI8IHG1K7MSWXTT6/nichole-jefferson.jpg Patients - Nichole JEFFERSON Nichole Jefferson, who currently resides in Dallas, TX, was diagnosed with end-stage renal disease in 2003 and experienced both forms of dialysis (HD and PD). On June 12, 2008, she received the gift of life, a kidney transplant. Due to the many obstacles she faced following her transplant, Nichole realized that a transplant was simply another form of treatment and not a cure. This realization initiated her enthusiasm for advocacy. Nichole shares her story with her community and underserved populations and speaks with legislators regarding the need for early detection and other issues relating to chronic kidney disease. She became a Field Ambassador for the American Association of Kidney Patients in 2017, joined the Home Dialyzors United (HDU) Board of Directors in 2017 and was recently elected President of the Board. In addition, she serves on the Kidney Precision Medicine Project Community Engagement Committee and is the co-leader of the NIDDK APOLLO Community Advisory Board. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1771406209853-JZC8KP5F136I0Z5XSAS2/Vincent+Headshot+2025-1.jpg Patients - Vincent KO Vincent Ko is the Founder and Executive Director of KidneyFuture (formerly the CAKUT Foundation), a patient-powered organization uniting families, clinicians, researchers and industry to build a brighter future for children born with kidney disease. Inspired by his daughter’s journey with congenital kidney disease (CAKUT) and his mother’s diabetic kidney disease, Vincent brings a caregiver’s perspective from both ends of the spectrum, from pediatric to adult care. He believes that patients and families can play a critical role in supporting innovation across kidney health, from pediatrics and rare diseases to dialysis and post-transplant care. A former entrepreneur, Vincent founded and led two mission-driven companies: VEVA, an air quality technology company, and Panda, a sustainable eyewear brand, before dedicating himself fully to advancing kidney innovation and patient advocacy. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773153506473-SN741SFSO6SFUTX2ML3P/Brittan_Kopittke+Headshot.png Patients - Brittan KOPITTKE Brittan Kopittke’s journey in clinical research began as a patient while participating in a clinical trial for CAR T-cell therapy led by Dr. Saira Sheikh at UNC Chapel Hill. Her experience receiving this novel therapy profoundly shaped her interest in advancing patient-centered research and the development of innovative treatments for autoimmune diseases. Today, Brittan is a clinical research professional at the UNC Thurston Arthritis Research Center, where she supports clinical and cell therapy trials focused on autoimmune and rheumatologic diseases. She is dedicated to bridging the gap between patients, providers, and research teams to expand access to emerging therapies, and ensure that patient voices remain central in the development of new therapies. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1742809000436-DAACCK0B13W61EZC8WZS/steven%2Bmacari.jpg Patients - Steven MACARI Steven is a retired French civil servant, a qualified secondary school teacher, adult educator, and online course developer. A Scots-Italian living in the Poitiers area of France since 1995, he has been living with chronic heart failure since June 2010, following a severe myocardial infarction. His first ICD was implanted in 2013, “upgraded” to a CRT-D in 2016 and replaced in January 2024. His multiple long term conditions include: T2DM, obesity and sleep apnea. He is a founding member and current president of AVEC (Association Vie Et Cœur), a patient-led, heart failure support & advocacy association. Steven is currently enroled in EUPATI Expert patient prgram (cohort 8) and holds two national certificates in THERAPEUTIC PATIENT EDUCATION, (practitioner & program coordinator) as well as a recent certificate as an e-trainer. As a “Patient Expert” he regularly co-hosts TPE workshops at the university teaching hospital in Poitiers and he also intervenes in primary training modules for health care professionals. He has a keen interest in digital health solutions and their integration in a blended healthcare solution and education. He has successfully completed courses at SDABocconi Milan; HTA (2022) and more recently (2024) Heart Health Empowerment Advocacy, Research & Strategic Planning. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634817379159-UR8LWJSTOJIS651YDNA5/vol-nicole.jpg Patients - Nicole SCHOLES After an autoimmune disease depleted her kidney function in 2009, Nicole spent nine months on home-dialysis before undergoing kidney transplant surgery. Since then, she has dedicated much of her life to help other dialysis patients and those with kidney disease. She helps to run the local Kidney Support Group in Armidale for patients and their families, assists with transport to ensure patients can get to their appointments and opens her home at Christmas time to patients who are away from home and cannot spend the holiday with loved ones. She works with many schools, clubs, organisations and local businesses in the Armidale region, to raise funds in order to improve the health journey of patients. In 2018, Nicole created The Norm Bourke Box for Home Dialysis - a free care package for those beginning their home peritoneal dialysis journey, in honour of her friend and for dialysis patient Norm Bourke. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772547157046-SRA3XI2Y2IC74UF08FZ6/Headshot.jpg Patients - Katie STRANGE Katie committed herself to advocacy after she was diagnosed with IgA Nephropathy in 2023. As a Patient Ambassador with the IgA Nephropathy Foundation she works to increase public awareness of IgAN, helping others receive a diagnosis sooner. In this role she advocates for better care for the condition, moderates a monthly online patient support group and serves as the Lead Ambassador for Legislative Advocacy through the IgA Nephropathy Foundation. Katie is a special education teacher in Ohio where she resides with her husband. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772547275266-3W1MRHT1FHKU3ODNSRCG/IMG_2437.jpeg Patients - Jackie SURLS Jackie Surls is a Lupus Foundation of America advocate and scientist, bringing both lived experience and professional expertise to the complexities of lupus. Her perspective is shaped not only by her own 20-year journey with lupus, but also by a strong multigenerational family history, as her mother and sister also live with the disease. This collective experience has given her deep insight into disease uncertainty, treatment burden, and the long-term implications of conditions such as lupus nephritis, as well as the lasting impact that clinical trial design decisions can have on patients and families. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745571235584-S7H7WPLT79X0OVR0BU4I/Josh+Tarnoff+headshot+%281%29.jpg Patients - Joshua TARNOFF JOSH TARNOFF joined NephCure as CEO in early 2018, fulfilling a long-held desire to serve the rare disease patient community more closely. He spent more than 30 years working in the pharmaceutical and biotechnology community, moving new therapies closer to reality. Personal connections with NephCure families fuel his passion to achieve NephCure’s mission-driven goals, and he always appreciates directly speaking with our community. Josh also has personal insights into renal disease as he was once a patient, likely a result of a snake bite. He lives in Pennsylvania, where he enjoys backpacking — while also trying to avoid further contact with venomous snakes. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599052614654-QHXOORFL9IWCEK3UUNTL/Wilkie+Caroline+photo.jpeg Patients - Caroline WILKIE Caroline Wilkie is a nocturnal home hemodialysis patient of 15 years, who is heavily involved in volunteer work with various kidney organizations. She has worked on numerous research projects with KHI, PCORI, NKF, the NIH and other various organizations with the aim of improving the patient quality of life. She resides in southwest Florida with her husband and travels as often as she can. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745571481617-FX8URGM2JX3JUZ4QVOBF/Kerry_willis_2023.png Patients - Kerry WILLIS Dr Willis is the Chief Scientific Officer of the National Kidney Foundation (NKF). Since joining NKF in 1998, her major focus has been on the analysis and application of clinical evidence to improve care and outcomes for people living with kidney disease. She oversees all NKF-sponsored research and professional education programs, including the Spring Clinical Meetings; population health programs that facilitate health system and practice engagement around CKD as a quality improvement target; the Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines; KDOQI quality measurement initiative; and four peer-reviewed journals devoted to chronic kidney disease. She led the development of and currently manages the Kidney CARE (Community Access to Research Equity) Study, the first national CKD patient registry to combine patient-reported data with clinical data from electronic health records. https://www.kdctmeeting.com/industry daily 0.75 2020-09-15 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599131915576-U8C6AA9HE8HA4EIU15NT/image-asset.jpeg Industry https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599144533574-IKJM88H1ZOW06NJ94P1E/JB1.jpg Industry - Juliane BERNHOLZ Dr. Juliane Bernholz has over 27 years of experience working in the pharmaceutical and biotech industry in a variety of senior R&D and business development roles. She joined AM-Pharma as Chief Operating Officer in October 2019. Prior to joining AM-Pharma Juliane was a Compound Development Team Leader at Janssen R&D LLC in New Jersey, US where she was responsible for leading the development of a next generation anticoagulant and CRISPR-Cas3 enhanced bacteriophage therapy. Before her time at Janssen, Dr. Bernholz held a number of international leadership roles in big Pharma and Biotech companies. These included Lead for International Partnering in the Diabetes Division at Sanofi-Aventis in Frankfurt, Germany where she successfully executed a cell therapy and drug discovery collaboration deal. She also served as Senior Global Program Head of the Critical Care Franchise at Novartis Pharma, where she led work on its cystic fibrosis projects. Her prior career included a variety of senior roles at Actelion, Novartis, Ciba and Sandoz. Juliane holds a PhD in Cell biology from the Biozentrum of the University of Basel, Switzerland. Juliane is a Swiss and German national. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054418636-VS007FFDDPJ9LITHDL5C/headshot+Gillespie+2016+plain+background.jpg Industry - Barbara GILLESPIE Barbara S. Gillespie, MD, MMS, FASN is a board-certified nephrologist who is a Vice President at Covance Global CRO and the Therapeutic Head of Nephrology, supporting sponsors on renal drug & device development. She serves on the Board of Directors at the Kidney Health Initiative, a public-private partnership between the FDA and American Society of Nephrology. She also cares for patients as an Adjunct Professor at the University of North Carolina, Division of Nephrology and Hypertension, and until recently as an Associate Medical Director at a local dialysis unit. Dr. Gillespie completed her residency in internal medicine at the University of North Carolina and her nephrology fellowship at Duke University Medical Center. She serves on multiple Stakeholder, Advisory Boards, Steering Committees (e.g. National Kidney Foundation Patient Registry, CardioRenal Society of America Board of Directors, NephCure, PCORI, SONG, etc) and an invited faculty speaker at several global Nephrology Conferences. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054318029-P5IR36WIKV0FT8MW7T63/Hauske+photo.jpg Industry - Sybille HAUSKE Sibylle Hauske is a nephrologist and Senior Global Medical Director leading the Global Clinical Development Program for Empagliflozin in CKD at Boehringer Ingelheim. She is a passionate clinical scientist who is constantly striving to improve outcomes of people living with chronic kidney disease. Her strategic mind-set and multifaceted experience across the spectrum of patient care, academic research, clinical development and regulatory submissions allows her a holistic view on unmet needs of various stakeholders to ultimately driving innovation to fill treatment gaps with the patient at its core. As such, she is currently leading a pragmatic clinical registrations programme in CKD, the EMPA-KIDNEY study, a unique academic collaboration with world-leading partners from the University of Oxford. She has nearly a decade of experience in clinical practice and academic research with a major focus on diabetic kidney disease. Her industry experience spans across identifying novel drug candidates for the treatment of diabetic nephropathy (Sanofi), and driving device development in the area of CGM and closed-loop systems (Roche). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054416803-YMUT2QT0SWFNKZFNO2VB/Landschulz+Katherine+photo.jpg Industry - Katherine LANDSCHULZ Katherine Landschulz, PhD, is the Cardiovascular / Metabolic Disease Therapeutic Area Lead for the Biomarker Solution Center at Covance. She is responsible for biomarker selection / strategy development and feasibility study design for Covance drug development clients. She provides guidance for translational and exploratory biomarker data analysis, and delivers therapeutic expertise for diabetes, metabolic disease and cardiovascular and rare diseases. Her expertise include drug discovery and development, target validation, in vitro screening, in vivo pharmacology, biomarker data for Phase 1-111 submissions and translational biomarkers in preclinical disease, safety models, among others. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600691988068-X49A9EXVHGOBP6D0XKDV/Milliet+photo.jpg Industry - Christian MILLIET Christian Milliet has over 20 years of experience in the pharmaceutical industry. He is currently Global Head Clinical Operations at Vifor Pharma, headquartered in Zurich, Switzerland. Previously, he worked for Novartis, Serono and Covance. Christian has a degree in Business Administration from Webster University in St. Louis, USA. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054393038-T7XHLSMJGOYX4CBMRDIQ/Photo.jpg Industry - Richard NKULIKIYINKA Richard Nkulikiyinka holds a Medical Degree from the University of Cambridge in the UK. He received his Membership of the Royal College of Physicians (MRCP) of London after completing his post-graduate training in general internal medicine at the Royal London and the Northwest London NHS Trusts, with a focus on emergency medicine and intensive care. He also holds a M.Sc. in Epidemiology from the London School of Hygiene and Tropical Medicine. He joined Bayer in 2008, where he has held positions in Pharmacovigilance and Clinical Development, with responsibility for the planning and oversight of Phase 2-3 clinical studies, leading to NDA/MAA submissions in several therapeutic areas. He is currently the Head of the Therapeutic Area Cardiology & Nephrology within the Clinical Development Organization at Bayer Pharmaceuticals, based in Wuppertal, Germany. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600071646776-09L8QJCZRRH4YATICLUG/Romero+Alain+photo.jpg Industry - Alain ROMERO Alain is the Vice President of Medical and Scientific Affairs for Relypsa Pharmaceuticals. Alain joined Relypsa in August 2015 with 25 years of experience in clinical research and development, medical affairs and business development. He has led clinical programs across a wide range of therapeutic areas, including drug delivery, anti-infectives, neuroscience, cardiovascular and respiratory medicine, resulting in the successful filing and launch of several new pharmacological treatments. Before joining Relypsa, Alain was Vice President of Medical Affairs at Actelion, where he launched Opsumit® for pulmonary arterial hypertension. Previously, Alain spent 18 years at Pfizer, where he worked in early clinical research on licensing assets to late-stage development, domestically and internationally, before becoming responsible for Medical Affairs. Prior to joining the biotechnology/pharma industry, Alain practiced at the Rennes University Hospital, was a Research Fellow at Ciba-Geigy, and served as a consultant for several companies and on FDA-mandated audits. He was an Adjunct Professor of Medicine at the University of Rennes and the Miller Medical School in Miami. Alain has a Pharm.D. from the University of Rennes School of Medicine and Pharmacy and a Ph.D. in biomedical and pharmaceutical sciences from the University of Rhode Island. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054305540-JW88O8UC7PIFY9XVL5ZP/Sharma+Amit+photo.jpeg Industry - Amit SHARMA Dr Sharma serves currently as the Vice President of Medical Affairs, Cardiovascular and Renal Division for Bayer, United States. Dr. Sharma received his medical degree from Louisiana State University Medical Center in New Orleans. Dr. Sharma completed his nephrology and hypertension fellowship at the University of California in San Diego where he served as a fellowship director for his site from 2000-2005. Dr. Sharma is board certified by the ABIM for internal medicine, nephrology, and he has an additional certification as a hypertension specialist by the American Society of Hypertension. He has held senior leadership industry positions at Reata, Keryx, Relypsa, and Akebia. Dr. Sharma has served has an appointed member for many national and international committees. He currently serves on the board of directors for the Kidney Health Initiative a public private partnership with the ASN and FDA. He also holds leadership positions for the National Kidney Foundation’s Patient Network as well as its National Leadership Council. He is a fellow of the National Kidney Foundation, the American Society of Nephrology, the American College of Physicians, and is a recently inducted member of the Royal Society of Medicine. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600936424815-XZWS7ISPKXU4Z01YYVBJ/FY+%282%29.jpg Industry - Fred YANG Fred has nearly 25 years of experience in clinical research and drug development, with expertise in on statistics and quantitative science. He assumed positions of increasing responsibility in both large pharmaceutical companies (Abbott, Pharmacia, GSK, etc.) and small biotechnology companies (Discovery Labs), overseeing biostatistics as well as trial conduct and strategic planning. He has successful end-to-end development and worldwide regulatory experience. His therapeutic experience ranges from diabetes and cardiovascular disease to arthritis, oncology, and neonatal care. He has published many peer-reviewed articles. Dr. Yang is currently an Adjunct Associate Professor at Drexel University Medical School. He is also a consultant for the International Breast Cancer Research Foundation (IBCRF). He received his undergraduate education at Peking University and his Ph.D. degree from the University of Wisconsin. https://www.kdctmeeting.com/regulatory daily 0.75 2026-03-10 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599131814428-6ZFVPHMYZ8H7NEIGYO5Y/image-asset.jpeg Regulatory https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634806330585-CL4QTP9RAZBCTDM1D0U0/t%C3%A9l%C3%A9chargement+%281%29.jpeg Regulatory - Carmen GACCHINA JOHNSON Carmen’s research interests are cardiovascular regenerative medicine, intravascular image‐guided thera‐pies, and local drug delivery. Her graduate research focused on regenerative medicine for treatment of ex‐tracellular matrix degradation from vascular disease. She utilized animal models that recapitulated varying stages of clinical abdominal aortic aneurysms (AAA), and then therapeutically delivered biomolecular agents to the derived cells. These biomolecules stimulated extracellular elastic matrix repair with signifi‐cant success. The challenges of sustained delivery of such therapeutic agents to a target pathologic location, such as the site of AAA, sparked her interest in local drug delivery. Therefore, she pursued an opportunity to expand her expertise into the field of image‐guided therapies and local drug delivery for her post‐doctoral training. Carmen’s postdoctoral research projects included image‐guided local embolic and drug delivery for liver cancer therapy, low temperature sensitive liposome (LTSL) drug delivery and high inten‐sity focused ultrasound (HIFU) for enhanced thrombolysis, MR‐guided HIFU for targeted drug delivery of LTSLs in a tumor model, and a minimally‐invasive large animal model of AAA for testing endovascular therapeutic devices. In all of these projects, she focused on understanding the biologic response to local therapy. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1773153946617-3V52K5A7FQFGINP66QCN/Gema+Gonzalez.AAMI+Award.High+Res.Picture+1.jpg Regulatory - Gema GONZALEZ Gema Gonzalez joined FDA in 1995 and has since been serving as a medical device reviewer in the renal, gastroenterology and transplantation fields. In 2015, she became the Team Lead for the Renal and Transplant Devices Team and also served as Acting Assistant Director for that Team from 2022 to 2023. In her role as lead medical device reviewer, she has overseen the regulation of numerous devices under a variety of regulatory premarket submissions, including 510(k)s, Premarket Approval applications (PMAs), Humanitarian Device Exemption applications (HDEs), Investigational Device Exemption applications (IDEs), Pre-submissions, Breakthrough Device Designation requests and Emergency Use Authorizations (EUAs), as well as facilitating various post-market actions. Ms. Gonzalez is also active in the development of standards in the field of renal diseases and apheresis and serves as co-chair for the AAMI Renal Diseases and Detoxification committee, as well as U.S. expert in the corresponding ISO and IEC committees. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634809768183-PSJYJEK9EEAWXZXC7MPM/1517471861957.jpeg Regulatory - Hrefna GUDMUNDSDOTTIR Dr. Guðmundsdóttir is a nephrologist and a doctorate in immunology. Currently, she works for the Icelandic Medicines Agency and serve as a member of CHMP (Committee for Medicinal Products for Human Use) of the European Medicines Agency and both the Scientific Advice Working Party (SAWP) and Rheumatology Immunology Working Party (RIWP). She also holds a part time (20%) position at Landspitali, The National Univeristy Hospital of Iceland. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634806592226-YZOMF3KAJS8DERY8GMO0/esa7qv9dzeoeeuy6lha2.jpg Regulatory - Frank HURST Dr. Hurst is currently a medical officer in the Renal Devices Branch at the Center for Devices and Radiological Health, the group responsible for the regulation of hemodialysis devices as well as other extracorporeal technologies at FDA. He is a Commander in the US Public Health Service, a part-time staff nephrologist at the Walter Reed National Military Medical Center, and an Adjunct Associate Professor in the Department of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD. He completed his internship and residency in Internal Medicine at Tripler Army Medical Center in Honolulu, HI and his nephrology fellowship at the Walter Reed Army Medical Center in Washington, DC. He served as a staff nephrologist at the Walter Reed Army Medical Center prior to transitioning to FDA. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634806765224-WFFHAE08SQ64CC83WSPQ/Rekha+Kambhampati+Headshot.jpg Regulatory - Rekha KAMBHAMPATI Rekha Kambhampati, MD, MHS is a Medical Officer in the Office of New Drugs, Division of Cardiovascular and Renal Products at the Food and Drug Administration. She was awarded her Doctor of Medicine from Drexel University College of Medicine in Philadelphia, PA. She completed her residency in Internal Medicine at Rutgers-Robert Wood Johnson School of Medicine in New Brunswick, NJ and her Nephrology fellowship at Johns Hopkins University School of Medicine in Baltimore, MD. Given her strong interest in public health, she pursued a Master of Health Sciences in Clinical Epidemiology at the Johns Hopkins Bloomberg School of Public Health during which she studied health disparities in chronic kidney disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1772551517677-GJRUROHY3WKMC7G34UEC/Vijay+Kumar.jpg Regulatory - Vijay KUMAR Dr. Vijay Kumar is a board-certified nephrologist and regulatory leader at the FDA who currently serves as Director of the Super Office of Therapeutic Products (OTP) in the Center for Biologics Evaluation and Research (CBER). Dr. Kumar joined the FDA in 2020 as a medical officer and was promoted to lead physician in 2024. During his tenure, he has performed and managed direct reviews of cutting-edge cell and gene therapies and tissue-engineered products, including xenotransplant organs. He is recognized within the office as a key scientific and thought leader in the field of xenotransplantation. Dr. Kumar's two decades of clinical nephrology experience provide him with a deep understanding of the patient care challenges that impact innovation in transplant medicine. His extensive background in nephrology offers valuable clinical perspective at the FDA when evaluating products for patients with kidney disease and other conditions requiring transplant intervention. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1741949796091-21Z0NKTRBLY8CLWHOTFE/katja.jpg Regulatory - Katja ROHWEDDER Katja Rohwedder heads the medical strategy for Finerenone in the Global Medical Affairs team, based in Berlin, Germany. She is a MD and joined Bayer in 2022 in her current role. She has extensive experience from working in the pharma industry for more than 20 years. Before, she worked in different global and local roles in AstraZeneca, including the clinical development of dapagliflozin. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599121338562-ZA3KGVDIDF15X2ZOKH48/IvonneSchulman_8x10.jpg Regulatory - Ivonne SCHULMAN As director of the Translational and Clinical Studies of Acute Kidney Injury Program, Dr. Schulman’s responsibilities include overseeing and managing research portfolios associated with the pathogenesis, prevention, and treatment of acute kidney injury. The portfolio aims to develop novel diagnostic and therapeutic strategies. Also of interest is research on the natural history of acute kidney injury, including studies on risk and outcome stratification, for early stages and progression to chronic kidney disease. Her responsibilities also involve the scientific and programmatic management of single site and multi-institutional studies of acute kidney injury, HIV-associated kidney disease, and COVID-19 associated kidney injury. Furthermore, Dr. Schulman assists with the data requests for the United States Renal Data System research files and with the KUH Loan Repayment Program. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634804071284-2SELVNNGG2CAL5UZ3N1T/21f1.jpg Regulatory - Robert STAR Dr. Robert A. Star is the director of the Division of Kidney, Urologic, and Hematologic Diseases at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). He is also a Senior Investigator and Chief of the Renal Diagnostics and Therapeutics Unit at the NIDDK. Dr. Star was a postdoctoral fellow at NIH in the mid-1980s before joining the faculty of the University of Texas Southwestern Medical Center in Dallas. In 1999, he returned to NIH as a senior scientific advisor for kidney disease and to run a lab studying acute kidney injury. In 2002, he became senior advisor for clinical research in the NIH Office of Science Policy and Planning. He worked on NIH Roadmap for Medical Research initiatives to re-engineer the clinical research enterprise. He developed training and career programs for clinical researchers and helped develop the clinical and translational science awards (CTSA). Dr. Star’s laboratory focuses on the early identification, prevention, and pre-emption of sepsis and acute kidney injury. His research has produced more than 110 published manuscripts, and he has written 8 textbook chapters and holds several patents. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599055950517-OPTFG0Y8ENETTXX4A6BE/Stockbridge+Norman+photo.png Regulatory - Norman STOCKBRIDGE Norman Stockbridge, MD, PhD received his MD in 1978 and PhD in Physiology in 1981 from Duke University. He received post-doctoral training at Duke and New York Medical College. Dr. Stockbridge was a Staff Fellow at the NIH National Eye Institute. In 1985 he joined the faculty of the Department of Surgery at University of Alberta doing basic cellular electrophysiology research. Dr. Stockbridge joined FDA's Division of Cardio-Renal Drug Products in 1991, serving a medical officer, medical team leader, and deputy division director, prior to becoming the division director. He is currently the Director of the Division of Cardiovascular and Renal Products within the FDA Center for Drug Evaluation and Research. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1741948430292-ZK7W905E2K87017PIG15/A+Thompson+photo.jpg Regulatory - Aliza THOMPSON Aliza Thompson is Director of the Division of Cardiology and Nephrology, Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA). The Division of Cardiology and Nephrology regulates and reviews Investigational New Drug applications and marketing applications for drug and biologic products for the treatment of cardiovascular and kidney diseases. Dr. Thompson joined the FDA in 2007. Prior to her current position, Dr. Thompson served as Deputy Director of the Division. Dr. Thompson received her medical degree from Johns Hopkins Medical School and completed her Internal Medicine and Nephrology training at Columbia University/New York-Presbyterian Hospital. She holds a Master of Science in Biostatistics/Patient Oriented Research Track from Columbia University Mailman School of Public Health. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634808789137-C7A0BAUR7BGKLTJAZLIE/karen_woo.jpg Regulatory - Karen WOO Dr. Woo is a vascular surgeon, associate professor of surgery and a health services researcher with clinical practice and research focus on hemodialysis vascular access. She trained in general surgery at Cedars Sinai Medical Center in Los Angeles. She went on to complete a fellowship in vascular surgery at the University of California San Diego and Scripps Clinic. To enhance her research skills, she completed a Master of Science in Clinical and Biomedical Investigation at the University of Southern California. She has received funding from the National Institute for Aging Resource Centers in Minority Aging Research and the National Institutes of Diabetes and Digestive and Kidney Diseases to study outcomes of vascular access. Dr. Woo is a Fellow of the American College of Surgeons and a Distinguished Fellow of the Society for Vascular Surgery. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1774874629374-2W9QGIGZ7FG6ADD51YE3/Kirtida+Mistry-1.png Regulatory - Kirtida MISTRY Kirtida Mistry is a senior physician and clinical reviewer in the Division of Cardiology and Nephrology, Center for Drug Evaluation and Research at the U.S. Food and Drug Administration. Dr. Mistry is a pediatric nephrologist and board certified in Pediatrics and Pediatric Nephrology. Before joining FDA, Dr. Mistry was a Clinical Associate Professor of Pediatrics at the George Washington University, and an attending physician and Medical Director of Dialysis at the Children’s National Health System in Washington, DC. Dr. Mistry completed her training in pediatrics at St. Louis Children’s Hospital, Washington University School of Medicine, St. Louis, MO, and in pediatric nephrology at Children’s Hospital Boston, Harvard Medical School, Boston, MA. https://www.kdctmeeting.com/abigail-ryan daily 0.75 2020-09-02 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599053791636-LJ7WNTKXKXJ4NRH2LIJC/Ryan+Agibal+photo.jpg Abigail RYAN Abigail RYAN https://www.kdctmeeting.com/scientific-committee daily 0.75 2025-09-23 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1598976800343-CME8YIBU3L46J66FWDJM/image-asset.jpeg Scientific Committee https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599056847816-09KDND5IC2HFEMVOHJWW/Rajiv%252BAgarwal%252BKDCT%252B2018.jpg Scientific Committee - Rajiv AGARWAL Dr. Rajiv Agarwal is a practicing nephrologist and a tenured Professor of Medicine at Indiana University School of Medicine at Indianapolis, IN. Dr. Agarwal earned his medical degree from the All India Institute of Medical Sciences in New Delhi. After completing residency in Internal Medicine at the same institution he completed a Nephrology fellowship at University of Texas, Southwestern Dallas. In July 1997, he joined Indiana University as Clinical Assistant Professor and within 10 years was promoted to the rank of full Professor. Dr. Agarwal has published > 250 original papers and reviews in Nephrology. Dr. Agarwal has received the Indiana University Trustee’s teaching award, the young scholar award of the American Society of Hypertension, and the Clinical Excellence award from the American Nephrologists of Indian Origin (ANIO). He serves on the Editorial Board of several nephrology journals and as an Editor for Nephrology Dialysis Transplantation and the American Journal of Nephrology. He also served as an Associate Editor of NephSAP and the Journal of the American Society of Hypertension. He has had numerous invited lectures nationally and internationally. Dr. Agarwal is an internationally recognized leader in the area of clinical and translational research in nephrology. He had chaired numerous event adjudication committees of trials related to diabetic nephropathy and developed methods to adjudicate end stage renal disease in this difficult group of patients. With funding from the National Institutes of Health he has recently uncovered through a randomized clinical trial the ill effects of parenteral iron in CKD. His foremost contribution has been in the area of hypertension in hemodialysis patients for which he has been funded since 2003 by the National Institutes of Health. He has refined the techniques to diagnose and treat hypertension in this complex group of patients and performed important randomized trials in this difficult group of patients. He has been federally funded since 2009 by the Veterans Administration for uncovering the prevalence and mechanisms of masked hypertension in chronic kidney disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1758622964172-59YQDFQKNNTLCVXCD5HA/Floege+2017.jpg Scientific Committee - Jürgen FLOEGE Professor Jürgen Floege is Senior Professor at the RWTH Aachen University Medical School, Germany. He is a former executive council member of the International Society of Nephrology (ISN), the European Renal Association (ERA-EDTA), and KDIGO, recipient of the 2018 ERA-EDTA Award for Outstanding Clinical Contributions to Nephrology and past-president of the German Society of Nephrology and the German Society of Internal Medicine. He co-edits the best-selling textbook “Comprehensive Clinical Nephrology”. Finally, Professor Floege is associate editor of Kidney International and editor-in-chief of Clinical Kidney Journal. Research interests encompass the progression of kidney disease in particular renal fibrosis, as well as clinical research in immune-mediated renal disease, in particular IgA-nephropathy, as well as bone and mineral disorders (CKD-MBD) and cardiovascular disease in uremic patients. He coordinates the KDIGO world-wide guidelines on the management of glomerular diseases. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1758622864511-CNEGA3CGAS4485VDBFHQ/Picture%2BMeg.jpg Scientific Committee - Meg JARDINE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1732286825602-AQOCKNZK9IYTWD1IXGOQ/RZ2_4839.jpg Scientific Committee - Hiddo HEERSPINK Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen. He is also visiting professor at the University of New South Wales in Sydney. He studied pharmacy at the University of Groningen and received his PhD from the University Medical Center Groningen. Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of kidney and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He leads numerous clinical trials with new interventions to reduce diabetes related kidney and cardiovascular complications. His main expertise includes clinical trial design, personalized medicine and methodological aspects and statistical analyses of clinical trials. Professor L. Heerspink has authored and co-authored over 350 peer-reviewed publications and is editorial board member of Diabetes Obesity and Metabolism and the Clinical Journal of the American Society of Nephrology. Prof L. Heerspink is a consultant and has received honoraria from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Pharma, Chinook, Dimerix, Janssen, Fresenius, Gilead, Merck, Mitsubishi Tanabe, Mundi Pharma, NovoNordisk and Travere Pharmaceuticals. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1732286861670-S7XJJB1N7S48DBZ9HJ9V/zz.-NEW-WEBSITE_Adeera-Levin-2.jpg Scientific Committee - Adeera LEVIN Dr Levin is a Professor of Medicine, Head, Division of Nephrology at the University of British Columbia, and Consultant nephrologist at Providence Health Care/ St Paul’s Hospital, in Vancouver Canada. She is the Executive Director of the BC Renal Agency, which oversees the care, planning and budgets for Kidney services in the province of British Columbia She is active in international activities across the spectrum of kidney activities, and has served as in leadership roles at the International Society of Nephrology (ISN), as President ( 2015-17), and is Chair of the ISN ACT ( Advancing clinical Trials) Committee. She was one of the founding members of the Declaration of Istanbul Custodian Group (DICG), serving as one of the first Co-Chairs of that Group. Her major research interests include non- traditional risk factors for CVD in CKD patients and progression of CKD variability, as well as models of care. She has over 600 peer reviewed publications, and numerous book chapters. She is the Principal Investigator on a large national patient-oriented research network grant CAN SOLVE CKD. She collaborates with investigators across Canada and internationally. She has received numerous teaching and research awards, from Canadian Society of Nephrology, Kidney Foundation of Canada, British Columbia Health Research Institute and is a Fellow of Canadian Academy of Health Sciences, and, was awarded the highest civilian honour, The Order of Canada in 2015. She received the ISN Jean Hamburger Award in 2024. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599057740299-4T4U7QF7EUJTB11REW1F/Matthieu+Legrand+photo.jpg Scientific Committee - Matthieu LEGRAND Dr. Matthieu Legrand is an intensivist and anesthesiologist, completed his postgraduate training in Anesthesiology and Critical Care from 2003 to 2010 at Pierre and Marie Curie University in Paris, France, receiving his medical degree in 2010. Thereafter, Dr. Legrand received a PhD degree in Cardiovascular Physiology from Sorbonne Paris Cite University in 2012 and was promoted associated to Full Professor of Anesthesiology and Critical Care Medicine in 2017. He had been serving as the Medical Director of Burn and surgical Intensive Care Units at Saint-Louis Hospital. He moved to the university of California San Francisco in august 2019 as a full Professor in residence in the department of Anesthesiology and Peri-operative care with the goals to pursue his translational research. His research interests cover the pathophysiology of acute kidney injury in peri-operative, the role of the microcirculation in kidney damage and sepsis, and the mechanisms of cardiovascular consequences of acute kidney injury. Dr. Legrand have worked on developing and validating several biomarkers in the setting of kidney injury, sepsis and amniotic fluid embolism. He is the principal investigator or scientific director of several large multicenter studies and randomized controlled trials. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599056910929-V36O9M81SYFG1VJKJEIR/G182+-+Copy.jpg Scientific Committee - Vlado PERKOVIC Professor Vlado Perkovic is the Provost and Scientia Professor at the University of New South Wales in Sydney, Australia, and was previously the Dean of the Faculty of Medicine & Health at UNSW. He is a Nephrologist and a leading clinical trialist in Nephrology. His research focuses on preventing the progression of kidney disease, and its complications. He has led the Steering Committees of a large number of ground-breaking international clinical trials including FLOW, APPLAUSE, DUPLEX, PROTECT, CREDENCE, TESTING, ASCEND, CARMELINA and other, and leads several that are ongoing. He has received several international awards and is a Fellow of the Australian Academy of Health and Medical Sciences. He serves on the Editorial Board of the New England Journal of Medicine, and is a Highly Cited Researcher (Clarivate, top 0.1% of cited authors). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1758624771147-9V0XHD91H5X3FWNDOYVH/interview-du-pr-patrick-rossignol.png Scientific Committee - Patrick ROSSIGNOL https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1758623025034-LQ6OU9Z25GDROH7NKKS4/Headshot+1.22.24.jpg Scientific Committee - Brad ROVIN Dr. Brad H. Rovin is the Lee A. Hebert Professor of Nephrology. Dr. Rovin received his Bachelor of Science in Chemical Engineering from Northwestern University in Evanston Illinois and his Doctor of Medicine from the University of Illinois Medical School in Chicago, Illinois. He completed a residency in Internal Medicine at Barnes Hospital in St. Louis Missouri, and a Fellowship in Nephrology at Washington University School of Medicine, St. Louis. He joined the Ohio State University College of Medicine Faculty in 1990, became Director of the Division of Nephrology in 2004, and served as Vice Chairman of Medicine for Research from 2009- 2019. In 2019 he became the Medical Director of the Ohio State University Center for Clinical Research Management. Dr. Rovin has had several committee and leadership roles in the American Society of Nephrology, including the annual meeting program committee, running the Glomerular Diseases Pre-Course and Co-Editing NephSAP-Glomerular Diseases, a continuing education program of the Society. He serves as deputy Editor of Kidney International, the flagship journal of the International Society of Nephrology, and he is Co-Chair for glomerular disease guideline development for the Kidney Disease Improving Global Outcomes effort. Most recently he received the Evelyn Hess Award from the Lupus Foundation of America for research contributions to improve the understanding of lupus nephritis. Dr. Rovin’s laboratory studies the immunopathogenesis of glomerular and autoimmune diseases and focuses on biomarker development for non-invasive assessment of kidney pathology. He is heavily involved in clinical trial development and design for investigator-initiated and industry-sponsored trials. He is a founding member of NephroNet, a grass-roots nephrology clinical trial organization, and the Lupus Nephritis Clinical Trials Network. He is and has been the Principal Investigator on several trials of novel therapeutics for glomerular diseases. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1598962706463-ZFN60IUKYOO21ONKL1SW/kdct%2B2018%2BPrabir%2BRoy-Chaudhury.jpg Scientific Committee - Prabir ROY-CHAUDHURY Prabir Roy-Chaudhury MD, PhD, FRCP (Edin) is a Professor of Medicine at the University of Arizona Health Sciences. He is also the Director of the Division of Nephrology and the Director of the Arizona Kidney and Vascular Center. After graduating, he trained in Internal Medicine and Nephrology at the University of Aberdeen, Scotland and at the Beth Israel Hospital, Harvard Medical School, Boston, USA. Dr. Roy-Chaudhury’s main research interest is in uremic vascular biology and he currently directs the Arizona Kidney and Vascular Center which is a comprehensive, integrated, multi-disciplinary translational research program that includes basic science, clinical science and patient care components. Dr. Roy-Chaudhury has also been actively involved in the public policy and administrative aspects of dialysis vascular access care and kidney disease as a board member/councilor/committee chair for the American Society of Diagnostic and Interventional Nephrology, the Renal Network, the Interventional Nephrology Advisory Group of the American Society of Nephrology (ASN), the Cardio-Renal Society of America, the Cincinnati chapter of the National Kidney Foundation and the Medical Advisory Board of the Life Center (Ohio). Dr. Roy-Chaudhury is also the American Society of Nephrology co-chair of the Kidney Health Initiative which is a public-private partnership between the ASN and the FDA which aims to bring together nephrologists, industry partners, patient advocacy groups and regulatory agencies; in an attempt to facilitate the passage of drugs, devices and biologics into the kidney disease space. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1598962758385-1RQ18OB5878CHJ19ARFO/photo%2BDr.%2BRuilope.jpg Scientific Committee - Luis RUILOPE Luis M. Ruilope graduated as an MD at the University of Madrid and his residence and fellowship in Nephrology was at the Jimenez Diaz Foundation in Madrid. He is currently the Professor at the Public Health and Preventative Medicine department of the Autonomia University and Head of Cardiovascular and Renal Risk at the Insituto de Investigacion 12 de Octubre. He is an international fellow of the Council for High Blood Pressure Research and of the Council of the Kidney in CV disease of the AHA. Pr Ruilop is the President of the Spanish Hypertension Society and was an Officer at large for the Scientific Council of the European Society from 1993 – 1997. Currently he is also a member of the the Steering Committee for the following studies: HOT, INSIGHT, SCOPE, CONVINCE, ROADMAP, ASCEND and the European coordinator of the study IDNT. A member of the editorial board of: Journal of Hypertension, Blood Pressure, Medicina Clinica, Hypertension, Journal of Human Hypertension, Journal American Society of Nephrology and Nephrology, Dialysis & Transplantation. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1732534830435-MNQUN0Q0TSLZ6YXRTQY9/Image1.jpg Scientific Committee - Christoph WANNER Prof. Christoph Wanner is Professor of Medicine and head of the Division of Nephrology at the University Hospital of Würzburg, Germany He has published more than 690 scientific papers and articles on diabetic kidney disease (HF 75), lipid disorders, statin treatment and rare kidney diseases. He is steering committee member of the EMPA-REG Outcome, the EMPEROR and the EMPA-KIDNEY trials, aiming in slowing the progression of kidney disease and improving cardiovascular outcomes. He is an Associate Editor of the Clinical Journal of the America Society of Nephrology and until this year was the Editor-in-Chief of the Journal of Renal Nutrition. He has received the 2016 Award from the ERA-EDTA for Outstanding Clinical Contributions to Nephrology and in 2018 from the DGfN the Franz Volhard medaille, the highest awards from the German & European Societies of Nephrology. Current Positions: ·Senior Professor of Medicine, Department of Clinical Research and Epidemiology, University Hospital of Würzburg ·Visiting Professor of Renal Medicine, Nuffield Department of Population Health, Clinical Trial Service Unit, University of Oxford, UK Research Focus: ·Diabetic Kidney Disease, Lipid Disorders ·Published over 1000 PubMed articles, Hirsch Index (Web of Science): 116 Landmark Studies: ·The 4D Study (2005), EMPA-REG Outcome (2015&16) Professional Leadership: ·Immediate Past President of the European Renal Association https://www.kdctmeeting.com/payers daily 0.75 2020-09-02 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599131878207-JMFN1NQWIOYK9P5PM8HK/image-asset.jpeg Payers https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599055097682-KWWSOEQQ9D1JA7V1AOAG/OAli+Pic.jpeg Payers - Omar ALI Qualified with a hospital pharmacy background, Omar has been working as the Formulary Advisor for Surrey & Sussex Healthcare NHS Trust for over 15 years, sitting on the regional Joint Drugs & Therapeutics Committee as well as the CCG/Commissioning Prescribing Clinical Network. Omar has been a visiting Lecturer at UCLH Pharmacy Programme and was both Lecturer & Examiner on the Independent Prescribing V300 Course at the University of Surrey and has over 30 publications to date. He has been appointed as Visiting Lecturer on Value Based Pricing & Innovative Contracting at the University of Portsmouth, is an Editorial Content Adviser to Guidelines, and has recently been invited to the position of Associate Editor to the Canadian Journal of Population Therapeutics & Clinical Pharmacology. Omar has served a position on the External Reference Group on Cost Impact Modelling for NICE for 6 years and was subsequently appointed Panel Member for the newly formed Adoption & Impact Program Reference for NICE. He advises foreign investors (US Embassy) on ‘Value Based Assessments (hosted by the UK Department of Trade & Industry) and recently delivered a Healthcare NHS Reform program to over 40 Healthcare Insurance Provider delegates visiting from the US. Last year he was invited to address the Italian Healthcare Senate [Senato della Repubblica] on Pharmaco-economic Evaluation & Sustainability Models of Healthcare and featured at the Westminster Health Forum Keynote Seminars [chaired by Lord Howe, All Party Parliamentary Group on Pharmacy] on the Future for Pharmacy Commissioning, Organisation & Delivery. At this current time he has embarked on a PhD with his doctorate thesis entitled “Value Based Pricing & Outcomes Based, Innovative Contracting of New Medicines”. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599053571565-NYLJKOXBJXF2N63SUGIN/Ryan%2BAgibal%2Bphoto.jpg Payers - Abigail RYAN Dr. Ryan received her Ph.D. in Endocrinology at the Medical College of Georgia. Her postdoctoral fellowship was at Baylor College of Medicine in Houston, Texas. She was on the faculty at the University of Texas Medical School in Houston, Texas. Her research focused on receptors and the mechanism of hormone action. In addition to her medical interests, she studied the financial aspects of health care. She has taught financial, cost and governmental accounting and at local colleges. For the past 15 years she has been with the Department of Health and Human Services, Centers for Medicare and Medicaid, where she has served in Medicaid and Medicare programs, including reimbursement and state financing, program integrity and fee-for-service payment programs. She is currently in the Center for Medicare, Chronic Care Policy Group, where she is the Deputy Director in the Division of Chronic Care Management, heading up the End-Stage Renal Disease Prospective Payment System program. https://www.kdctmeeting.com/fellows daily 0.75 2020-09-02 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599132025872-QH5EWUWC57072KWNM9P4/image-asset.jpeg Fellows https://www.kdctmeeting.com/live daily 0.75 2023-03-02 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1677778598653-6XR2819WQX1US5RI1W9K/KDCT+placeholder+slide+%286%29.png KDCT 2023 Hybrid Workshop https://www.kdctmeeting.com/partners daily 0.75 2026-03-03 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600894330008-ROBN8GQYQT48M6PUPLU3/image-asset.jpeg Partners https://www.kdctmeeting.com/feedback daily 0.75 2020-09-26 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601147744475-U0VO9Y8DX5OLA5PYSQ2O/KDCT+platform.png Give us your feedback https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1601149941435-1H1ZM4GJ1LYMO11TFD0E/Capture+d%E2%80%99%C3%A9cran+%2836%29.png Give us your feedback - THANK YOU! https://www.kdctmeeting.com/academia-1 daily 0.75 2021-08-31 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599131245051-2M9KC0YGI2AYPMWQ17UE/image-asset.jpeg Academia 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600691422580-7W3HTMO6LZV7UJVTZ5LW/Alberti+photo.jpg Academia 2020 - Corinne ALBERTI (copie) Doctor, professor of epidemiology and public health at the UFR of medicine of the University of Paris since 2008, Corinne Alberti heads the clinical epidemiology unit (UEC) of the Robert-Debré university hospital of the AP-HP hospital group North - University of Paris ; the clinical investigation and the clinical epidemiology center (CIC-EC) 1426 (since 2004), and the clinical research unit (URC) of the Robert-Debré Hospital since 2010. Since 2013, she has also been coordinating the F-CRIN PARTNERS platform. Her research are focused on the specific issues of pediatric research whether they are methodological, epidemiological or public health. More particularly in public health, her work is focused on the care pathways for adolescents with chronic disease by mixing anthropo-sociological and clinical epidemiology approaches, and the development of interventions for the well-being of adolescents and young adults and the prevention of risky behavior. Corinne Alberti has also developed a license course for PACES receipts, thus offering these excellent students the opportunity to pursue research-based health training. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1598885847240-JPYYRHDZJTAW33X5HWAJ/Badve+photo.JPG Academia 2020 - Sunil BADVE (copie) Associate Professor Sunil Badve is a staff specialist nephrologist at St George Hospital, Sydney, Australia and Conjoint Associate Professor of Medicine at the George Institute for Global Health, University of New South Wales, Sydney, Australia. He obtained his nephrology training in Mumbai, India and Ottawa, Canada and has been practising as a consultant nephrologist in Australia since 2009. He was awarded PhD by the University of Queensland in 2016 for a thesis ‘Therapeutic interventions to improve clinical outcomes in advanced chronic kidney disease’. He is a fellow of the Australasian College of Physicians and the American Society of Nephrology. A/Prof Badve’s specific areas of research interest are interventions to slow the progression of CKD, reducing cardiovascular mortality in chronic kidney disease, atrial fibrillation and anticoagulation in chronic kidney disease; and determining endpoints for randomised controlled trials. He is the lead investigator of the CKD-FIX, TRACK and PHOSPHATE trials. A/Prof Badve has received more than $10 million NHMRC research funding as a chief investigator. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060860134-OJ0G8EJAXYUAYGXI7NA2/Beddhu+photo.jpg Academia 2020 - Srinivasan BEDDHU (copie) Dr. Beddhu is Professor and DRF Presidential Endowed Chair in the Department of Medicine at the University of Utah, Salt Lake City, UT. His research is focused on hypertension, obesity and cardiovascular disease in CKD and dialysis patients and is supported by funding from NIDDK, NHLBI, VA and industry. He has published more than 125 manuscripts, book-chapters and reviews. He has successfully mentored several medical students, graduate students, residents, fellows, post-docs and junior faculty. He has served on several national panels including NIH, VA, ASN and NKF committees. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1598886923568-OUYUS73E2QT2TMFO34KW/Bonventre-525x700.jpg Academia 2020 - Joseph BONVENTRE (copie) Dr. Bonventre is the Samuel A. Levine Professor of Medicine at Harvard Medical School and Professor of Health Sciences and Technology at the Massachusetts Institute of Technology. He is Chief of the Renal Division and Founding Chief of the Engineering in Medicine Division of the Brigham and Women's Hospital. In addition to his B.S. with distinction in Engineering Physics from Cornell, he holds M.D. and Ph.D. degrees in biophysics from Harvard University. He has honorary doctorate degrees from Mt. Saint Mary’s College and from the Norwegian Institute of Science and Technology in Norway. Dr. Bonventre’s research focuses primarily on the study of kidney injury and repair and signal transduction, with a special emphasis on the role of inflammation, biomarkers and stem cells. His recent work involves the generation of kidney organoids from stem cells and their use in kidney disease modeling. He has more than 350 original research publications, 150 reviews/chapters and editorials and 3 books. His work has been referenced more than 60,000 times and he has an h-index of 129. Dr. Bonventre has been elected to the American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), the American Clinical and Climatological Association (ACCA) and the American Institute for Medical and Biological Engineering (AMBIE). He has been awarded the Osler Medal of the Royal Society of Physicians and the Bywaters Award of the International Society of Nephrology. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599147008486-6QRE63FKDAE7FN19DH2N/Coresh+Joe+copy.jpg Academia 2020 - Josef CORESH (copie) Dr. Joe Coresh is the George W. Comstock Professor of Epidemiology, Biostatistics and Medicine at The Johns Hopkins University Bloomberg School of Public Health. He is an international expert in kidney and cardiovascular disease epidemiology having co-authored over 800 research articles cited over 100,000 times. Each year since 2014 he was recognized as being among the top 1% of researchers in Clinical Medicine globally (by article citations). Among other awards, he received the top scientific and patient impact awards of the United States National Kidney Foundation (NKF Eknoyan and Hume awards) and American Society of Nephrology (ASN Scribner award). Dr. Coresh was vice-chair of the 2002 NKF guideline whose definition of kidney disease which is now used globally. With Drs. Levey, Inker and he published the equations used for estimating kidney function globally. He co-leads the CKD Prognosis Consortium (CKD-PC) which includes over 80 cohorts and >10 million participants from 40+ countries. CKD-PC research regularly informs clinical practice guidelines, regulatory agencies and CKD prevention policies through high impact publications. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060176051-BVB95L2ERT0OCHTQDME5/dember_laura.jpg Academia 2020 - Laura DEMBER (copie) Dr. Dember has more than 20 years of experience as a general nephrologist and is internationally recognized for her expertise in the systemic amyloidoses, a group of rare disorders that often affect the kidneys. She is a member of the Penn multidisciplinary amyloidosis program that evaluates and treats patients with all types of amyloidosis. She conducts patient-oriented research, including mechanistic studies and clinical trials in chronic kidney disease and end-stage renal disease (ESRD). She focuses particularly on hemodialysis vascular access and interventions to improve clinical outcomes in ESRD. Her research is funded by the National Institutes of Health. Dr. Dember is principal investigator for several major projects. The Data Coordinating Center of the NIDDK Hemodialysis Novel Therapies Consortium conducts early-phase clinical trials that target ESRD-associated inflammation and cardiovascular disease. She is a member of the Scientific and Data Coordinating Center for the NIDDK Chronic Renal Insufficiency Cohort Study. She is a deputy editor of the American Journal of Kidney Diseases and has served on multiple NIH grant review panels and committees of the American Society of Nephrology. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599147159544-V28ZZ4CZU3E4CXO243AN/harv-feldman-e1460999211796.jpg Academia 2020 - Harold FELDMAN (copie) Harold (Harv) Feldman, MD, MSCE is the George S. Pepper Professor of Public Health and Preventive Medicine, a Professor of Epidemiology and Medicine (nephrology), and the Director of the Center for Clinical Epidemiology and Biostatistics (CCEB) at the University of Pennsylvania (Penn). Dr. Feldman earned his MD in 1982 from Boston University before training in Internal Medicine at UCLA, as well as nephrology and Clinical Epidemiology at the Penn. He is the former chair of the Department of Biostatistics, Epidemiology, and Informatics at Penn and Past-President of the American College of Epidemiology. He is currently the Editor-in-Chief of the American Journal of Kidney Diseases. Dr. Feldman has led NIH's Chronic Renal Insufficiency Cohort Study (CRIC) for 20 years. Under his leadership, CRIC has extensively published on numerous discoveries with great promise to advance development of novel therapies to reduce morbidity in this population worldwide. For ten years, Dr. Feldman has also led the Scientific and Data Coordinating Center for NIH’s principal initiative addressing biomarkers in chronic kidney disease, the CKD Biomarkers Consortium. His published scholarship of more than 300 research publications has appeared in many leading biomedical journals. It has been recognized through membership in the American Society of Clinical Investigation, the Association of American Physicians, and the American Epidemiological Society. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599147253588-ZY5F1NXHPPMX1DXP2YIB/DSC4732-1024x683.jpg Academia 2020 - William FISSEL (copie) William H. Fissell, M.D., is an Associate Professor of Medicine and Biomedical Engineering within the medical and engineering schools at Vanderbilt University. Dr. Fissell completed an accelerated Internal Medicine residency at University Hospitals of Cleveland, and a fellowship in Nephrology at University of Michigan Medical Center. As a dual-appointee between medicine and engineering , Dr. Fissell has played the leading role in developing an implantable artificial kidney that will allow us to improve access, decrease costs, and improve outcomes for patients with end-stage renal disease. His goal is to create and implement a bioartificial device as a permanent solution to kidney failure. Dr. Fissell began his career by developing submicron systems as an undergraduate at MIT. He has successfully co-developed, implemented, and evaluated the silicon nanotechnology toolkit for renal replacement therapy. Using this approach, he has developed the first new technology to be applied to end-stage renal disease in 30 years. Dr. Fissell is a member of the American Society of Nephrology (ASN), Canadian Society of Nephrology, and is President-Elect of the American Society for Artificial Internal Organs (ASAIO). Dr. Fissell is an active member of the ASN’s Acute Kidney Injury Advisory Group and the ASN Research Advocacy Committee. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599120936760-8NGZW4BWZ33G7SHUCW0X/Ganz+Peter+photo.jpg Academia 2020 - Peter GANZ (copie) Dr. Peter Ganz is a Professor of Medicine at University of California, San Francisco (UCSF). He is a pioneer in two areas of cardiovascular research, human endothelial function and proteomics. Dr. Ganz is using modified aptamers as binding reagents to quantify proteins in blood. He is using proteomics to construct prognostic models of disease (JAMA 2016; 315: 2532-2541) and to understand the biological pathways of diseases and biological mechanisms of drug therapies (Circulation. 2018; 137: 999–1010). He co-led a study on using proteins as a single source of health care (Nature Medicine 2019; 25: 1851–1857). Dr. Ganz received his M.D. from Harvard, completed his residency at the Massachusetts General Hospital and cardiovascular fellowship at the Brigham and Women’s Hospital. He spent 25 years directing cardiovascular research in the cardiac catheterization laboratories at the Brigham and Harvard Medical School, prior to arriving to UCSF in 2008. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060501864-Y8E0KT28ZWYR3URAYBYO/Greene+Tom+photo.jpg Academia 2020 - Tom GREENE (copie) Dr. Tom Greene is chief of the Division of Biostatistics in the Department of Population Health Sciences, and a Professor in the Division of Epidemiology. He is also Director of the Population Health Research Foundation in the Utah Center for Clinical and Translational Science, and currently holds an H.A. and Edna Benning Endowed Chair. Dr. Greene received his PhD in Statistics from Cornell University in 1985, and worked as an Assistant Professor in the Department of Statistics at the University of Kentucky from 1985 to 1989. He then served as a statistician at Case Western University and the Cleveland Clinic Foundation, where he was the lead statistician on a substantial number of multi-center clinical trials. Dr. Greene was the acting head of the Cleveland Clinic’s Cancer Biostatistics Core for 2 years from 1991-1993. Dr. Greene moved to the University of Utah in 2006, where he founded the Study Design and Biostatistics Center and subsequently the Population Health Research Foundation. Dr. Greene serves as the lead statistician on many research projects in collaboration with clinical and translational investigators across the University of Utah and elsewhere, and carries out methodological research in the areas of clinical trial design, causal inference, and validation of surrogate endpoints. He is particularly interested in the problem of integrating information from multiple surrogate and clinical endpoints to evaluate treatment efficacy in randomized clinical trials. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1598887796263-5MAA1QB5F2XEQVD21QSO/jgfv.jpg Academia 2020 - Hiddo Lambers HEERSPINK (copie) Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen and visiting professor at the University of New South Wales in Sydney. He received his PhD from the University Medical Center Groningen. Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He leads and participates in international clinical trials focused on renal and cardiovascular complications of type 2 diabetes. His main expertise includes clinical trial design and personalized medicine as well as methodological aspects and statistical analyses of clinical trials. He is an editorial board member of the Clinical Journal of the American Society of Nephrology and served as guest editor for the scientific journals Diabetes Obesity & Metabolism and Nephrology Dialysis Transplantation. He has authored and co-authored over 300 peer-reviewed publications. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059302525-SC2KJQMP0ZEE5ARZDQBX/Wenjun+Ju+photo.jpg Academia 2020 - Wenjun JU (copie) Dr. Wenjun Ju is an associate research scientist in the Department of Medicine and Department of Computational Medicine and Bioinformatics at the University of Michigan. Dr. Ju has extensive experience on integration of patients’ kidney biopsy transcriptomics, plasma and urinary proteomics, highly granular morphometrics data, cross-sectional and longitudinal clinical data to determine critical molecular networks and pathways for risk stratification, molecular subgrouping, and targeted therapy followed by identification of non-invasive surrogates and final validation in the global research network. Her long term goal is to translate these molecular markers into clinically implementable tools for kidney precision medicine. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060879538-8NZH065D1I7CVGT9C282/Sachin+Kheterpal%2C+M.D.%2C+M.B.A..jpg Academia 2020 - Sachin KHETERPAL (copie) Kheterpal is Professor of Anesthesiology and Associate Dean for Research Information Technology at the University of Michigan Medical School. At the University level, he leads the campus-wide Precision Health Initiative. His career has been focused on the novel use of IT and electronic health records for patient care, quality improvement and research. Sachin leads the Multicenter Perioperative Outcomes Group, a research and quality improvement consortium of more than 50 anesthesiology and surgical departments integrating 14 million patient records. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059317711-MI9I4DGNZAKR4OIXCTKR/Kretzler+Matthias+photo.jpg Academia 2020 - Matthias KRETZLER (copie) Dr. Kretzler is the Warner-Lambert/Parke-Davis Professor of Internal Medicine/Nephrology and Computational Medicine and Bioinformatics. The overarching goal of his research is to define chronic organ dysfunction in mechanistic terms and use this knowledge for targeted therapeutic interventions. To reach this goal he has developed a translational research pipeline centered on integrated systems biology analysis of renal disease. He leads the NIH U54 Nephrotic Syndrome Research Network (Neptune) in the Rare Disease Clinical Research Network II. He co-leads the Coordinating center of the Kidney Precision Medicine Program (KPMP) and the CureGN research network, is the Director of the Applied Systems Biology Core, a principle investigator in the R24 “Integrated Systems Biology Approach to Diabetic Microvascular Complications” and in the NIH Acceleration of Medicine (AMP) program in autoimmunity. He has 20 years of experience in integration of bioinformatics, molecular and clinical approaches in more than 250 papers. He has a tract record on interdisciplinary data integration of large-scale data sets in international multi-disciplinary research networks in the US, Europe, China and sub-Saharan Africa. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600690923619-XCMJ1ZOEKMHCJ6XDFCR5/Laing%2Bphoto.jpg Academia 2020 - Chris LAING (copie) Dr Chris Laing is a consultant nephrologist at UCLH and Royal Free and is Divisional Clinical Director of Emergency Services UCLH. He trained in nephrology, internal medicine and critical care and undertook research in renal tubular disease and physiology with UCL and INSERM Paris. He founded London AKI Network, was a guideline development group member for NICE AKI, co-chaired the education workstream of the National AKI Programme (Think Kidneys) and clinically led a large scale improvement programme in AKI for the UCLPartenrs AHSN. He clinically led the DeepMind Health Royal Free Streams-AKI implementation and has an interest in digital health and data science. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600070755178-DCQ5BBJG5MJ13M1SY3U6/Lok+photo.jpg Academia 2020 - Charmaine LOK (copie) Dr. Charmaine Lok is a Professor of Medicine at the University of Toronto and a Senior Scientist at the Toronto General Research Institute, Toronto, Canada. She is the Medical Director of the multidisciplinary chronic kidney disease (CKD) and hemodialysis programs at the University Health Network-Toronto General Hospital, Toronto, Canada. Her research interests are in clinical trials, patient health outcomes and functional ability, dialysis access and cardiovascular disease in CKD and ESKD. Dr. Lok is also active in raising awareness of CKD and ESKD and its importance in public health. She is the Chair of the KDOQI Vascular Access Guidelines and is involved in a variety of local and international scientific and educational programs, including ASN, CIHR, DOPPS, National Kidney Foundation (NKF), and Kidney CARE Network International. Dr. Lok was recently awarded the NKF’s prestigious Garabed Eknoyan award for improving kidney patients’ quality of life through her exceptional contributions. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060780442-C56MPM6WIFLT067TZSK8/Maerz+Winfried+photo.JPG Academia 2020 - Winfried MAERZ (copie) Winfried Maerz is chair of the Clinical Institute of Medical and Chemical Laboratory Diagnostics at the Medical University of Graz, Austria and has become affiliated with the Mannheim Institute of Public Health, Social and Preventive Medicine at the Medical Faculty Mannheim, University of Heidelberg. Dr. Maerz was deputy head the Division of Clinical Chemistry, University of Freiburg until 2003. Dr. März is also a member of the management advisory board of the Synlab Holding GmbH, head of the Synlab Academy for Continued Medical Education and head of business development at the Synlab Services GmbH. His research interests are epidemiology, the genetics of vascular diseases and the pharmacological treatment of lipid disorders. He has published more than 350 original articles, several book articles and reviews in these fields; He is among the ten mostly cited scientists both in the areas of laboratory medicine and metabolism research in Germany. Dr. Maerz is principal investigator of the Ludwigshafen Risk Factor and Cardiovascular Health Study (LURIC), has been a member of the steering committee of the 4D trial (Die Deutsche Diabetes Dialyse Studie), an endpoint study of atorvastatin in diabetic patients with end-stage renal disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059341243-A0KALUM13N0CVOYTCMMU/Mann+Hans+photo.jpg Academia 2020 - Johaness MANN (copie) Johannes F. E. Mann, M.D., is a Professor of Medicine, Univ. of Erlangen-Nürnberg & Head, KfH Kidney Center, Munich, Germany & International Scholar at PHRI, McMaster University, Canada. He is board-certified in Internal Medicine, Nephrology, Intensive Care and Pharmacology. His work focused initially on the physiology of the RAS in experimental animals and later the role of this system for diseases of the kidney & the heart. From there, his interest moved to the treatment of progressive renal diseases. The latter included steering, adjudication and DSMB memberships in outcome trials, namely AIPRI, HOPE, MICRO-HOPE, HOPE-TOO, RENAL-ONTARGET, RENAL-TRANSCEND, ASCEND, DIABHYCAR, ORIGIN, LEADER, SONAR, SOUL, FLOW, DAPA-CKD. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059371885-YEXK01ECERY77FVUH9AH/Mehta+Ravindra+photo.jpg Academia 2020 - Ravindra MEHTA (copie) Dr Mehta is a Professor Emeritus of Medicine in the Division of Nephrology in the Department of Medicine at University of California San Diego where he directs the UCSD Masters in Clinical Research Program and is the site PI of the NIH funded UAB/UCSD O’Brien Center for AKI research. He is an internationally recognized expert in the field of acute kidney injury (AKI) and CRRT. He chairs the annual International AKI and CRRT Conference in San Diego that is in its 25th year in 2020. He is a founding member of the Acute Dialysis Quality Initiative (ADQI) and the Acute Kidney Injury network (AKIN). His research has informed the development of the RIFLE and AKIN diagnostic and staging criteria for AKI and development of KDIGO guidelines for AKI. He has spearheaded several innovative multicenter studies including the CRRT vs IHD study. He has been recognized as one of the Best Doctors in San Diego and the US for several years. In 2008 he was recognized by the American Nephrologists of Indian Origin and in March 2009 he was elected as a Fellow of the Royal College of Physicians in the UK. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059933979-Q10OHN8F84Z18T6MSG82/Parikh+Chirag+photo.png Academia 2020 - Chirag PARIKH (copie) Dr. Parikh is a Professor of Medicine and the Division Director of Nephrology at Johns Hopkins University. He received his medical degree from Seth G.S. Medical College and KEM Hospital in Mumbai, India and subsequently completed his Nephrology fellowship and a PhD in Clinical Investigation at the University of Colorado Health Sciences Center. Dr. Parikh’s research focuses on the translation and validation of novel biomarkers for the diagnosis and prognosis of acute kidney injury. Progress in kidney diseases has been hamstrung by significant heterogeneity within the current disease definitions, which are largely based on serum creatinine. Dr. Parikh’s research has addressed this critical challenge by developing biomarkers of renal tubular injury, repair, and inflammation to dissect this heterogeneity. Dr. Parikh also conducts a successful mentoring program for fellows interested in patient-oriented research in AKI and kidney diseases, with a focus on translational research. He has over 150 publications with his mentees and nine of his mentees are pursuing careers as physician scientists. Dr. Parikh has been the recipient of numerous honors and awards, including the 2017 Young Investigator Award from the American Society of Nephrology. He also was elected to the prestigious American Society of Clinical Investigation in 2018. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600849506240-UOK7S4WPJ6C78TDXYBFZ/Pitt_Bertram_photo.jpg Academia 2020 - Bertram PITT (copie) Bertram Pitt is a professor of medicine emeritus at the University of Michigan, School of Medicine. Dr Pitt obtained his MD degree from the University of Basel in Switzerland in 1959. He completed a fellowship in cardiology at the Johns Hopkins University School of Medicine and remained on the faculty until 1977, when he left to direct the division of cardiology at the University of Michigan. He has been chairman or co-chairman of a number of clinical trials in cardiology including: SOLVD; ELITE I and II; Prevent; Rales and Ephesus. He is currently chairman of the steering committee of the NHLBI TOPCAT trial examining the effect of spironolactone in patients with HF and preserved LV systolic function; co-chairman of the Emphasis-HF trial examining the role of eplerenone in patients with NYHA Class II HF, chairman of Break- DHF, co-chairman of STOP-CKD, co-chairman of Exceed, co-chairman of Escape-SHF and Escape-DH F, chairman of a study evaluating the role of an aldostereone synthase inhibitor in patients with HF and is a member of the executive committee of the Accomplish trial. In addition, he serves as the chairman of the DSMB for the NHLBI HF-Action trial and has over 500 articles in peer reviewed journals. Dr Pitt has been a member of a number of medical organizations and has served as an advisor to the clinical trials branch of the NHLBI and a member of the FDA cardio-renal advisory board. He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association and has been elected to the Society of Scholars of the Johns Hopkins University. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059940514-383NPZAU7GIDIOV6XX3M/Tangri+photo.jpg Academia 2020 - Navdeep TANGRI (copie) Dr. Tangri is an attending physician and Associate Professor in the Division of Nephrology, Department of Medicine and the Department of Community Health Sciences at the University of Manitoba. Dr. Tangri’s research program is clinical and translational and focused on improving clinical decision making for patients with advanced chronic kidney disease. He developed and validated the Kidney Failure Risk Equation to predict the need for dialysis in patients with CKD, and is presently engaged in multiple validation and implementation exercises to increase the uptake of the KFRE. In addition, Dr. Tangri is conducting a large prospective study on frailty, physical and cognitive function in advanced CKD, as well as leading a multinational randomized trial on the safety and efficacy of a new therapy in this population. He has published over 200 manuscripts and presented at multiple national and international scientific meetings, and is a recipient of the CIHR New Investigator Award and a CIHR Foundation grant. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600764589826-Y1SJBL1ZCV84COQIO86G/Turan%2Bphoto.jpg Academia 2020 - Alparslan TURAN (copie) Dr. Alparslan is an Associate Professor of Anesthesiology and staff in the Department of Outcomes Research at the Cleveland Clinic. He is the author of more than 100 peer reviewed papers including a landmark paper on post operative nausea and vomiting (New England Journal of Medicine). Post surgical chronic pain is one of his areas of interest and he has conducted numerous clinical studies on the role of gabapentin in the peri-operative setting. Dr. Alparslan has extensive experience in the training of fellows and residents including supervision of three PhD theses. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060092615-0BOOKK92NU6MS7TTCQ8K/Verhaar+Marianne+photo.jpg Academia 2020 - Marianne VERHAAR (copie) Trained as a medical doctor and internist-nephrologist, Marianne Verhaar always combined her clinical work with basic, translational and clinical research. After her cum laude PhD in Vascular Biology and next to her work as consultant nephrologist, she established the research laboratory for Regenerative Nephrology and Vascular Biology within the department of Nephrology at the University Medical Center Utrecht (UMCU). She is now head of this department. General aim of her research is to improve care for patients with cardiovascular and chronic kidney disease, particularly by bringing new vascular and renal regenerative treatments and innovations in renal replacement therapies to clinical practice. Research of her group is part of the UMCU Regenerative Medicine & Stem Cells program (chaired by Verhaar). She received many prestigious research grants, and she is one of six research leaders of the NWO Gravitation program ‘Materials-driven regeneration’. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600764882382-TNW080QRZJ8006EFEOBQ/image-asset.jpeg Academia 2020 - Michael WALSH (copie) Dr. Walsh is a graduated from the University of Calgary with a MD (2001), postgraduate training in in Internal Medicine (2005) and Nephrology (2006) and a MSc in Community Health Science (2008), completed training in lupus and vasculitis in Cambridge, UK (2009), and his PhD in Health Research Methods at McMaster University (2014). He is now an Associate Professor of Medicine and Health Research Methods, Evidence & Impact at McMaster University and has an active nephrology practice at St. Joseph’s Healthcare Hamilton where he is also the medical director of the Glomerulonephritis Clinic. Dr. Walsh’s research focuses on improving the treatment of patients with chronic kidney disease and vascular diseases by evaluating the effects of therapies on outcomes important to patients and healthcare providers. His interests include treatments to reduce the incidence of kidney failure from autoimmune diseases, the prevention of heart related complications of kidney disease and the reduction of symptoms caused by kidney disease. He is a member of the European Vasculitis Research Group EUVAS and the Population Health Research Institute. Dr. Walsh's research is funded by the Canadian Institutes of Health Research, National Institute of Health Research, Food and Drug Administration, National Health and Medical Research Council, and the Canadian Centre and Network for Trials Internationally. He is the co-principal investigator of the PEXIVAS trial and the Remote IMPACT trial and leads a large prospective cohort study in perioperative acute kidney injury. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060169751-HTKJSGG5UC0PHEM0ZEEM/Wang+Angela+photo.JPG Academia 2020 - Angela WANG (copie) Angela Yee Moon WANG is a staff nephrologist and clinician Scientist at the Queen Mary Hospital, University of Hong Kong, Hong Kong. She is the current President of the International Society of Renal Nutrition and Metabolism (ISRNM), Council member of the International Society of Peritoneal Dialysis (ISPD), ISN Regional Board member, Executive Committee member of the SONG Initiative and previous Executive Committee Member of KDIGO. She is a Steering member of ISPD Prescribing High Quality PD Practice Recommendation 2019 and KDOQI Nutrition Guidelines in CKD 2019. She previously chaired the ISPD Adult Cardiovascular and Metabolic Guidelines 2015 and was a Core member of the KDIGO –CKD-MBD guidelines 2009. She received the United States National Kidney Foundation Joel D. Kopple Award 2018, John Maher Award of ISPD 2006 and Travelling Lecturer Award of Asia Pacific Federation of Clinical Biochemistry 2012. She currently serves on the editorial boards of journals including J Am Soc Nephrol, Clin JASN, NDT Theme Editor, Nephron Clinical Practice (Associate Editor), J Renal Nutrition, Kidney Medicine and Renal Replacement Therapy (RRT) (Associate Editor) and is Editor-in-Chief of European Medical Journal-Nephrology. She was previous Associate Editor of Am J Kidney Dis and International Editor of Clin JASN. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060102663-VGPCQPDLHRVUZKJJO30E/Weir+Matt+photo.jpg Academia 2020 - Matthew WEIR (copie) Matthew R. Weir, M.D. is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore. He is also Professor of Medicine at the University of Maryland School of Medicine. Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, cardiovascular disease in patients with chronic kidney disease, and mineralocorticoid receptor antagonism to treat atherosclerosis. He has written more than 600 manuscripts and book chapters about these topics. He has edited 8 books on topics in nephrology, transplantation, and hypertension. He has presented at numerous international scientific association meetings, hospitals, and medical schools. Dr. Weir currently reviews manuscripts for more than 30 major medical journals, including the American Society of Nephrology, and Archives of Internal Medicine. He is on the editorial board of 18 journals and is Section Editor of Current Hypertension Reports and Current Opinion in Hypertension and Nephrology, and Associate Editor of Clinical Nephrology and the American Journal of Nephrology. He has 5 active NIH supported grants: three from NIDDK, and two from NHLBI. In addition, he is a member of numerous associations, including the American Society of Nephrology, the National Kidney Foundation, the American Heart Association, and the American Society of Transplantation. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599553108245-EKPHLJL4WEBH7J2TJHA4/MWest%283%29.jpg Academia 2020 - Melissa WEST (copie) Melissa West is the Projet Director for the Kidney Health Initiative (KHI), a public-private partnership between the American Society of Nephrology, U.S. Food and Drug Administration and over 75 member companies and organization focused on fostering innovation and enhancing patient safety in kidney disease. Prior to joining KHI in 2012, Ms. West served as a consultant for the pharmaceutical industry coordinating their activities at scientific conferences. She was employed with Abbott Laboratories during their launch of Zemplar Capsules in 2004-2006. Her career started in toe not-for-profit industry with Smith, Bucklin and Associates, including management positions with the American Society of Psychiatric Nurses, International Society of Clinical Densitometry and ending with the American Society of Nephrology. She joined the American Society of Nephrology as a full time employee in 2000 as Director of Programs with Kidney Week and assisting with corporate development. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060157909-SLZPYYI05ZNBZ80PUVT1/Wittes+Janet+photo.jpg Academia 2020 - Janet WITTES (copie) Janet Wittes, PhD is President of Statistics Collaborative, Inc. which she founded in 1990. Previously, she was Chief, Biostatistics Research Branch, National Heart, Lung, & Blood Institute (1983–89). The 2006 monograph, “Statistical Monitoring of Clinical Trials – A Unified Approach” by Proschan, Lan, and Wittes, deals with sequential trials. Her research has focused on design of randomized clinical trials, capture‑recapture methods in epidemiology, and sample size recalculation. She has served on a variety of advisory committees and data monitoring committees for government (NHLBI, the VA, NEI, and NCI) and industry. For the FDA, she has in the past been a member of the Circulatory Devices Advisory Panel and of the Cell and Gene Therapy Advisory Committee. She was formerly Editor in Chief of Controlled Clinical Trials (1994-98). https://www.kdctmeeting.com/program-2024 daily 0.75 2024-12-23 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1701864330260-UZANEITXWWEKUQ0CDVV1/image-asset.jpeg Scientific Program https://www.kdctmeeting.com/prerecording daily 0.75 2021-09-14 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1631115233059-07E8DXFSQEP5DZJYMQEC/unsplash-image-TXb3gowXIHU.jpg Pre-recording https://www.kdctmeeting.com/academia-2 daily 0.75 2021-09-16 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599131245051-2M9KC0YGI2AYPMWQ17UE/image-asset.jpeg Academia (Copy) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060176051-BVB95L2ERT0OCHTQDME5/dember_laura.jpg Academia (Copy) - Laura DEMBER (Copy) Dr. Dember has more than 20 years of experience as a general nephrologist and is internationally recognized for her expertise in the systemic amyloidoses, a group of rare disorders that often affect the kidneys. She is a member of the Penn multidisciplinary amyloidosis program that evaluates and treats patients with all types of amyloidosis. She conducts patient-oriented research, including mechanistic studies and clinical trials in chronic kidney disease and end-stage renal disease (ESRD). She focuses particularly on hemodialysis vascular access and interventions to improve clinical outcomes in ESRD. Her research is funded by the National Institutes of Health. Dr. Dember is principal investigator for several major projects. The Data Coordinating Center of the NIDDK Hemodialysis Novel Therapies Consortium conducts early-phase clinical trials that target ESRD-associated inflammation and cardiovascular disease. She is a member of the Scientific and Data Coordinating Center for the NIDDK Chronic Renal Insufficiency Cohort Study. She is a deputy editor of the American Journal of Kidney Diseases and has served on multiple NIH grant review panels and committees of the American Society of Nephrology. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599147159544-V28ZZ4CZU3E4CXO243AN/harv-feldman-e1460999211796.jpg Academia (Copy) - Harold FELDMAN (Copy) Harold (Harv) Feldman, MD, MSCE is the George S. Pepper Professor of Public Health and Preventive Medicine, a Professor of Epidemiology and Medicine (nephrology), and the Director of the Center for Clinical Epidemiology and Biostatistics (CCEB) at the University of Pennsylvania (Penn). Dr. Feldman earned his MD in 1982 from Boston University before training in Internal Medicine at UCLA, as well as nephrology and Clinical Epidemiology at the Penn. He is the former chair of the Department of Biostatistics, Epidemiology, and Informatics at Penn and Past-President of the American College of Epidemiology. He is currently the Editor-in-Chief of the American Journal of Kidney Diseases. Dr. Feldman has led NIH's Chronic Renal Insufficiency Cohort Study (CRIC) for 20 years. Under his leadership, CRIC has extensively published on numerous discoveries with great promise to advance development of novel therapies to reduce morbidity in this population worldwide. For ten years, Dr. Feldman has also led the Scientific and Data Coordinating Center for NIH’s principal initiative addressing biomarkers in chronic kidney disease, the CKD Biomarkers Consortium. His published scholarship of more than 300 research publications has appeared in many leading biomedical journals. It has been recognized through membership in the American Society of Clinical Investigation, the Association of American Physicians, and the American Epidemiological Society. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1598887796263-5MAA1QB5F2XEQVD21QSO/jgfv.jpg Academia (Copy) - Hiddo Lambers HEERSPINK (Copy) Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen and visiting professor at the University of New South Wales in Sydney. He received his PhD from the University Medical Center Groningen. Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular diseases in patients with diabetes with a specific focus on personalized medicine. He leads and participates in international clinical trials focused on renal and cardiovascular complications of type 2 diabetes. His main expertise includes clinical trial design and personalized medicine as well as methodological aspects and statistical analyses of clinical trials. He is an editorial board member of the Clinical Journal of the American Society of Nephrology and served as guest editor for the scientific journals Diabetes Obesity & Metabolism and Nephrology Dialysis Transplantation. He has authored and co-authored over 300 peer-reviewed publications. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060879538-8NZH065D1I7CVGT9C282/Sachin+Kheterpal%2C+M.D.%2C+M.B.A..jpg Academia (Copy) - Sachin KHETERPAL (Copy) Kheterpal is Professor of Anesthesiology and Associate Dean for Research Information Technology at the University of Michigan Medical School. At the University level, he leads the campus-wide Precision Health Initiative. His career has been focused on the novel use of IT and electronic health records for patient care, quality improvement and research. Sachin leads the Multicenter Perioperative Outcomes Group, a research and quality improvement consortium of more than 50 anesthesiology and surgical departments integrating 14 million patient records. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059317711-MI9I4DGNZAKR4OIXCTKR/Kretzler+Matthias+photo.jpg Academia (Copy) - Matthias KRETZLER (Copy) Dr. Kretzler is the Warner-Lambert/Parke-Davis Professor of Internal Medicine/Nephrology and Computational Medicine and Bioinformatics. The overarching goal of his research is to define chronic organ dysfunction in mechanistic terms and use this knowledge for targeted therapeutic interventions. To reach this goal he has developed a translational research pipeline centered on integrated systems biology analysis of renal disease. He leads the NIH U54 Nephrotic Syndrome Research Network (Neptune) in the Rare Disease Clinical Research Network II. He co-leads the Coordinating center of the Kidney Precision Medicine Program (KPMP) and the CureGN research network, is the Director of the Applied Systems Biology Core, a principle investigator in the R24 “Integrated Systems Biology Approach to Diabetic Microvascular Complications” and in the NIH Acceleration of Medicine (AMP) program in autoimmunity. He has 20 years of experience in integration of bioinformatics, molecular and clinical approaches in more than 250 papers. He has a tract record on interdisciplinary data integration of large-scale data sets in international multi-disciplinary research networks in the US, Europe, China and sub-Saharan Africa. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600070755178-DCQ5BBJG5MJ13M1SY3U6/Lok+photo.jpg Academia (Copy) - Charmaine LOK (Copy) Dr. Charmaine Lok is a Professor of Medicine at the University of Toronto and a Senior Scientist at the Toronto General Research Institute, Toronto, Canada. She is the Medical Director of the multidisciplinary chronic kidney disease (CKD) and hemodialysis programs at the University Health Network-Toronto General Hospital, Toronto, Canada. Her research interests are in clinical trials, patient health outcomes and functional ability, dialysis access and cardiovascular disease in CKD and ESKD. Dr. Lok is also active in raising awareness of CKD and ESKD and its importance in public health. She is the Chair of the KDOQI Vascular Access Guidelines and is involved in a variety of local and international scientific and educational programs, including ASN, CIHR, DOPPS, National Kidney Foundation (NKF), and Kidney CARE Network International. Dr. Lok was recently awarded the NKF’s prestigious Garabed Eknoyan award for improving kidney patients’ quality of life through her exceptional contributions. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060780442-C56MPM6WIFLT067TZSK8/Maerz+Winfried+photo.JPG Academia (Copy) - Winfried MAERZ (Copy) Winfried Maerz is chair of the Clinical Institute of Medical and Chemical Laboratory Diagnostics at the Medical University of Graz, Austria and has become affiliated with the Mannheim Institute of Public Health, Social and Preventive Medicine at the Medical Faculty Mannheim, University of Heidelberg. Dr. Maerz was deputy head the Division of Clinical Chemistry, University of Freiburg until 2003. Dr. März is also a member of the management advisory board of the Synlab Holding GmbH, head of the Synlab Academy for Continued Medical Education and head of business development at the Synlab Services GmbH. His research interests are epidemiology, the genetics of vascular diseases and the pharmacological treatment of lipid disorders. He has published more than 350 original articles, several book articles and reviews in these fields; He is among the ten mostly cited scientists both in the areas of laboratory medicine and metabolism research in Germany. Dr. Maerz is principal investigator of the Ludwigshafen Risk Factor and Cardiovascular Health Study (LURIC), has been a member of the steering committee of the 4D trial (Die Deutsche Diabetes Dialyse Studie), an endpoint study of atorvastatin in diabetic patients with end-stage renal disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059341243-A0KALUM13N0CVOYTCMMU/Mann+Hans+photo.jpg Academia (Copy) - Johaness MANN (Copy) Johannes F. E. Mann, M.D., is a Professor of Medicine, Univ. of Erlangen-Nürnberg & Head, KfH Kidney Center, Munich, Germany & International Scholar at PHRI, McMaster University, Canada. He is board-certified in Internal Medicine, Nephrology, Intensive Care and Pharmacology. His work focused initially on the physiology of the RAS in experimental animals and later the role of this system for diseases of the kidney & the heart. From there, his interest moved to the treatment of progressive renal diseases. The latter included steering, adjudication and DSMB memberships in outcome trials, namely AIPRI, HOPE, MICRO-HOPE, HOPE-TOO, RENAL-ONTARGET, RENAL-TRANSCEND, ASCEND, DIABHYCAR, ORIGIN, LEADER, SONAR, SOUL, FLOW, DAPA-CKD. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059371885-YEXK01ECERY77FVUH9AH/Mehta+Ravindra+photo.jpg Academia (Copy) - Ravindra MEHTA (Copy) Dr Mehta is a Professor Emeritus of Medicine in the Division of Nephrology in the Department of Medicine at University of California San Diego where he directs the UCSD Masters in Clinical Research Program and is the site PI of the NIH funded UAB/UCSD O’Brien Center for AKI research. He is an internationally recognized expert in the field of acute kidney injury (AKI) and CRRT. He chairs the annual International AKI and CRRT Conference in San Diego that is in its 25th year in 2020. He is a founding member of the Acute Dialysis Quality Initiative (ADQI) and the Acute Kidney Injury network (AKIN). His research has informed the development of the RIFLE and AKIN diagnostic and staging criteria for AKI and development of KDIGO guidelines for AKI. He has spearheaded several innovative multicenter studies including the CRRT vs IHD study. He has been recognized as one of the Best Doctors in San Diego and the US for several years. In 2008 he was recognized by the American Nephrologists of Indian Origin and in March 2009 he was elected as a Fellow of the Royal College of Physicians in the UK. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059933979-Q10OHN8F84Z18T6MSG82/Parikh+Chirag+photo.png Academia (Copy) - Chirag PARIKH (Copy) Dr. Parikh is a Professor of Medicine and the Division Director of Nephrology at Johns Hopkins University. He received his medical degree from Seth G.S. Medical College and KEM Hospital in Mumbai, India and subsequently completed his Nephrology fellowship and a PhD in Clinical Investigation at the University of Colorado Health Sciences Center. Dr. Parikh’s research focuses on the translation and validation of novel biomarkers for the diagnosis and prognosis of acute kidney injury. Progress in kidney diseases has been hamstrung by significant heterogeneity within the current disease definitions, which are largely based on serum creatinine. Dr. Parikh’s research has addressed this critical challenge by developing biomarkers of renal tubular injury, repair, and inflammation to dissect this heterogeneity. Dr. Parikh also conducts a successful mentoring program for fellows interested in patient-oriented research in AKI and kidney diseases, with a focus on translational research. He has over 150 publications with his mentees and nine of his mentees are pursuing careers as physician scientists. Dr. Parikh has been the recipient of numerous honors and awards, including the 2017 Young Investigator Award from the American Society of Nephrology. He also was elected to the prestigious American Society of Clinical Investigation in 2018. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600849506240-UOK7S4WPJ6C78TDXYBFZ/Pitt_Bertram_photo.jpg Academia (Copy) - Bertram PITT (Copy) Bertram Pitt is a professor of medicine emeritus at the University of Michigan, School of Medicine. Dr Pitt obtained his MD degree from the University of Basel in Switzerland in 1959. He completed a fellowship in cardiology at the Johns Hopkins University School of Medicine and remained on the faculty until 1977, when he left to direct the division of cardiology at the University of Michigan. He has been chairman or co-chairman of a number of clinical trials in cardiology including: SOLVD; ELITE I and II; Prevent; Rales and Ephesus. He is currently chairman of the steering committee of the NHLBI TOPCAT trial examining the effect of spironolactone in patients with HF and preserved LV systolic function; co-chairman of the Emphasis-HF trial examining the role of eplerenone in patients with NYHA Class II HF, chairman of Break- DHF, co-chairman of STOP-CKD, co-chairman of Exceed, co-chairman of Escape-SHF and Escape-DH F, chairman of a study evaluating the role of an aldostereone synthase inhibitor in patients with HF and is a member of the executive committee of the Accomplish trial. In addition, he serves as the chairman of the DSMB for the NHLBI HF-Action trial and has over 500 articles in peer reviewed journals. Dr Pitt has been a member of a number of medical organizations and has served as an advisor to the clinical trials branch of the NHLBI and a member of the FDA cardio-renal advisory board. He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association and has been elected to the Society of Scholars of the Johns Hopkins University. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059940514-383NPZAU7GIDIOV6XX3M/Tangri+photo.jpg Academia (Copy) - Navdeep TANGRI (Copy) Dr. Tangri is an attending physician and Associate Professor in the Division of Nephrology, Department of Medicine and the Department of Community Health Sciences at the University of Manitoba. Dr. Tangri’s research program is clinical and translational and focused on improving clinical decision making for patients with advanced chronic kidney disease. He developed and validated the Kidney Failure Risk Equation to predict the need for dialysis in patients with CKD, and is presently engaged in multiple validation and implementation exercises to increase the uptake of the KFRE. In addition, Dr. Tangri is conducting a large prospective study on frailty, physical and cognitive function in advanced CKD, as well as leading a multinational randomized trial on the safety and efficacy of a new therapy in this population. He has published over 200 manuscripts and presented at multiple national and international scientific meetings, and is a recipient of the CIHR New Investigator Award and a CIHR Foundation grant. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600764589826-Y1SJBL1ZCV84COQIO86G/Turan%2Bphoto.jpg Academia (Copy) - Alparslan TURAN (Copy) Dr. Alparslan is an Associate Professor of Anesthesiology and staff in the Department of Outcomes Research at the Cleveland Clinic. He is the author of more than 100 peer reviewed papers including a landmark paper on post operative nausea and vomiting (New England Journal of Medicine). Post surgical chronic pain is one of his areas of interest and he has conducted numerous clinical studies on the role of gabapentin in the peri-operative setting. Dr. Alparslan has extensive experience in the training of fellows and residents including supervision of three PhD theses. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060092615-0BOOKK92NU6MS7TTCQ8K/Verhaar+Marianne+photo.jpg Academia (Copy) - Marianne VERHAAR (Copy) Trained as a medical doctor and internist-nephrologist, Marianne Verhaar always combined her clinical work with basic, translational and clinical research. After her cum laude PhD in Vascular Biology and next to her work as consultant nephrologist, she established the research laboratory for Regenerative Nephrology and Vascular Biology within the department of Nephrology at the University Medical Center Utrecht (UMCU). She is now head of this department. General aim of her research is to improve care for patients with cardiovascular and chronic kidney disease, particularly by bringing new vascular and renal regenerative treatments and innovations in renal replacement therapies to clinical practice. Research of her group is part of the UMCU Regenerative Medicine & Stem Cells program (chaired by Verhaar). She received many prestigious research grants, and she is one of six research leaders of the NWO Gravitation program ‘Materials-driven regeneration’. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600764882382-TNW080QRZJ8006EFEOBQ/image-asset.jpeg Academia (Copy) - Michael WALSH (Copy) Dr. Walsh is a graduated from the University of Calgary with a MD (2001), postgraduate training in in Internal Medicine (2005) and Nephrology (2006) and a MSc in Community Health Science (2008), completed training in lupus and vasculitis in Cambridge, UK (2009), and his PhD in Health Research Methods at McMaster University (2014). He is now an Associate Professor of Medicine and Health Research Methods, Evidence & Impact at McMaster University and has an active nephrology practice at St. Joseph’s Healthcare Hamilton where he is also the medical director of the Glomerulonephritis Clinic. Dr. Walsh’s research focuses on improving the treatment of patients with chronic kidney disease and vascular diseases by evaluating the effects of therapies on outcomes important to patients and healthcare providers. His interests include treatments to reduce the incidence of kidney failure from autoimmune diseases, the prevention of heart related complications of kidney disease and the reduction of symptoms caused by kidney disease. He is a member of the European Vasculitis Research Group EUVAS and the Population Health Research Institute. Dr. Walsh's research is funded by the Canadian Institutes of Health Research, National Institute of Health Research, Food and Drug Administration, National Health and Medical Research Council, and the Canadian Centre and Network for Trials Internationally. He is the co-principal investigator of the PEXIVAS trial and the Remote IMPACT trial and leads a large prospective cohort study in perioperative acute kidney injury. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060169751-HTKJSGG5UC0PHEM0ZEEM/Wang+Angela+photo.JPG Academia (Copy) - Angela WANG (Copy) Angela Yee Moon WANG is a staff nephrologist and clinician Scientist at the Queen Mary Hospital, University of Hong Kong, Hong Kong. She is the current President of the International Society of Renal Nutrition and Metabolism (ISRNM), Council member of the International Society of Peritoneal Dialysis (ISPD), ISN Regional Board member, Executive Committee member of the SONG Initiative and previous Executive Committee Member of KDIGO. She is a Steering member of ISPD Prescribing High Quality PD Practice Recommendation 2019 and KDOQI Nutrition Guidelines in CKD 2019. She previously chaired the ISPD Adult Cardiovascular and Metabolic Guidelines 2015 and was a Core member of the KDIGO –CKD-MBD guidelines 2009. She received the United States National Kidney Foundation Joel D. Kopple Award 2018, John Maher Award of ISPD 2006 and Travelling Lecturer Award of Asia Pacific Federation of Clinical Biochemistry 2012. She currently serves on the editorial boards of journals including J Am Soc Nephrol, Clin JASN, NDT Theme Editor, Nephron Clinical Practice (Associate Editor), J Renal Nutrition, Kidney Medicine and Renal Replacement Therapy (RRT) (Associate Editor) and is Editor-in-Chief of European Medical Journal-Nephrology. She was previous Associate Editor of Am J Kidney Dis and International Editor of Clin JASN. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060102663-VGPCQPDLHRVUZKJJO30E/Weir+Matt+photo.jpg Academia (Copy) - Matthew WEIR (Copy) Matthew R. Weir, M.D. is attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore. He is also Professor of Medicine at the University of Maryland School of Medicine. Dr. Weir’s primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans, cardiovascular disease in patients with chronic kidney disease, and mineralocorticoid receptor antagonism to treat atherosclerosis. He has written more than 600 manuscripts and book chapters about these topics. He has edited 8 books on topics in nephrology, transplantation, and hypertension. He has presented at numerous international scientific association meetings, hospitals, and medical schools. Dr. Weir currently reviews manuscripts for more than 30 major medical journals, including the American Society of Nephrology, and Archives of Internal Medicine. He is on the editorial board of 18 journals and is Section Editor of Current Hypertension Reports and Current Opinion in Hypertension and Nephrology, and Associate Editor of Clinical Nephrology and the American Journal of Nephrology. He has 5 active NIH supported grants: three from NIDDK, and two from NHLBI. In addition, he is a member of numerous associations, including the American Society of Nephrology, the National Kidney Foundation, the American Heart Association, and the American Society of Transplantation. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599553108245-EKPHLJL4WEBH7J2TJHA4/MWest%283%29.jpg Academia (Copy) - Melissa WEST (Copy) Melissa West is the Projet Director for the Kidney Health Initiative (KHI), a public-private partnership between the American Society of Nephrology, U.S. Food and Drug Administration and over 75 member companies and organization focused on fostering innovation and enhancing patient safety in kidney disease. Prior to joining KHI in 2012, Ms. West served as a consultant for the pharmaceutical industry coordinating their activities at scientific conferences. She was employed with Abbott Laboratories during their launch of Zemplar Capsules in 2004-2006. Her career started in toe not-for-profit industry with Smith, Bucklin and Associates, including management positions with the American Society of Psychiatric Nurses, International Society of Clinical Densitometry and ending with the American Society of Nephrology. She joined the American Society of Nephrology as a full time employee in 2000 as Director of Programs with Kidney Week and assisting with corporate development. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599060157909-SLZPYYI05ZNBZ80PUVT1/Wittes+Janet+photo.jpg Academia (Copy) - Janet WITTES (Copy) Janet Wittes, PhD is President of Statistics Collaborative, Inc. which she founded in 1990. Previously, she was Chief, Biostatistics Research Branch, National Heart, Lung, & Blood Institute (1983–89). The 2006 monograph, “Statistical Monitoring of Clinical Trials – A Unified Approach” by Proschan, Lan, and Wittes, deals with sequential trials. Her research has focused on design of randomized clinical trials, capture‑recapture methods in epidemiology, and sample size recalculation. She has served on a variety of advisory committees and data monitoring committees for government (NHLBI, the VA, NEI, and NCI) and industry. For the FDA, she has in the past been a member of the Circulatory Devices Advisory Panel and of the Cell and Gene Therapy Advisory Committee. She was formerly Editor in Chief of Controlled Clinical Trials (1994-98). https://www.kdctmeeting.com/patients-1 daily 0.75 2021-09-16 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599059983384-YLF64GREV8LELEE3UYDW/image-asset.jpeg Patients (Copy) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599052586578-U1CNM08RFUJKSNSVP3YD/tib-chauhanc-401-200+%281%29.jpg Patients (Copy) - Cynthia CHAUHAN (Copy) Cynthia Chauhan has stage III heart failure with preserved ejection fraction which was diagnosed 3 1/2 years ago and multiple comorbidities including stage III kidney failure secondary to kidney cancer and nephrectomy. There are very few treatment options for heart failure patients with preserved ejection fraction and 50% of us die within the first five years from diagnosis so I enter every clinical trial for HFpEF for which I am eligible. The heart failure has turned my life into having to take twice as long to do things half as well but I remain an active, engaged, contributing member of society including working to increase awareness of HFpEF and bringing the patient perspective to the research table and to professional discussions. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599052494480-SUYOZQ2IZUOR1PEXKAP3/Gee+Patrick+photo.png Patients (Copy) - Patrick GEE (Copy) Patrick Gee était un patient en dialyse péritonéale depuis décembre 2013. Le 21 avril 2017, Patrick a reçu une greffe de rein au Hume-Lee Transplant Center du Medical College of Virginia / Virginia Commonwealth University. Après avoir passé 33 jours à l'hôpital, quatre chirurgies et une attente de 47 jours jusqu'à ce que son rein commence à fonctionner, Patrick revient à plaider en faveur de soins de santé plus complets, de l'engagement des patients, de ressources éducatives communautaires et d'une meilleure qualité de vie pour les patients atteints de reins. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599146885645-GEQ6UZKQX62YOAZIDH84/Quella_photo.jpg Patients (Copy) - Susan QUELLA (Copy) Susan Quella, RN, BSN, had a 37 year career at Mayo Clinic, first as a Physician Extender in Urology for 11 years, then as a clinical trial nursing chair for a 35 U.S. clinic Oncology research group (NCCTG, North Central Cancer Treatment Group), then became the Project Manager for international clinical trials, and finally Lead RN for Nicotine Research Clinical Trials. Susan has been published in several U.S. medical journals and has received the Literary Award from the British Journal of Medicine. Susan had developed the Oncology Patient Advocate Committee for Mayo Clinic and since retirement has volunteered for research committees at Mayo as a patient advocate herself. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599052614654-QHXOORFL9IWCEK3UUNTL/Wilkie+Caroline+photo.jpeg Patients (Copy) - Caroline WILKIE (Copy) Caroline Wilkie is a nocturnal home hemodialysis patient of 8 years, who is heavily involved in volunteer work with the National Kidney Foundation, and Kidney Health Initiative. Caroline is a member of the National Kidney Foundation’s (NKF) Kidney Advocacy Committee and the NKF PEERS program. She is a member of the Kidney Health Initiative’s (KHI) Patient and Family Partnership Council. She served on a KHI steering committee workgroup project entitled: “Prioritizing Symptoms of ESRD Patients for Developing Therapeutic Interventions.” She worked on a PCORI Project as part of the investigative team entitled: “Building Research Capacity in the Dialysis Community at the Local Level.” She is also one of the co-chairs on a new KHI project entitled: “Fostering Innovation in Fluid Management,” which focueses on new strategies for management of hypervolemia. She and her husband, Jeff Kuhns, reside in Southwest Florida. https://www.kdctmeeting.com/industry-1 daily 0.75 2021-09-16 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599131915576-U8C6AA9HE8HA4EIU15NT/image-asset.jpeg Industry (Copy) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600084745807-QJURMGDZS7MKSA2IXZY3/Adler+photo.jpg Industry (Copy) - John ADLER (Copy) John Adler has more than 20 years’ experience as a statistician working across several therapeutic areas. He is currently VP and Head of Biometrics for Cardiovascular, Renal and Metabolism at AstraZeneca. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600848670985-6O3DFTRV6M8JWQP28OCQ/Alcorn+photo.jpg Industry (Copy) - Harry ALCORN (Copy) Harry Alcorn Jr., Pharm.D. was appointed our Chief Medical Officer and Vice President of Clinical Affairs in August 2018. Prior to joining DiaMedica, Dr. Alcorn served as Chief Scientific Officer of Total Renal Research, Inc., doing business as DaVita Clinical Research (“DCR”), a clinical research facility, from November 1997 to July 2018. While at DCR, Dr. Alcorn was responsible for clinical research operations, including management of the early clinical research unit. Dr. Alcorn also designed and created the U.S. Renal Network, the first network of Phase I renal research sites in the U.S. Dr. Alcorn developed DCR's site management organization for clinical trials. Dr. Alcorn also served as an Executive Director, a Pharmacist and an Investigator at DCR. From March 1996 to November 1997, Dr. Alcorn served as Executive Director of Clinical Programs for GalaGen, Inc., a Pharmaceutical company. From March 1992 to March 1996, Dr. Alcorn served as Vice President, Marketing/Sales and Clinical Programs of In Home Health, Inc., a national home health provider. Dr. Alcorn served on the board of directors of Medtox Scientific Inc. Dr. Alcorn is also a Clinical Assistant Professor at Creighton University School of Pharmacy, Virginia Commonwealth University School of Pharmacy, University of Minnesota, College of Pharmacy and University of Nebraska Medical Center, College of Pharmacy. Dr. Alcorn is also on the adjunct clinical faculty at the University of Colorado. Dr. Alcorn graduated from Creighton University with his Bachelor of Science degree in Pharmacy and went on to receive his Doctor of Pharmacy degree from the University of Nebraska Medical Center. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599566259962-B2D4CD91PGM1O2GEQ98K/Auerbach+photo.JPG Industry (Copy) - Pernille AUERBACH (Copy) Pernille Auerbach joined Novo Nordisk A/S, Copenhagen, Denmark, in 2016 and currently holds the position of Associate Global Medical Director for once-weekly Semaglutide Diabetes, Diabetes & Outcomes, Global Medical Affairs. She graduated as a medical doctor from the University of Copenhagen in 2010 and completed a PhD in Health and Medical Sciences in 2014. Her PhD research focussed on the metabolic function and distribution of adipose tissue in relation to obesity-induced insulin resistance and adaptations after lifestyle interventions. Prior to starting with Novo Nordisk, Dr Auerbach worked in various clinical settings specialised in endocrinology, orthopaedic surgery and general medicine. She is co-author of several peer-reviewed articles and co-founder of the University of Copenhagen’s Food, Fitness and Pharma Young Investigator Network, established in 2010. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599144533574-IKJM88H1ZOW06NJ94P1E/JB1.jpg Industry (Copy) - Juliane BERNHOLZ (Copy) Dr. Juliane Bernholz has over 27 years of experience working in the pharmaceutical and biotech industry in a variety of senior R&D and business development roles. She joined AM-Pharma as Chief Operating Officer in October 2019. Prior to joining AM-Pharma Juliane was a Compound Development Team Leader at Janssen R&D LLC in New Jersey, US where she was responsible for leading the development of a next generation anticoagulant and CRISPR-Cas3 enhanced bacteriophage therapy. Before her time at Janssen, Dr. Bernholz held a number of international leadership roles in big Pharma and Biotech companies. These included Lead for International Partnering in the Diabetes Division at Sanofi-Aventis in Frankfurt, Germany where she successfully executed a cell therapy and drug discovery collaboration deal. She also served as Senior Global Program Head of the Critical Care Franchise at Novartis Pharma, where she led work on its cystic fibrosis projects. Her prior career included a variety of senior roles at Actelion, Novartis, Ciba and Sandoz. Juliane holds a PhD in Cell biology from the Biozentrum of the University of Basel, Switzerland. Juliane is a Swiss and German national. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600158516651-Q6T8QAVXKELMPFS13YY1/Cha+Teddy.jpeg Industry (Copy) - Teddy CHA (Copy) Teddy Cha is the CEO and cofounder of pulseData, data intelligence for chronic disease management. Our mission is to deliver proactive, precise care to every chronic disease sufferer, eliminating preventable sickness. In 1999, Teddy left Wall Street to rent a garage and build an instant messenger, which was a great product but terrible business. He's been in starting and leading high-growth, enterprise software product teams ever since. Three years ago he reunited with his cofounder, a classmates and good friend from undergrad at MIT, and discovered what is possible with health care data - a messy, giant data set in a messy, giant industry, with an opportunity to eliminate predictable sickness. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054336625-GWN8Y15CBQ3KL6IR87VA/image002.jpg Industry (Copy) - Frank CZERWIEC (Copy) Frank Czerwiec is Chief Medical Officer of Goldfinch Bio, “The Kidney Company” based in Cambridge MA. In this role, he is responsible for leading all aspects of clinical development and partners with the CMO, CSO and CBO/COO in driving the overall strategy for the company’s current and future R&D pipeline. Dr. Czerwiec comes to Goldfinch Bio from Otsuka Pharmaceutical Development & Commercialization, Inc, where as VP Global Clinical Development he co-led a department of physicians of CNS, Oncologic and Renal products. Most notably, his team was responsible for the approval of tolvaptan, the first treatment approved to delay chronic kidney disease progression in autosomal dominant polycystic kidney disease and the first US-FDA approved drug for treating an important form of CKD in the past decade. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599566299656-XV5JZPUUGU474OK2SL4Z/De+Remigis+photo.jpg Industry (Copy) - Alessandra DE REMIGIS (Copy) MD, certified Endocrinologist/diabetologist, worked also as Internal Medicine Specialist for 8 years. 2 years ago transitioned into Pharma as Medical Advisor in Eli Lilly & Co. to work on SGLT2i, responsible to drive education and communication on new outcome trials regarding CV and renal benefits. Recently moved to a Global position as Global Medical Manger in Novo Nordisk A/S In Diabetes Outcomes Teams, dedicated to CV and renal outcomes in GLP1RA trials and beyond. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054365487-4M99ZG4I8NJKTK3TC9UI/Elliott+Jay+photo.JPG Industry (Copy) - Jay ELLIOTT (Copy) Jay Elliott is a Senior Scientist in Bayer’s U.S. Medical Affairs organization supporting clinical-stage renal and cardiovascular assets. In this role, he manages strategic medical planning and execution including data generation, scientific communication and collaboration with external stakeholders. Jay has over 12 years of diverse pharmaceutical industry experience as a Medical Science Liaison, Field Medical Director and Clinical Trial Manager of Phase II-IV clinical trials. He is currently based in Cincinnati Ohio and holds a PhD from the University of North Carolina at Chapel Hill with a postdoctoral fellowship at the Medical University of South Carolina. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599822805050-VL8I77T8TFUDULNMG468/Erlandsson+photo.png Industry (Copy) - Fredrik ERLANDSSON (Copy) Fredrik received his basic medical training at Karolinska Institute, were he subsequently also presented his PhD thesis. After working for the Swedish national health service Fredrik joined Bayer Pharmaceuticals, where he contributed to the development of Nexavar, the first tyrosine kinase inhibitor approved for renal clear cell cancer and hepatocellular carcinoma. After the blockbuster launch of Nexavar Fredrik joined Antisoma, a UK clinical stage biotech company, where he was the senior medical lead on projects from pre-clinical to clinical stage. He subsequently returned to Sweden and the national health service before joining AstraZeneca in 2011. Fredrik has experience from all stages of drug development, from target identification to phase IV, and has worked with small molecules. antibodies, oligonucleotides and fusion proteins. Fredrik has developed drugs for nephrology for 8 years, and currently focuses on the development of URAT1 inhibitor verinurad for chronic kidney disease and heart failure. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054418636-VS007FFDDPJ9LITHDL5C/headshot+Gillespie+2016+plain+background.jpg Industry (Copy) - Barbara GILLESPIE (Copy) Barbara S. Gillespie, MD, MMS, FASN is a board-certified nephrologist who is a Vice President at Covance Global CRO and the Therapeutic Head of Nephrology, supporting sponsors on renal drug & device development. She serves on the Board of Directors at the Kidney Health Initiative, a public-private partnership between the FDA and American Society of Nephrology. She also cares for patients as an Adjunct Professor at the University of North Carolina, Division of Nephrology and Hypertension, and until recently as an Associate Medical Director at a local dialysis unit. Dr. Gillespie completed her residency in internal medicine at the University of North Carolina and her nephrology fellowship at Duke University Medical Center. She serves on multiple Stakeholder, Advisory Boards, Steering Committees (e.g. National Kidney Foundation Patient Registry, CardioRenal Society of America Board of Directors, NephCure, PCORI, SONG, etc) and an invited faculty speaker at several global Nephrology Conferences. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054318029-P5IR36WIKV0FT8MW7T63/Hauske+photo.jpg Industry (Copy) - Sybille HAUSKE (Copy) Sibylle Hauske is a nephrologist and Senior Global Medical Director leading the Global Clinical Development Program for Empagliflozin in CKD at Boehringer Ingelheim. She is a passionate clinical scientist who is constantly striving to improve outcomes of people living with chronic kidney disease. Her strategic mind-set and multifaceted experience across the spectrum of patient care, academic research, clinical development and regulatory submissions allows her a holistic view on unmet needs of various stakeholders to ultimately driving innovation to fill treatment gaps with the patient at its core. As such, she is currently leading a pragmatic clinical registrations programme in CKD, the EMPA-KIDNEY study, a unique academic collaboration with world-leading partners from the University of Oxford. She has nearly a decade of experience in clinical practice and academic research with a major focus on diabetic kidney disease. Her industry experience spans across identifying novel drug candidates for the treatment of diabetic nephropathy (Sanofi), and driving device development in the area of CGM and closed-loop systems (Roche). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600952434451-UWEA2MSHFYH4ZMWOYE4T/Kraus+photo.png Industry (Copy) - Bettina KRAUS (Copy) Bettina J Kraus, MD, is a clinician-scientist, cardiologist, heart failure and hypertension specialist at the university hospital of Wuerzburg, Germany. She has long-standing expertise in the treatment of HF, resistant hypertension and diabetes, especially in patients with CKD. Kidney protection in challenging situations such as decompensated HF is one of her missions. Bettina Kraus was trained at Charité, Harvard University and the German Comprehensive Heart Failure Centre, and she is a nucleus member of the working group on cardiometabolic interaction “Herz und Diabetes” of the German Cardiac Society. In various translational research projects she explored the interaction of glucose metabolism and myocardial function. For many years she worked in major cardiovascular outcomes trials such as IMPROVE-IT, EMPHASIS-HF, REVEAL or COMPASS. Her current research focuses on the impact of cardio-renal interactions in patients with and without diabetes. She is convinced that an interdisciplinary approach to the cardio-kidney-metabolic continuum is fundamentally important for future patient care. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054416803-YMUT2QT0SWFNKZFNO2VB/Landschulz+Katherine+photo.jpg Industry (Copy) - Katherine LANDSCHULZ (Copy) Katherine Landschulz, PhD, is the Cardiovascular / Metabolic Disease Therapeutic Area Lead for the Biomarker Solution Center at Covance. She is responsible for biomarker selection / strategy development and feasibility study design for Covance drug development clients. She provides guidance for translational and exploratory biomarker data analysis, and delivers therapeutic expertise for diabetes, metabolic disease and cardiovascular and rare diseases. Her expertise include drug discovery and development, target validation, in vitro screening, in vivo pharmacology, biomarker data for Phase 1-111 submissions and translational biomarkers in preclinical disease, safety models, among others. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600691988068-X49A9EXVHGOBP6D0XKDV/Milliet+photo.jpg Industry (Copy) - Christian MILLIET (Copy) Christian Milliet has over 20 years of experience in the pharmaceutical industry. He is currently Global Head Clinical Operations at Vifor Pharma, headquartered in Zurich, Switzerland. Previously, he worked for Novartis, Serono and Covance. Christian has a degree in Business Administration from Webster University in St. Louis, USA. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054393038-T7XHLSMJGOYX4CBMRDIQ/Photo.jpg Industry (Copy) - Richard NKULIKIYINKA (Copy) Richard Nkulikiyinka holds a Medical Degree from the University of Cambridge in the UK. He received his Membership of the Royal College of Physicians (MRCP) of London after completing his post-graduate training in general internal medicine at the Royal London and the Northwest London NHS Trusts, with a focus on emergency medicine and intensive care. He also holds a M.Sc. in Epidemiology from the London School of Hygiene and Tropical Medicine. He joined Bayer in 2008, where he has held positions in Pharmacovigilance and Clinical Development, with responsibility for the planning and oversight of Phase 2-3 clinical studies, leading to NDA/MAA submissions in several therapeutic areas. He is currently the Head of the Therapeutic Area Cardiology & Nephrology within the Clinical Development Organization at Bayer Pharmaceuticals, based in Wuppertal, Germany. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600071646776-09L8QJCZRRH4YATICLUG/Romero+Alain+photo.jpg Industry (Copy) - Alain ROMERO (Copy) Alain is the Vice President of Medical and Scientific Affairs for Relypsa Pharmaceuticals. Alain joined Relypsa in August 2015 with 25 years of experience in clinical research and development, medical affairs and business development. He has led clinical programs across a wide range of therapeutic areas, including drug delivery, anti-infectives, neuroscience, cardiovascular and respiratory medicine, resulting in the successful filing and launch of several new pharmacological treatments. Before joining Relypsa, Alain was Vice President of Medical Affairs at Actelion, where he launched Opsumit® for pulmonary arterial hypertension. Previously, Alain spent 18 years at Pfizer, where he worked in early clinical research on licensing assets to late-stage development, domestically and internationally, before becoming responsible for Medical Affairs. Prior to joining the biotechnology/pharma industry, Alain practiced at the Rennes University Hospital, was a Research Fellow at Ciba-Geigy, and served as a consultant for several companies and on FDA-mandated audits. He was an Adjunct Professor of Medicine at the University of Rennes and the Miller Medical School in Miami. Alain has a Pharm.D. from the University of Rennes School of Medicine and Pharmacy and a Ph.D. in biomedical and pharmaceutical sciences from the University of Rhode Island. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600071907820-5OULJDJ1Y26WVQSE2A1O/Schiller+photo.jpg Industry (Copy) - AnnaLotta SCHILLER (Copy) Regional manager for Southern Europe & France. AnnaLotta has a Ph.D. in molecular biology and nutrigenomics and more than 25 years’ experience as a life science professional with previous roles in research & development, application support, marketing, sales and product management. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054305540-JW88O8UC7PIFY9XVL5ZP/Sharma+Amit+photo.jpeg Industry (Copy) - Amit SHARMA (Copy) Dr Sharma serves currently as the Vice President of Medical Affairs, Cardiovascular and Renal Division for Bayer, United States. Dr. Sharma received his medical degree from Louisiana State University Medical Center in New Orleans. Dr. Sharma completed his nephrology and hypertension fellowship at the University of California in San Diego where he served as a fellowship director for his site from 2000-2005. Dr. Sharma is board certified by the ABIM for internal medicine, nephrology, and he has an additional certification as a hypertension specialist by the American Society of Hypertension. He has held senior leadership industry positions at Reata, Keryx, Relypsa, and Akebia. Dr. Sharma has served has an appointed member for many national and international committees. He currently serves on the board of directors for the Kidney Health Initiative a public private partnership with the ASN and FDA. He also holds leadership positions for the National Kidney Foundation’s Patient Network as well as its National Leadership Council. He is a fellow of the National Kidney Foundation, the American Society of Nephrology, the American College of Physicians, and is a recently inducted member of the Royal Society of Medicine. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600952075531-GVDSMIIRPH4H6PI9YJQV/Sheldon+photo.jpg Industry (Copy) - Murray SHELDON (Copy) Dr. Murray Sheldon, MD received his medical degree from the University of Michigan Medical School in 1975 and his cardiovascular fellowship at the Montefiore Hospital and Medical Center in New York. After practicing cardiac, thoracic and vascular surgery in Northern California for over 20 years, he entered the medical device industry, leading device development projects and providing expert consultative services to numerous start-up innovative medical device development firms. Dr. Sheldon joined the FDA in 2013 as the Associate Director for Technology and Innovation overseeing the Center's initiative to proactively facilitate medical device innovation to address unmet public health needs and to align what is traditionally done at FDA with what is required to support the US medical device ecosystem. His primary focus is working with FDA staff, the medical device industry, the clinical community and other stakeholders on ways to facilitate bringing innovative medical devices to the patients in the US first in the world. Dr. Sheldon currently leads the Medical Device Payer Communication Task Force, identifying methods to streamline the path from FDA approval to reimbursement. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600085838170-9S0OAZSQUOH6EVXY29HG/Stefansson+photo.jpg Industry (Copy) - Bergur STEFANSSON (Copy) Bergur V. Stefansson has a doctoral degree from the University of Gothenburg, where he has studied treatment of renal anemia in patients on chronic hemodialysis. From 2000 to 2002, he has been a chief physician in the department of Nephorology, in the Central Hospital KSS, Sweden. Today, he leads the Global Clinical Program, R&D, CVRM, AZ in Gothenburg, Sweden. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600936424815-XZWS7ISPKXU4Z01YYVBJ/FY+%282%29.jpg Industry (Copy) - Fred YANG (Copy) Fred has nearly 25 years of experience in clinical research and drug development, with expertise in on statistics and quantitative science. He assumed positions of increasing responsibility in both large pharmaceutical companies (Abbott, Pharmacia, GSK, etc.) and small biotechnology companies (Discovery Labs), overseeing biostatistics as well as trial conduct and strategic planning. He has successful end-to-end development and worldwide regulatory experience. His therapeutic experience ranges from diabetes and cardiovascular disease to arthritis, oncology, and neonatal care. He has published many peer-reviewed articles. Dr. Yang is currently an Adjunct Associate Professor at Drexel University Medical School. He is also a consultant for the International Breast Cancer Research Foundation (IBCRF). He received his undergraduate education at Peking University and his Ph.D. degree from the University of Wisconsin. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600870536516-VVDRB7M6O4HC5CKLDT8V/Yavin+photo.png Industry (Copy) - Yshai YAVIN (Copy) Yshai Yavin, MBChB MFPM, is Director in Cardiovascular and Metabolism Development and has been the Study Responsible Physician for the CREDENCE study since joining Janssen in March 2016. He received his medical degree from the University of Pretoria, South Africa, where he qualified in General Medicine and practiced in several fields. He subsequently completed specialist training in Pharmaceutical Medicine from the Faculty of Pharmaceutical Medicine, UK. Before joining Janssen, Yshai worked at Bristol-Myers Squibb in Medical Affairs as well as Clinical Development. Before his career in industry, Yshai worked for several years as a clinical research fellow and co-investigator at Kings College Hospital, London. https://www.kdctmeeting.com/fellows-1 daily 0.75 2021-09-16 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599132025872-QH5EWUWC57072KWNM9P4/image-asset.jpeg Fellows (Copy) https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599055556207-AB8IXEQRP060SDP1KN3N/D%C3%A9pret+Fran%C3%A7ois+photo.jpg Fellows (Copy) - François DEPRET (Copy) François Dépret is an intensivist and anesthesiologist, assistant professor at Saint-Louis hospital in Paris. His major clinical interests include hemodynamic, septic shock and burn patients. Dr Dépret research focuses on clinical research related to randomized control trial in septic patients and burn patients, epidemiology as well as outcomes research in burn patients, septic patients and critically ill patients in general. Dr Dépret has published over 30 manuscript in peer review journals such as Critical Care, Critical care Medicine, Burns and others. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599055570596-LJA2JUOOFSQUW6I3OHIP/Lazzareschi+Daniel+photo.JPEG Fellows (Copy) - Daniel LAZZARESCHI (Copy) Daniel is a research fellow and resident physician in anesthesiology at the University of California, San Francisco. He completed his undergraduate studies in biology at the University of California, Berkeley, and later attended medical school at Stanford University. As a medical student, he completed a yearlong junior fellowship in anatomic pathology at Stanford Hospital as well as a master’s degree in clinical research and epidemiology. Daniel is currently exploring perioperative use of albumin and its association with acute kidney injury (AKI) following major surgery. Ultimately, Daniel is interested in the heterogeneity of systemic inflammatory responses and how these may predispose to and prognosticate outcomes of sepsis, ARDS, AKI, and other important sequelae. As a resident physician in anesthesiology, he hopes to explore targeted interventions that could improve treatment guidelines in these and related conditions in the perioperative and critical care settings. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1600699004178-YC97GG59VVST6KF1W7BQ/Wagner+photo.jpg Fellows (Copy) - Sandra WAGNER (Copy) Sandra Wagner has a doctorate from the University of Burgundy focusing on food science and epidemiology. Then, she did a post-doctorate in epidemiology at the Center for Research in Epidemiology and Population Health. She currently holds the position of biostatistician / epidemiologist within the INI-CRCT network. https://www.kdctmeeting.com/industry-2 daily 0.75 2021-10-21 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599131915576-U8C6AA9HE8HA4EIU15NT/image-asset.jpeg Industry https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634818513139-11M9FPH44J1Y3GL3SZZK/Calque-9-e1616483475498.png Industry - Maurice BERENGER Maurice is a seasoned entrepreneur with more than 30 years of experience in medical devices. During the last 20 years he has been the CEO of several start-ups of which few were successfully exited. He is the co-author of 5 patent applications. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634818715255-4H5T4CQIIZBJBGHBBHE1/Juliane+Bernholz++Website+zakelijk+portret-14.JPG Industry - Juliane BERNHOLZ Dr. Juliane Bernholz has over 27 years of experience working in the pharmaceutical and biotech industry in a variety of senior R&D and business development roles. She joined AM-Pharma as Chief Operating Officer in October 2019. Prior to joining AM-Pharma Juliane was a Compound Development Team Leader at Janssen R&D LLC in New Jersey, US where she was responsible for leading the development of a next generation anticoagulant and CRISPR-Cas3 enhanced bacteriophage therapy. Before her time at Janssen, Dr. Bernholz held a number of international leadership roles in big Pharma and Biotech companies. These included Lead for International Partnering in the Diabetes Division at Sanofi-Aventis in Frankfurt, Germany where she successfully executed a cell therapy and drug discovery collaboration deal. She also served as Senior Global Program Head of the Critical Care Franchise at Novartis Pharma, where she led work on its cystic fibrosis projects. Her prior career included a variety of senior roles at Actelion, Novartis, Ciba and Sandoz. Juliane holds a PhD in Cell biology from the Biozentrum of the University of Basel, Switzerland. Juliane is a Swiss and German national. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634819573272-WLULL2JKJPXYGIWF446F/image%252B15.jpg Industry - Erwin BERTHIER Dr. Erwin Berthier is an adept innovator, with over 35 publications, 9 filed patents and significant research funding. Erwin holds a Masters in Mechanical Engineering from ENSTA in Paris, France, an MS in Electrical Engineering from the University of Canterbury in Christchurch, New Zealand, and a PhD in Biomedical Engineering from the University of Wisconsin-Madison. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745572532212-TBLBKPIJDJUM7TMPTKX2/meike.brinker%40bayer.com.jpg Industry - Meike Daniele BRINKER https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745570407506-UG5TY5TWQVRC2K2DBTZF/martin.cowie%40astrazeneca.com.jpg Industry - Martin COWIE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634819829857-QP6SP8ZKCVES7H2S3LVM/Erlandsson_Fredrik_0721b.jpg Industry - Fredrik ERLANDSSON Fredrik received his medical degree and his PhD from Karolinska Institute in Stockholm. Following this he worked in clinical medicine at Västervik Hospital before joining Bayer Pharmaceuticals to work in medical affairs and on the development of sorafenib for renal cancer. He subsequently moved to London and UK biotech Antisoma where he became head of clinical pharmacology and was involved in both pre-clinical and clinical development of a number of projects. From this Fredrik returned to work in clinical medicine in Sweden before joining AstraZeneca in 2011, where he worked on both early and late stage drugs primarily in development for nephrology indications. In May 2021 Fredrik joined Vifor as VP head of global clinical development. Fredrik has co-authored about 25 peer reviewed papers, and presented data at international conferences. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634819693682-4MSF7SSN96FQ0U2BFBC7/photo+BF1.jpg Industry - Bruno FLAMION Bruno Flamion, MD/PhD, is full professor of Clinical Pharmacology at the University of Namur and SVP, Head Strategic Development at Idorsia Pharmaceuticals, Allschwil, Switzerland. He has clinical expertise in internal medicine, was Research Associate at the National Institutes of Health, Bethesda, USA, and at the Belgian FNRS. He headed the Laboratory of Physiology and Pharmacology at the University of Namur for 20 years and worked part-time at the European Medicines Agency, London, UK, for 12 years (6 years as Chair of the Scientific Advice Working Party). https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1742808260347-NO7AGX2P0BKO5L65KZV2/Julie+Funch+Furberg.png Industry - Julie FUNCH FURBERG Julie F. Furberg works as a statistician in the pharmaceutical company Novo Nordisk, Denmark. Within Novo Nordisk, she is responsible for the clinical trials within chronic kidney disease, including the renal outcome trial FLOW which investigated the renal benefits of semaglutide. She has a PhD in Biostatistics from the University of Copenhagen. Her main statistical areas of interest are survival analysis, recurrent event analysis, multi-state models and causal inference. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054318029-P5IR36WIKV0FT8MW7T63/Hauske+photo.jpg Industry - Sybille HAUSKE Sibylle joined Boehringer Ingelheim in 2016 and is the Global Lead of the Clinical Development for Empagliflozin & Pipeline in Chronic Kidney Disease (CKD) at Boehringer Ingelheim headquarters in Germany. Sibylle is a Nephrologist with a nearly decade-long experience in clinical practice and academic research with a major focus on diabetic kidney disease. Sibylle is currently leading the Clinical Development in CKD, including the pragmatic global outcome trial EMPA-KIDNEY in collaboration with world-leading academic partners at the University at Oxford and BI´s innovative CKD Pipeline. Thereby, she is steering a large cross-functional team providing her with extensive and multifaceted knowledge spanning across all aspects of clinical drug development to marketing authorization. In addition, Sibylle was appointed Assistant Professor by the University of Heidelberg (Medical Center Mannheim) where she headed the Clinical Research Group for Diabetic Nephropathy and where she continues to be a lecturer for Medical students. Sibylle obtained an MBA double degree for General Management at the Mannheim & ESSEC Business School. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745571601554-CGE1HR3C8ZOOTSOKZISI/thid%40novonordisk.com+%281%29.jpg Industry - Thomas IDORN https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745571770302-GPVAHHMQVGKXH8TLSEHK/radko.komers%40travere.com.jpg Industry - Radko KOMERS https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054416803-YMUT2QT0SWFNKZFNO2VB/Landschulz+Katherine+photo.jpg Industry - Katherine LANDSCHULZ Katherine T. Landschulz, PhD, Sr Director and Therapeutic Area Lead, Cardiovascular, Metabolic, Renal and Neurodegenerative Diseases, Labcorp Biomarker Solution Center. As Renal Disease Therapeutic Area Lead for the Labcorp Biomarker Solution Center, Dr. Landschulz is responsible for the delivery of biomarker strategies for sponsor programs in Acute Kidney Injury and Chronic Kidney Disease-related Renaindications. Dr. Landschulz serves as a consultant to sponsors and teams, advising regarding biomarker selection and strategy development, laboratory placement of testing, feasibility designs, and overall guidance around translational and exploratory biomarker data in drug development. Dr. Landschulz serves further as a liaison, directing questions and connecting sponsor and Labcorp biomarker scientists. Finally, Dr. Landschulz participates in enterprise-wide assessments, licensing and implementation of new laboratory biomarker and tests transitioning from clinical trial to clinical care utilization. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745571942360-5HO171IT0QFG8TMCJTT2/dustin.little%40astrazeneca.com.png Industry - Dustin LITTLE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634823036155-2N2P5G2AZV0ROIGI4EXS/MatthiasMeier_Aug2020.jpg Industry - Matthias MEIER Matthias Meier is a board-certified physician in Germany and Switzerland qualified in Internal Medicine with specialization in Nephrology and Diabetology as well as long-term experience in pharmaceutical drug development. He is currently serving as Global Program Clinical Head and providing leadership support to the ongoing renal activities within Cardio-Renal-Metabolism Franchise at Novartis Pharma. Prior taking up this role, Matthias held positions at Novartis as global medical lead of transplant portfolio being responsible for successful submission of new indications in Japan, China and Taiwan. Matthias joined Novartis Pharma in Basel in May 2015 while previously working in various pre-clinical and clinical development positions at Roche-Genentech in Basel/Switzerland. He formerly received medical and scientific training at the Diabetes Research Institute in Munich/Germany, the University of Leicester/UK, the Joslin Diabetes Center/Harvard Medical School in Boston/USA as well as the Hannover Medical School/Germany where today he is an associate professor and faculty member. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1741881599367-RBVOWVWNELIPRZCUTZNG/Juliane+Meyerhoff.jpg Industry - Juliane MEYERHOFF Graduated in biochemistry, PhD from University of Hannover, Germany. Joined Boehringer Ingelheim in 1996, worked in various medical roles related to cardiovascular-renal metabolic indications, e.g. acute stroke treatment, stroke prevention, diabetes, chronic kidney disease. 2020-22 initiated and led a drug-agnostic global initiative for guideline implementation in type-2 diabetes. Since 2022 leading a global pipeline Medical Affairs team for a pipeline asset currently in phase III, evaluated for chronic kidney disease and heart failure. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054393038-T7XHLSMJGOYX4CBMRDIQ/Photo.jpg Industry - Richard NKULIKIYINKA Richard Nkulikiyinka holds a Medical Degree from the University of Cambridge in the UK. He received his Membership of the Royal College of Physicians (MRCP) of London after completing his post-graduate training in general internal medicine at the Royal London and the Northwest London NHS Trusts, with a focus on emergency medicine and intensive care. He also holds a M.Sc. in Epidemiology from the London School of Hygiene and Tropical Medicine. He joined Bayer in 2008, where he has held positions in Pharmacovigilance and Clinical Development, with responsibility for the planning and oversight of Phase 2-3 clinical studies, leading to NDA/MAA submissions in several therapeutic areas. He is currently the Head of the Therapeutic Area Cardiology & Nephrology within the Clinical Development Organization at Bayer Pharmaceuticals, based in Wuppertal, Germany. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634821650947-QGAE7ZLFR0P1BJPVHCXC/alain_romero.jpg Industry - Alain ROMERO Alain is the Vice President of Medical and Scientific Affairs for Relypsa Pharmaceuticals. Alain joined Relypsa in August 2015 with 25 years of experience in clinical research and development, medical affairs and business development. He has led clinical programs across a wide range of therapeutic areas, including drug delivery, anti-infectives, neuroscience, cardiovascular and respiratory medicine, resulting in the successful filing and launch of several new pharmacological treatments. Before joining Relypsa, Alain was Vice President of Medical Affairs at Actelion, where he launched Opsumit® for pulmonary arterial hypertension. Previously, Alain spent 18 years at Pfizer, where he worked in early clinical research on licensing assets to late-stage development, domestically and internationally, before becoming responsible for Medical Affairs. Prior to joining the biotechnology/pharma industry, Alain practiced at the Rennes University Hospital, was a Research Fellow at Ciba-Geigy, and served as a consultant for several companies and on FDA-mandated audits. He was an Adjunct Professor of Medicine at the University of Rennes and the Miller Medical School in Miami. Alain has a Pharm.D. from the University of Rennes School of Medicine and Pharmacy and a Ph.D. in biomedical and pharmaceutical sciences from the University of Rhode Island. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1741278432528-XY3189CE3FW5AIQZAE0I/Michael_REUSCH.JPG Industry - Michael REUSCH Physician and pharmacist with over 30 years of strategic and operational experience in global Clinical Research & Development within leading pharmaceutical companies. Proven expertise in planning and executing complex phase 2 and 3 clinical development programs and large-scale phase 4 studies. Most recently Medical Lead in a global development project covering a new treatment for anemia of CKD with oversight of trials, safety, and regulatory approvals, leading to EU approval in 2021. Since 2022 serving as Chief Medical Officer for Guard Therapeutics, a Swedish biotech company focused on development of novel therapies targeting kidney disease. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1742307101357-BJ3TB6DLUBKN4TG84MSO/Uptal%252BPatel_v1.jpg Industry - Uptal PATEL Uptal Patel is Senior Vice President and Head of Development at HI-Bio, at Biogen, focused on targeted therapies for immune-mediated diseases. Prior to HI-Bio, he led clinical strategy, translation, and development of the kidney portfolios at AstraZeneca (within early CVRM) and Gilead Sciences (within Inflammation therapeutic area). He currently also serves as Chair of the Board of Directors for the Kidney Health Initiative. He is an adjunct Professor at Duke University where he has led clinical and translational research programs to improve detection and management of kidney disease in populations. He completed training at the University of Michigan in internal medicine, pediatrics, adult nephrology, pediatric nephrology, and health services research after attending medical school at UCSF. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634822176710-4067BGVZ7V7HE3FAH9EH/5e9a31535d7db632f9ae81b5_about__emma_schroeter.jpg Industry - Emma SCHROETER https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745569788477-NNJZRKT3JJTVUDOU2D8A/svenja.seide%40boehringer-ingelheim.com.jpg Industry - Svenja SEIDE https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1599054305540-JW88O8UC7PIFY9XVL5ZP/Sharma+Amit+photo.jpeg Industry - Amit SHARMA Dr Sharma serves currently as the Vice President of Medical Affairs, Cardiovascular and Renal Division for Bayer, United States. Dr. Sharma received his medical degree from Louisiana State University Medical Center in New Orleans. Dr. Sharma completed his nephrology and hypertension fellowship at the University of California in San Diego where he served as a fellowship director for his site from 2000-2005. Dr. Sharma is board certified by the ABIM for internal medicine, nephrology, and he has an additional certification as a hypertension specialist by the American Society of Hypertension. He has held senior leadership industry positions at Reata, Keryx, Relypsa, and Akebia. Dr. Sharma has served has an appointed member for many national and international committees. He currently serves on the board of directors for the Kidney Health Initiative a public private partnership with the ASN and FDA. He also holds leadership positions for the National Kidney Foundation’s Patient Network as well as its National Leadership Council. He is a fellow of the National Kidney Foundation, the American Society of Nephrology, the American College of Physicians, and is a recently inducted member of the Royal Society of Medicine. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745570238551-YOMI3ASM55VYYA30GXE7/bergur.stefansson%40roche.com.jpg Industry - Bergur STEFANSSON https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745569872160-8B364CXMT04I8EJA31BE/dominik.steubl%40boehringer-ingelheim.com.png Industry - Dominik STEUBL https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634822643581-GER49O836CPNB03L4IWZ/Anna-McVittie-Szafranski%402x.jpg Industry - Anna SZAFRANSKI Anna McVittie Szafranski is the vice president of Marketing for Medtronic’s Peripheral business where she is responsible for global and U.S. downstream marketing, strategic planning, analytics, market development, sales training, and new product pipeline management. Anna has been with Medtronic for nearly 12 years. Early in her time at Medtronic she won the Marketing Excellence Award for accelerating the growth of Medtronic’s cardiac ablation franchise, before leading the integration and US launch of the disruptive ArcticFront Cardiac Cryoballoon. Anna then led the peripheral vascular pipeline and strategic marketing teams through the Medtronic/Covidien acquisition and brought multiple innovative products from concept to market entry. Prior to Medtronic, Anna worked in engineering and clinical research at start-up companies, including Percardia, Fox Hollow, and Heartport. Anna has engineering degrees from M.I.T and Stanford, and an MBA from Kellogg School of Business. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1745572392137-HQV65QMACEFCCMNQC2IO/iturfanda%40lilly.com.jpg Industry - Ibrahim TURFANDA https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1634822830197-B6L1TBE7PBUJAZKPRFP3/330x185_auto.jpg Industry - Fred YANG Dr. Yang leads the development of the medical strategies of the company. In this capacity, he provides leadership and insight into the development of the Company’s clinical-stage compounds. He has nearly 20 years of experience in clinical research and drug development, with expertise in on statistics and quantitative science. He assumed positions of increasing responsibility in both large pharmaceutical companies (Abbott, Pharmacia, GSK, etc.) and small biotechnology companies (Discovery Labs), overseeing biostatistics as well as trial conduct and strategic planning. He has successful end-to-end development and worldwide regulatory experience. His therapeutic experience ranges from diabetes and cardiovascular disease to arthritis, oncology, and neonatal care. He has published many peer-reviewed articles. Dr. Yang is currently an Adjunct Associate Professor at Drexel University Medical School. He is also a consultant for the International Breast Cancer Research Foundation (IBCRF). He received his undergraduate education at Peking University and his Ph.D. degree from the University of Wisconsin. https://www.kdctmeeting.com/kdct-2020 daily 0.75 2021-10-27 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341023186-EDSLWZ6TRNM8NNM2GKFH/Session+1.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341023286-KQ338KQGFP2X1Y2W5EG1/Session+2.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341023776-IFIWSJS6KP3Z0UUGCMVW/Session+2b.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341024196-9IREEDKE9MC5PWXKUMKI/Session+2C.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341024497-2UP853AJSP2BQYEIG5EQ/Session+3.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341024834-YR13HTPYZT9R64G6YP3J/Session+4.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341025150-M5IJK0B18L20H6KT3URV/Session+5a.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341025466-TGXB5181XXHR4OES9KKX/Session+5b.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341025928-9LT3DKW04BWUZ4XY14VP/Session+6a.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341026131-7EGY3JFUA0SMX588JI6G/Session+6b.JPG KDCT 2020 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635341026571-0YRHPY4DMIOHFJDXVTJP/Special+session.JPG KDCT 2020 https://www.kdctmeeting.com/evaluation21 daily 0.75 2023-02-28 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1635601425360-Y1BZBTR0DNX8DAGQ7ZFF/Capture%2Bd%25E2%2580%2599%25C3%25A9cran%2B%2528409%2529.jpg Thank you for your participation in KDCT 2021 https://www.kdctmeeting.com/literature daily 0.75 2024-10-18 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1710533716590-J5P78K5Z4K152ZMSMLDM/WhatsApp+Image+2024-03-15+at+21.13.29+%281%29.jpeg Literature https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/84181004-3c27-494c-b089-5cfcb72aba59/PdfPageImage.01277230-990000000-00452.0.jpeg Literature - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.kdctmeeting.com/practical-information daily 0.75 2026-01-09 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1677591596601-NAMVH07NSQMVETRDUY40/unsplash-image-rUXh5USKfUQ.jpg Practical Information https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/d08d5eef-8bf6-4461-821d-d4c2602159ef/AFKL-GM-E-Logo.png Practical Information - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/00cc78c6-c8bd-4fd1-92bd-efee251f1a4d/AFKL-GM-E-Official-Carrier-logo.png Practical Information - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1677591439438-N0092LG9A3K8BWRG1Y1M/unsplash-image-nTixYjudYyA.jpg Practical Information - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.kdctmeeting.com/evaluation2023 daily 0.75 2024-03-15 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1677866576350-IM8K4QST3MVAF76BX7IH/IMG_5592.jpg Evaluation https://www.kdctmeeting.com/peter-blankestijn daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/721edb9b-9a85-4cf6-abf4-372fb53f0672/DSC_0472_Portrait.jpg Peter Blankestijn - Peter Blankestijn Utrecht, NED https://www.kdctmeeting.com/jule-pinter-copy daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1709203423141-TNLJNYN6ZBE2HO7Q1G9M/Pinter_Jule_2023_page-0001%2B%281%29.jpg Jule Pinter https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/312dd9d3-f961-43d9-8846-362208a7895e/Pinter_Jule_2023_page-0001%2B%281%29.jpg Jule Pinter - Jule Pinter Würzburg, GER https://www.kdctmeeting.com/christoph-wanner-copy daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1709204173300-PK1M5NRULLPIRP0ABEKJ/210224_wanner_nephro_ukw_DSC_2179.jpg Christoph Wanner https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/3812100a-37b2-4e4e-bfba-d48ff0744e1f/210224_wanner_nephro_ukw_DSC_2179.jpg Christoph Wanner - Christoph Wanner Würzburg, GER https://www.kdctmeeting.com/jonathan-barratt daily 0.75 2024-03-14 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/3e1d53fe-0770-43f6-bcb2-020152c55832/Screenshot%2B2022-10-19%2Bat%2B16.41.29.png Jonathan Barratt - Jonathan Barratt Leicester, GBR https://www.kdctmeeting.com/dana-rizk daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/5bd57551-685b-441b-a481-791b9360d54c/Dana+Rizk-rev-2021.jpg Dana Rizk - DANA RIZK Birmingham, USA https://www.kdctmeeting.com/matthias-kretzler daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/903472e9-b907-4845-8fd6-c3a81f311b8d/IMG_3551.jpg Matthias Kretzler - Matthias Kretzler Ann Arbor, USA https://www.kdctmeeting.com/ivonne-schulmann daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/323c5b2c-d54e-4077-82df-24d852f742c1/IvonneSchulman_8x10.jpg Ivonne Schulmann - Ivonne Schulmann NIDDK, USA https://www.kdctmeeting.com/tom-greene daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/4240e2a5-17cc-475b-8ae6-6472d53354e5/algorithms_shoot_CloseUpWideSmile.jpg Tom Greene - Tom Greene Salt Lake City, USA https://www.kdctmeeting.com/peter-rossing daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/34e1e17b-b84c-4e52-8b60-f6e8713ba346/PR1.JPG Peter Rossing - Peter Rossing Copenhagen, DEN https://www.kdctmeeting.com/tim-friede daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/68029f07-e781-41ce-a33c-3d84e1a47748/Friede.jpg Tim Friede - Patrick Rossignol Göttingen, GER https://www.kdctmeeting.com/marlies-ostermann daily 0.75 2025-03-12 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/d77dd270-b53a-4f93-88c5-22f14712807c/Foto+%28Aug+2023%29.jpg Marlies Ostermann - Marlies Ostermann London, GBR https://www.kdctmeeting.com/amit-garg daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/f4325d9e-246d-4479-aeb0-30acf1a74895/Amit+picture.jpg Amit Garg - Amit Garg London, CAN https://www.kdctmeeting.com/darcy-duquette daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/eceffbed-5ffb-4cdb-9577-7340e59264fd/image.jpg D’Arcy Duquette - D’Arcy Duquette Calgary, CAN https://www.kdctmeeting.com/dana-fuhrman daily 0.75 2025-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/45dd3968-2873-46d5-a4b2-fcc8c5d73535/Dana+Fuhrman.jpg Dana Fuhrman - Dana Fuhrman Pittsburgh, USA https://www.kdctmeeting.com/natalja-stanski daily 0.75 2024-02-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/b893ba5f-6926-47bd-a9c7-f31f98293069/NS+Headshot.jpg Natalja Stanski - Natalja Stanski Cincinatti, USA https://www.kdctmeeting.com/bruno-garcia daily 0.75 2024-11-27 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/d084cba0-b060-417f-8baf-04818ea28dd9/Bruno.jpg Bruno Garcia - Bruno Garcia Lille, FRA https://www.kdctmeeting.com/jaykoyner daily 0.75 2025-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1859b9fe-8d3b-4e84-8a9d-89f46900267c/Koyner+Head+shot+Sept+2022.jpg Jay Koyner - Jay Koyner Chicago, USA https://www.kdctmeeting.com/marc-froissart daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/0cbf0e12-98e1-4db2-98c0-2e965aab9d90/FROISSART_Marc.jpg Marc Froissart - Marc Froissart Lausanne, SUI https://www.kdctmeeting.com/hiddo-heerspink daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1349c542-e41c-489b-a984-59d8b1f65c33/RZ2_4839.jpg Hiddo Heerspink - Hiddo Heerspink Groningen, NED https://www.kdctmeeting.com/matt-weir daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/823c5998-b107-45c0-899b-50255dd029ca/Weir%2BMatt%2Bphoto.jpg Matt Weir - Matt Weir Baltimore, USA https://www.kdctmeeting.com/toshiyuki-takahashi daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/ae4926ee-9b4d-448e-8744-54734ae23430/photo+T.Takahashi+%281%29.jpeg Toshiyuki Takahashi - Toshiyuki Takahashi PMDA, JPN https://www.kdctmeeting.com/meg-jardine daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/c261e65a-fe54-4533-8037-f9d3a5e6a821/Meg+Jardine-May23-GeorgeFetting-002b.jpg Meg Jardine - Meg Jardine Sydney, AUS https://www.kdctmeeting.com/kiyoshiro-tanaka daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/56a1ec0e-6935-4076-bbe3-ed07a9467597/tanakakiyoshiro.jpg.png Kiyoshiro Tanaka - Kiyoshiro Tanaka PMDA, JPN https://www.kdctmeeting.com/svenja-seide daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/8575a7cb-7828-4661-afc7-ce527da55c94/7499.jpg Svenja Seide - Svenja Seide Boehringer Ingelheim, GER https://www.kdctmeeting.com/glen-chertow daily 0.75 2024-03-06 https://www.kdctmeeting.com/erwin-berthier daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/ce440a73-1297-4b58-a51f-327438bede22/Erwin+Profile.png Erwin Berthier - Erwin Berthier Tasso Inc, USA https://www.kdctmeeting.com/paul-hockings daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/6645c66b-34c3-4107-bcef-7c73a910f02f/_73A0884zoom.jpg Paul Hockings - Paul Hockings Antaros Medical, SWE https://www.kdctmeeting.com/harold-feldman daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/c46ee1d6-4dad-4cc3-8015-e3d18775afbd/Feldman%2C+Harv-600x600-2_+2023_jpg.jpg Harold Feldman - Harold Feldman PCORI, USA https://www.kdctmeeting.com/joseph-bonventre daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/e6130ed5-c72d-4336-ac35-f1c3813a0c6e/Joe+Head+shot+2024+%282%29_page-0001.jpg Joseph Bonventre - Joseph Bonventre Boston, USA https://www.kdctmeeting.com/thomas-idorn daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/db4af5d9-66c4-4b1e-9b0a-310527990755/Thomas-Idorn.jpg Thomas Idorn - Thomas Idorn Novo Nordisk, DEN https://www.kdctmeeting.com/rajiv-poduval daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/b0bdb654-cfe2-4307-8020-6fd8a63e5ca1/CMQHeadshots-DrPoduval_Cropped.jpg Rajiv Poduval - Rajiv Poduval Panoramic Health, USA https://www.kdctmeeting.com/robert-lee daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/6a36429a-560d-4b80-9ec0-e5e916d0eb90/RLee+Headshot+2023.jpg Robert Lee - Robert Lee FDA, USA https://www.kdctmeeting.com/daniel-gossett daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/7b44ad2c-0035-4a17-8ecf-7fd128eaf752/Gossett+Danny_Headshot+8x10+%282%29.jpg Daniel Gossett - Daniel Gossett NIDDK, USA https://www.kdctmeeting.com/despina-rssmann daily 0.75 2024-03-06 https://www.kdctmeeting.com/michel-jadoul daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/37394bd5-463d-4aa4-b849-86ae809bc159/MJ%2Bphoto.jpg Michel Jadoul - Michel Jadoul Brussels, BEL https://www.kdctmeeting.com/cassandra-kennedy daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/e9de3fae-dfaf-4be5-94c5-83131384689f/1517694896087.jpg Cassandra Kennedy - Cassandra Kennedy Fortrea, USA https://www.kdctmeeting.com/amanda-siriwardana daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/2cd6df04-810a-4ce1-8af0-464c3f601b40/KDCT+picture.jpg Amanda Siriwardana - Amanda Siriwardana Sydney, AUS https://www.kdctmeeting.com/chirag-parikh daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/2fc360dd-38eb-4dae-8010-9db667b53078/Chirag+Parikh-2023_NG.jpg Chirag Parikh - Chirag Parikh Baltimore, USA https://www.kdctmeeting.com/sradha-kotwal daily 0.75 2024-03-06 https://www.kdctmeeting.com/sean-bagshaw daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/ae9ba5af-f5c8-4abf-a33a-72c41de88c3d/bagshaw.jpg Sean Bagshaw - Sean Bagshaw Edmonton, CAN https://www.kdctmeeting.com/matthieu-legrand daily 0.75 2024-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/9e0dfe90-c89c-4814-bd03-cdb2b4a0c15a/Matthieu%2BLegrand%2Bphoto.jpg Matthieu Legrand - Matthieu Legrand San Francisco, USA https://www.kdctmeeting.com/andrew-mclachlan daily 0.75 2024-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/58bcffca-71b8-447a-9fad-67622deb12ba/Andrew+profile+picture.jpg Andrew Mclachlan - Andrew Mclachlan Sydney, AUS https://www.kdctmeeting.com/harold-feldman-1 daily 0.75 2024-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/8b24c3ec-2d5c-4adb-b3dd-24d74dc1701c/Feldman%2C+Harv-600x600-2_+2023_jpg.jpg Harold Feldman - Harold Feldman PCORI, USA https://www.kdctmeeting.com/uptal-patel daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/9925bb60-df53-4f95-b0c5-618c515c270e/NinaPomeroyPhotography-23-09-18_Uptal+Patel.jpg Uptal Patel - Uptal Patel KHI, USA https://www.kdctmeeting.com/yves-rosenberg daily 0.75 2024-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/e7541b07-dd32-44a1-a994-e1ac54b394de/Rosenberg_Yves-Picture_1.png Yves Rosenberg - Yves Rosenberg NHLBI, USA https://www.kdctmeeting.com/abigail-ryan-1 daily 0.75 2024-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/656509ed-8991-43ce-a6a5-fd99d360d334/2022_09+19_Abby+Ryan.png Abigail Ryan - Abigail Ryan CMS, USA https://www.kdctmeeting.com/evaluation daily 0.75 2024-03-15 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1710533762553-HPLKB1770BBEQVVTR00Y/WhatsApp+Image+2024-03-15+at+21.13.29.jpeg Evaluation https://www.kdctmeeting.com/recommendations-2025 daily 0.75 2024-03-29 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1710533762553-HPLKB1770BBEQVVTR00Y/WhatsApp+Image+2024-03-15+at+21.13.29.jpeg Recommendations 2025 https://www.kdctmeeting.com/scientific-program-2026 daily 0.75 2026-04-03 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1731492349517-B98RYVXXLB8F763CSDNU/unsplash-image-qE0ztd12U_c.jpg Scientific Program https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/69c548c4-9410-4502-9175-6cce11eb63c3/KDCT+2026+Agenda.png Scientific Program - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.kdctmeeting.com/vineeta-kumar daily 0.75 2025-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/bd226361-65f2-4057-8cdf-7241bbf4c940/RS32134_Vineeta+Kumar-20190726-013-8482RT+4x3.jpg Vineeta Kumar - vineeta kumar Birmingham (USA) https://www.kdctmeeting.com/vandana-niyyar daily 0.75 2024-11-25 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/29ca0ed3-00c8-44a1-8995-09e0f6818679/VandanaNiyyar.JPG Vandana Niyyar - Vandana Niyyar https://www.kdctmeeting.com/jurgen-floege daily 0.75 2024-11-25 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/9306fd45-ceeb-4837-ae5c-8c00d7d5eb95/177949+13x18+kleiner.jpg Jürgen Floege - Jürgen Floege https://www.kdctmeeting.com/kathleen-liu daily 0.75 2024-11-25 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/73089420-bde4-4370-9aed-567f67d68d09/Liu.Kathleen.jpg Kathleen Liu - Kathleen liu https://www.kdctmeeting.com/alexander-zarbock daily 0.75 2024-11-27 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/d3018467-308a-4690-92b9-0b58ed0eca1b/zarbock.jpg Alexander Zarbock - Alexander Zarbock https://www.kdctmeeting.com/ravindra-mehta daily 0.75 2024-12-02 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/5aef50e1-3293-4c1c-ab8c-3a601404fe06/Image1.jpg Ravindra Mehta - ravindra mehta https://www.kdctmeeting.com/mark-lim daily 0.75 2024-12-20 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/6afd0f8f-e9cf-4093-95a9-f9c08084f30b/Mark+Lim+Headshot+1-Medium+Res.jpg Mark Lim - MARK LIM https://www.kdctmeeting.com/janani-rangaswami daily 0.75 2025-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/b80b497f-992f-491d-9322-e36c3d86cb58/JR+file+photo+cropped.jpg Janani Rangaswami - Janani Rangaswami https://www.kdctmeeting.com/navdeep-tangri daily 0.75 2025-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/fcb96cbc-00df-4437-9edd-26f137d56f60/NTheadshot2025.jpg Navdeep Tangri - Navdeep Tangri https://www.kdctmeeting.com/william-lawrence daily 0.75 2025-02-19 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/d3499fef-b4a9-4c82-96da-92f59956385d/PCORI_Lawrence+%282%29.jpg William Lawrence - William Lawrence M.D., M.S. https://www.kdctmeeting.com/adeera-levin daily 0.75 2025-02-21 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/593e134d-a2ea-4f7d-874a-9a8c423d96eb/Levin.jpg Adeera Levin - Adeera levin https://www.kdctmeeting.com/michael-reusch daily 0.75 2025-03-06 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/7c9c46b9-68de-40ef-8531-496fc45c16d9/Michael_REUSCH.JPG Michael Reusch - michael reusch https://www.kdctmeeting.com/kirtida-mistry daily 0.75 2025-03-14 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/07a4dc08-bcc3-496d-907e-ddb2a6eec52b/Kirtida+Mistry+10+%282%29.jpg Kirtida Mistry - Kirtida Mistry https://www.kdctmeeting.com/kianoush-kashani daily 0.75 2025-03-12 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/30ce894f-5500-484c-ba06-e87270d2bbfa/Kashani_Kianoush_2017-Final.JPG Kianoush Kashani - Kianoush Kashani https://www.kdctmeeting.com/juliane-meyerhoff daily 0.75 2025-03-13 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/b49f6e75-cac9-4852-9723-5b093f5e6490/Juliane+Meyerhoff.jpg Juliane Meyerhoff - Juliane meyerkoff Frankfurt, Germany https://www.kdctmeeting.com/caroline-wilkie-1 daily 0.75 2025-03-14 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/40c64e62-c1d2-40ed-8d17-431fc8e59dda/Wilkie%2C+Caroline+headshot.JPG Caroline Wilkie - Caroline wilkie Punta Gorda, USA https://www.kdctmeeting.com/aliza-thompson daily 0.75 2025-03-14 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/4878e2e1-2fd8-4e7a-936c-c0babcc2f622/A+Thompson+photo.jpg Aliza Thompson - aliza thompson https://www.kdctmeeting.com/katja-rohwedder daily 0.75 2025-03-14 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/2bf5fe7d-f833-4eea-90c5-d737557b1d02/katja.jpg Katja Rohwedder - katja rohwedder https://www.kdctmeeting.com/lesley-inker daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/b6dda336-ae21-4315-8f5b-45a669196392/lesley+inker.png Lesley Inker - lesley inker Boston, USA https://www.kdctmeeting.com/evaluation-2025 daily 0.75 2025-04-05 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1710533762553-HPLKB1770BBEQVVTR00Y/WhatsApp+Image+2024-03-15+at+21.13.29.jpeg Evaluation 2025 https://www.kdctmeeting.com/julie-funch-furberg daily 0.75 2025-03-24 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/28d367f4-e3f9-413c-a925-04399bf6b604/Julie+Funch+Furberg.png Julie Funch Furberg - JULIE FUNCH FURBERG Søborg, DENMARK https://www.kdctmeeting.com/steven-macari-1 daily 0.75 2025-03-24 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/8bbcb42a-8fd6-41fc-b644-7fef10b70f9f/steven+macari.jpg Steven Macari - Steven macari FRANCE https://www.kdctmeeting.com/flavia-geraldes daily 0.75 2025-03-24 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/216a6431-9858-4d59-b45c-132ebf7ee4c8/IMG-20241028-WA0028.jpg Flavia Geraldes - flavia geraldes THE LANCET https://www.kdctmeeting.com/story-tremont daily 0.75 2025-05-12 https://images.squarespace-cdn.com/content/v1/5755bccb8259b515333df0e1/1466115070758-QDGTM4SMWWF57NK026OU/Stocksy_comp_543118.jpg Story https://www.kdctmeeting.com/program-at-a-glance-copy daily 0.75 2025-12-03 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1731492349517-B98RYVXXLB8F763CSDNU/unsplash-image-qE0ztd12U_c.jpg Program at a glance 2025 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/6ead8374-fe8e-42e8-bed6-7abf31b1dd3b/KDCT+2025+Preliminary+Program+at+a+glance+%285%29.png Program at a glance 2025 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.kdctmeeting.com/initial-track-copy daily 0.75 2025-12-03 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1731492349517-B98RYVXXLB8F763CSDNU/unsplash-image-qE0ztd12U_c.jpg Initial Track (Copy) https://www.kdctmeeting.com/parallel-track-copy-2025 daily 0.75 2025-12-03 https://images.squarespace-cdn.com/content/v1/5a7c1cb78dd041a5e11c9f6b/1731492349517-B98RYVXXLB8F763CSDNU/unsplash-image-qE0ztd12U_c.jpg Parallel Track (Copy) 2025